var title_f24_53_25424="Phalen test carpal tunnel";
var content_f24_53_25424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The Phalen maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with nerve compression in the carpal tunnel, acute wrist flexion maintained for 30 to 60 seconds reproduces symptoms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25424=[""].join("\n");
var outline_f24_53_25424=null;
var title_f24_53_25425="Acropustulosis of infancy 1";
var content_f24_53_25425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acropustulosis of infancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small pustules are present on the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25425=[""].join("\n");
var outline_f24_53_25425=null;
var title_f24_53_25426="Adjuvant medical therapy for HER2-positive breast cancer";
var content_f24_53_25426=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/53/25426/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25426/contributors\" id=\"au6807\">",
"       Harold Burstein, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/53/25426/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25426/contributors\" id=\"se4959\">",
"       Daniel F Hayes, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/53/25426/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25426/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/53/25426?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Breast cancer is the most common female cancer in the United States and up to 20 percent of women with breast cancer have tumors that have high levels of HER2, which is a protein that is involved in cell growth, differentiation, and blood vessel formation (angiogenesis). In the past, tumors with high levels of HER2 (also known as HER2-positive tumors) were associated with an increased risk of both recurrence and death from breast cancer. However, with the use of chemotherapy and targeted treatment against HER2, the prognosis of HER2-positive breast cancers has improved substantially.",
"    </p>",
"    <p>",
"     This article focuses on the adjuvant medical treatment of HER2 positive breast cancer. An introduction to breast cancer and an overview of treatments, including surgery, radiation therapy, and medical therapy, is also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"      \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"      \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WILL I NEED TREATMENT AFTER SURGERY?",
"     </span>",
"    </p>",
"    <p>",
"     After breast cancer is removed with surgery, there is still a risk that cancer cells remain and may return or spread to other parts of the body. Adjuvant therapy is given after surgery to destroy these cells. Adjuvant therapy improves the chance of curing breast cancer and decreases the risk of dying of breast cancer. Thus, adjuvant therapy is a very important part of modern breast cancer treatment for most patients. There are different forms of adjuvant treatment and your doctor will help you decide what is best for you. Some patients need radiation therapy after surgery. For HER2-positive breast cancer, adjuvant medical therapy options include: endocrine therapy and chemotherapy, and HER2-directed treatment, such as trastuzumab (Herceptin). Each works on your cancer differently.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28828042\">",
"     <span class=\"h2\">",
"      Will I need radiation treatment?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy refers to the use of high-energy x-rays to slow or stop the growth of cancer cells. Exposure to x-rays damages cells. Unlike normal cells, cancer cells cannot repair the damage caused by exposure to x-rays over several days. This prevents the cancer cells from growing further and causes them to eventually die. For patients with breast cancer, adjuvant radiation is given to decrease the risk of the cancer coming back in the breast or chest wall (this is called locoregional recurrence).",
"    </p>",
"    <p>",
"     Radiation is usually given as external beam radiation, meaning that the radiation beam is generated by a machine that is outside the patient. Exposure to the beam typically takes only a few seconds (similar to having an x-ray). Some patients will need radiation therapy after surgery and you should discuss this option with a radiation oncologist, who is specialized in the use of radiation treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20356920\">",
"     <span class=\"h2\">",
"      Will I need HER2 directed therapy?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Studies have shown that adjuvant treatment using a combination of HER2 targeted therapy and chemotherapy greatly improves survival of women with HER2-positive breast cancer. In contrast, HER2 targeted therapy by itself is not used in the adjuvant setting. Trastuzumab is the HER2 targeted therapy used in this setting. Trastuzumab is appropriate for most patients with HER2 positive breast cancer. However, some patients with very small tumors (eg, &lt;0.5 cm) may not require trastuzumab therapy after surgery. Your doctor can help you decide if HER2 targeted therapy is right for you.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H62465601\">",
"     <span class=\"h3\">",
"      How is trastuzumab given?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Trastuzumab is given",
"     <em>",
"      during",
"     </em>",
"     and then",
"     <em>",
"      after",
"     </em>",
"     chemotherapy, for a total treatment duration of 12 months. During chemotherapy, trastuzumab is given with each cycle of chemotherapy. Once your course of chemotherapy is completed, trastuzumab is given by itself, usually every three weeks, for one year. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28828221\">",
"     <span class=\"h3\">",
"      What are the side effects of trastuzumab?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effect of trastuzumab is fever",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     chills. Heart failure develops in about 3 to 5 percent of women treated with trastuzumab. However, trastuzumab-related heart damage may not be permanent.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28828124\">",
"     <span class=\"h2\">",
"      Will I need chemotherapy?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy is a treatment given to stop the growth of cancer cells. It aims to destroy any remaining cancer cells to increase the chance of cure. This type of chemotherapy is called \"adjuvant\", which means that it is given after surgery with curative intent. Chemotherapy is given in addition to HER2-directed therapy for most patients with HER2-positive breast cancer. However, some patients with very small tumors (eg, &lt;0.5 cm) may not require chemotherapy after surgery. Your doctor can help you decide if adjuvant chemotherapy is right for you. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28828131\">",
"     <span class=\"h3\">",
"      How is chemotherapy given?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy is not given every day but instead is given in cycles. A cycle of chemotherapy (which is typically 21 or 28 days) refers to the time it takes to give the treatment and then allow the body to recover from the side effects of the medicines. This treatment usually involves a combination of several chemotherapy drugs (called regimens). Following surgery, it is usually started within four to six weeks postoperatively, and precedes radiation therapy, if this too has been recommended. Since different combinations of chemotherapy can be used, your doctor will describe which specific chemotherapy drugs will be needed, how long treatment will last, and what side effects are expected from your treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28828138\">",
"     <span class=\"h3\">",
"      What side effects does chemotherapy cause?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy can cause side effects during and after treatment. The type and severity of these side effects depends upon which chemotherapy drugs are used. Side effects that occur during chemotherapy are usually temporary and reversible. The most common side effects are nausea, vomiting, mouth soreness, temporary lowering of the blood counts, and hair loss. Long term side effects can include premature menopause (ovarian failure), damage to the heart, and a small risk of leukemia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28828170\">",
"     <span class=\"h2\">",
"      Will I need endocrine therapy?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Endocrine therapy helps to prevent breast cancer cells from being fed by estrogen and is only indicated for women with estrogen-responsive (ER-positive) or progesterone-responsive (PR-positive) cancers. Not all women with HER2-positive breast cancers have ER- or PR-positive tumors. But, if the tumor is ER- or PR-positive, then you should discuss this option with your doctor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28828177\">",
"     <span class=\"h3\">",
"      How is endocrine therapy given?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Endocrine therapy is given after completion of chemotherapy and is given as a pill to be taken every day for five years. More information on endocrine therapy can be found elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"      \"Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"      \"Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28828184\">",
"     <span class=\"h3\">",
"      Are there side effects of endocrine treatment?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The side effects of endocrine treatment depend on the drug that you are taking, but common side effects include nausea, mood disturbances, cataracts, and cardiac disease. Tamoxifen can cause vaginal bleeding and clot formation. The aromatase inhibitors (anastrazole, letrozole) can cause bone and joint pain, bone loss (osteopenia) or osteoporosis, which can result in fractures.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      WHICH TREATMENT IS RIGHT FOR ME?",
"     </span>",
"    </p>",
"    <p>",
"     There are many options for the adjuvant therapy of breast cancer and deciding which is best can be confusing. Expert guidelines help clarify which treatments are most appropriate for large groups of women. However, individual factors (your preferences, cancer stage) are also important to consider. You should discuss your options for adjuvant therapy with your doctor to determine which therapy is best.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      FOLLOW UP AFTER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     A summary of the American Society of Clinical Oncology's recommendations for follow up after breast cancer treatment is provided in the following table (",
"     <a class=\"graphic graphic_table graphicRef77225 \" href=\"UTD.htm?9/63/10236\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804496244\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12675050\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=see_link\">",
"      Patient information: Breast reconstruction after mastectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=see_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12675087\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"      Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34826?source=see_link\">",
"      Adjuvant systemic therapy for older women with early stage breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=see_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=see_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.org/\">",
"      www.nccn.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Adjuvant! Online",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.adjuvantonline.com/\">",
"      www.adjuvantonline.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Susan G. Komen Breast Cancer Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.komen.org/\">",
"      www.komen.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Breast Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://breastcancer.about.com/forum\">",
"      file://breastcancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/53/25426/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/53/25426?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25426/abstract/1\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25426/abstract/2\">",
"      Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 2008; 100:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25426/abstract/3\">",
"      Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25426/abstract/4\">",
"      Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25426/abstract/5\">",
"      Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25426/abstract/6\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_53_25426=[""].join("\n");
var outline_f24_53_25426=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WILL I NEED TREATMENT AFTER SURGERY?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           WHICH TREATMENT IS RIGHT FOR ME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           FOLLOW UP AFTER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?9/63/10236\" title=\"table 1\">",
"           Breast ca surveillance PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_53_25427="Antigenic peptide processing";
var content_f24_53_25427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Degradation and transport of antigens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The process of degradation of proteins into peptides, transport to the endoplasmic reticulum, binding of antigenic peptides to major histocompatibility (MHC) class I molecules, presentation of antigen to a CD8 + T cell, followed by intracellular signalling (steps a-l): (a) In an antigen-presenting cell (APC), newly sythesized MHC class I molecules bind to calnexin (Cx), which retains them in a partially folded state in the endoplasmic reticulum (ER). (b) Binding of MHC class I molecules to &szlig;2 microglobulin (&szlig;2m) displaces Cx and allows binding of chaperonin proteins (calreticulin and tapasin; not shown). (c) The MHC class I-&szlig;2m complex binds to the TAP complex (TAP1-TAP2), which awaits the delivery of peptides. (d) Peptides (eg, from antigens) are formed from the degradation of cytosolic proteins (self-, pathogen- and tumor-derived proteins in the cytoplasm). (e) These are degraded by proleasomes into (f) short peptides. (g) Peptides are transported into the ER by the TAPs, where they meet the MHC class I-&szlig;2m complex (h). This peptide binding in the antigenic groove of the MHC stabilizes the structure of the MHC class I molecule and (i) releases the TAP complex. (j) The fully folded MHC class I molecule with its peptide is transported to the cell surface via the Golgi apparatus. (k) Recognition of the MHC class I-peptide complex by the T-cell receptor (TCR) of an antigen-specific (CD8*, CD3*) cytotoxic T lymphocyte (CTL) takes place and (l) a signal transduction event activates effector functions in the MHC-class-I-restricted T cell; this requires co-simulation to occur (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Man, S. Human cellular immune responses against human papillomaviruses in cervical neoplasia. Exp Rev Mol Med, Cambridge University Press 1998. Reprinted with permission of Cambridge University Press",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25427=[""].join("\n");
var outline_f24_53_25427=null;
var title_f24_53_25428="Ketotifen (ophthalmic): Pediatric drug information";
var content_f24_53_25428=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketotifen (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44453?source=see_link\">",
"    see \"Ketotifen (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/1/3092?source=see_link\">",
"    see \"Ketotifen (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alaway&trade; [OTC];",
"     </li>",
"     <li>",
"      Claritin&trade; Eye [OTC];",
"     </li>",
"     <li>",
"      Zaditor&reg; [OTC];",
"     </li>",
"     <li>",
"      ZyrTEC&reg; Itchy Eye [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zaditor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiallergic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Histamine H",
"       <sub>",
"        1",
"       </sub>",
"       Antagonist, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44453?source=see_link\">",
"      see \"Ketotifen (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Children &ge;3 years and Adults: Instill 1 drop into lower conjunctival sac of affected eye(s) twice daily, every 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.025% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alaway&trade;: 0.025% (10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&trade; Eye: 0.025% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaditor&reg;: 0.025% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Itchy Eye: 0.025% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Instill into conjunctival sac avoiding contact of bottle tip with skin or eye; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects. Administer other topical ophthalmic medications at least 5 minutes apart.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of eye itching due to allergic conjunctivitis (FDA approved in children &ge;3 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6821374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Claritin&trade; Eye (ketotifen) may be confused with Claritin&reg; (loratadine)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ketotifen may be confused with ketoprofen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyrTEC&reg; Itchy Eye (ketotifen) may be confused with ZyrTEC&reg; (cetirizine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F186154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Allergic reactions, burning or stinging, conjunctivitis, discharge, dry eyes, eye pain, eyelid disorder, itching, keratitis, lacrimation disorder, mydriasis, photophobia, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketotifen or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in eye irritation due to contact lenses; patients should be advised not to wear contact lens if their eye is red; solution contains benzalkonium chloride which may be absorbed by soft contact lenses; wait at least 10 minutes after administration before inserting contact lenses. When used for self-medication (OTC use), notify healthcare provider if symptoms worsen or do not improve within 3 days. Contact healthcare provider if change in vision, eye pain, or redness occur. Do not use if solution is cloudy or changes color.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5278361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical ocular administration has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improvement in symptomatology (eg, reduction in itching, tearing, and hyperaemia)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ketotifen is an H",
"     <sub>",
"      1",
"     </sub>",
"     receptor antagonist and mast cell stabilizer which inhibits the release of mediators from cells involved in hypersensitivity reactions. Decreased chemotaxis and activation of eosinophils has also been demonstrated.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 5-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/1/3092?source=see_link\">",
"      see \"Ketotifen (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not let tip of the applicator touch eye; do not contaminate tip of applicator (may cause eye infection, eye damage, or vision loss); wait at least 10 minutes before putting soft contact lenses in; do not wear contact lenses if eyes are red",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Horak F, et al, &ldquo;Onset and Duration of Action of Ketotifen 0.025% and Emedastine 0.05% in Seasonal Allergic Conjunctivitis,&rdquo;",
"      <i>",
"       Clin Drug Invest",
"      </i>",
"      , 2003, 23(5): 329-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25428/abstract-text/17535045 /pubmed\" id=\"17535045 \" target=\"_blank\">",
"        17535045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12902 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-217.16.9.173-E29AE5AA73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25428=[""].join("\n");
var outline_f24_53_25428=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186116\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186117\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059574\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059567\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186102\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186089\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059577\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059570\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059576\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821374\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186154\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059580\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059566\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299559\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5278361\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186099\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186108\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059573\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059565\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059579\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059572\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12902\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12902|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44453?source=related_link\">",
"      Ketotifen (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/1/3092?source=related_link\">",
"      Ketotifen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/29/39379?source=related_link\">",
"      Ketotifen (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_53_25429="Osteoblasts";
var content_f24_53_25429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteoblasts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A clump of osteoblasts is seen in this bone marrow aspirate. The cells have a small, highly eccentric nucleus, and are similar in appearance to plasma cells. One distinguishing feature is the large Golgi zone separate from the nucleus (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD and William C Moloney, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25429=[""].join("\n");
var outline_f24_53_25429=null;
var title_f24_53_25430="Mastectomy incisions for central breast tumors";
var content_f24_53_25430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Mastectomy incisions for central breast tumors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Design of the classic Stewart elliptical incision for central and subareolar primary lesions of the breast. The medial extent of the incision ends at the margin of the sternum. The lateral extent of the skin incision should overlie the anterior margin of the latissimus dorsi. The design of the skin incision should incorporate the primary neoplasm en bloc with margins that are 1 to 2 cm from the cranial and caudal edges of the tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25430=[""].join("\n");
var outline_f24_53_25430=null;
var title_f24_53_25431="Hydroxyurea: Pediatric drug information";
var content_f24_53_25431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxyurea: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"    see \"Hydroxyurea: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/61/29653?source=see_link\">",
"    see \"Hydroxyurea: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Droxia&reg;;",
"     </li>",
"     <li>",
"      Hydrea&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydroxyurea&reg;;",
"     </li>",
"     <li>",
"      Gen-Hydroxyurea;",
"     </li>",
"     <li>",
"      Hydrea&reg;;",
"     </li>",
"     <li>",
"      Mylan-Hydroxyurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"      see \"Hydroxyurea: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Dosage should typically be based on IBW; however, actual body weight can be used for most pediatric patients unless they are obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants &ge;6 months, Children, and Adolescents:",
"     <b>",
"      Sickle cell anemia:",
"     </b>",
"     20 mg/kg/dose once daily; increase by 5 mg/kg/day every 2-6 months to a maximum dose of 35 mg/kg/day (maximum daily dose: 2000 mg); dose is titrated to patient response; if bone marrow suppression occurs, hold therapy  until counts recover; if recovery is prolonged (&gt;2 weeks) or toxicity is recurrent, decrease dose by 2.5-5 mg/kg/day (Ferster, 2001; Hankins, 2005; Heeney, 2008; Thornburg, 2009; Wang, 2001; Wang, 2011; Zimmerman, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Antineoplastic uses:",
"     </b>",
"     Titrate dose to patient response; if WBC count falls to &lt;2500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or the platelet count to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , therapy should be stopped for at least 3 days and resumed when values rise toward normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Chronic myelocytic leukemia (resistant):",
"     </b>",
"     Continuous therapy: 20-30 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Solid tumors:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intermittent therapy: 80 mg/kg as a single dose every third day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Continuous therapy: 20-30 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Concomitant therapy with irradiation (head and neck cancer): 80 mg/kg as a single dose every third day starting at least 7 days before initiation of irradiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Sickle cell anemia:",
"     </b>",
"     Oral: Initial: 15 mg/kg/dose once daily; if blood counts are in an acceptable range, may increase by 5 mg/kg every 12 weeks until the maximum tolerated dose of 35 mg/kg/day is achieved or the dose that does not produce toxic effects (do not increase dose if blood counts are between acceptable and toxic ranges). Monitor for toxicity every 2 weeks; if toxicity occurs, withhold treatment until the bone marrow recovers, then restart with a dose reduction of 2.5 mg/kg/day; if no toxicity occurs over the next 12 weeks, then the subsequent dose may be increased by 2.5 mg/kg/day every 12 weeks to a maximum tolerated dose (dose which does not produce hematologic toxicity for 24 consecutive weeks). If hematologic toxicity recurs a second time at a specific dose, do not retry that dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Acceptable hematologic ranges: Neutrophils &ge;2500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; platelets &ge;95,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; hemoglobin &gt;5.3 g/dL, and reticulocytes &ge;95,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     if the hemoglobin concentration is &lt;9 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Toxic hematologic ranges: Neutrophils &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; platelets &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; hemoglobin &lt;4.5 g/dL; and reticulocytes &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     if the hemoglobin concentration is &lt;9 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: The following guidelines have been used by some clinicians: Reduce initial dose to 15 mg/kg/dose once daily (Heeney, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sickle cell anemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No adjustment (of initial dose) required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute: Reduce initial dose to 7.5 mg/kg/day; titrate to response/avoidance of toxicity (refer to usual dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ESRD: Reduce initial dose to 7.5 mg/kg/dose (administer after dialysis on dialysis days); titrate to response/avoidance of toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Other approved indications: It is recommended to reduce the initial dose; however, no specific guidelines are available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Aronoff, 2007: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 20% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Hemodialysis: Administer dose after dialysis on dialysis days; supplemental dose is not necessary. Hydroxyurea is a low molecular weight compound with high aqueous solubility that may be freely dialyzable; however, clinical studies confirming this hypothesis have not been performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Continuous renal replacement therapy (CRRT): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 85% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer 75% of dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Droxia&reg;: 200 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrea&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: The manufacturer does not recommend opening the capsules; observe proper handling procedures (eg, wear gloves). Doses rounded to the nearest 100 mg when using capsules allows for dosing accuracy within ~2 mg/kg/day (Heeney, 2008). For patients unable to swallow capsules, an oral solution may be prepared.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in a tightly sealed container since the drug is degraded by moisture; store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory chronic myelocytic leukemia (CML), melanoma, and recurrent, metastatic or inoperable ovarian carcinoma (Hydrea&reg;: FDA approved in adults); treatment of  primary squamous cell carcinomas of the head and neck with radiation (excluding lip cancer) (Hydrea&reg;: FDA approved in adults); adjunct therapy in the management of sickle cell  anemia in patients who have had at least three painful crises in the previous 12 months (to reduce frequency of these crises and the need for blood transfusions) (Droxia&reg;: FDA approved in adults); has also been used in  the treatment of hematologic conditions, such as essential thrombocythemia, polycythemia vera, and hypereosinophilic syndrome; treatment of hyperleukocytosis due to acute myeloid leukemia; treatment of cervical cancer; treatment of meningiomas",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hydroxyurea may be confused with hydrOXYzine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hydrea [U.S., Canada, and multiple international markets] may be confused with Hydra brand name for isoniazid [Japan]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F181067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, disorientation, dizziness, drowsiness (dose-related), fever, hallucinations, headache, malaise, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, cutaneous vasculitic toxicities, dermatomyositis-like skin changes, facial erythema, gangrene, hyperpigmentation, maculopapular rash, nail atrophy, nail discoloration, peripheral erythema, scaling, skin atrophy, skin cancer, skin ulcer, vasculitis ulcerations, violet papules",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, gastrointestinal irritation and mucositis, (potentiated with radiation therapy), nausea, pancreatitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression (anemia, leukopenia/neutropenia [common], thrombocytopenia; hematologic recovery: within 2 weeks); macrocytosis, megaloblastic erythropoiesis, secondary leukemias (long-term use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic enzymes increased, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal:  BUN increased, creatinine increased, renal tubular dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Acute diffuse pulmonary infiltrates (rare), dyspnea, pulmonary fibrosis (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyurea or any component; severe bone marrow suppression or severe anemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with marked renal impairment; clearance is decreased; reduce dosage in some cases. Patients with previous radiation therapy are at risk for an exacerbation of postirradiation erythema. Administer under the supervision of a physician experienced in the treatment of sickle cell anemia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     or in cancer chemotherapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; wear gloves when handling and wash hands before and after contact to decrease risk of exposure.  Hydroxyurea is mutagenic, clastogenic, and presumed to be a human carcinogen",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; secondary leukemia and skin cancer have been reported in patients receiving long-term hydroxyurea therapy for myeloproliferative disorders; it is unknown if this is drug-related or disease-related. Hydroxyurea impairs fertility and is embryotoxic causing fetal malformations; women of childbearing potential should be advised to avoid becoming pregnant.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Myelosuppression (severe or life-threatening) may occur; leukopenia occurs more frequently than thrombocytopenia and anemia; typically reversible with interruption of therapy or dosage reduction. Severe anemia should be corrected prior to initiating treatment. Monitor hematologic status at baseline and periodically during therapy; in patients with sickle cell anemia, do not initiate or continue ongoing treatment if neutrophil count &lt;2000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &lt;4.5 g/dL, reticulocyte count &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     when hemoglobin &lt;9 g/dL. Use with caution in patients with a history of prior chemotherapy or radiation therapy; myelosuppression is more common; do not administer if WBC &lt;2500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Self-limiting megaloblastic erythropoiesis may be seen early in treatment and can resemble pernicious anemia; however, it is unrelated to a vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     or folic acid deficiency. Plasma iron clearance may be delayed and the rate of utilization of iron by erythrocytes may be reduced. May cause macrocytosis, which can mask folic acid deficiency; prophylactic folic acid administration is recommended for sickle cell patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Vasculitic ulcerations and gangrene have been reported in patients who received hydroxyurea for myeloproliferative disorders with a previous or concurrent history of interferon use; discontinue and consider alternate cytoreductive therapy if cutaneous vasculitic ulcerations develop.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When treated concomitantly with hydroxyurea and antiretroviral agents (including didanosine), HIV-infected patients are at higher risk for developing  fatal and nonfatal pancreatitis, hepatotoxicity, hepatic failure, and severe peripheral neuropathy; evaluate hepatic function at baseline and periodically with therapy; discontinue immediately if signs of  hepatic impairment or pancreatitis develop. Most fatal hepatic events occurred in patients receiving hydroxyurea, didanosine, and stavudine; avoid this combination.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Hydroxyurea may enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Didanosine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: Hydroxyurea may enhance the adverse/toxic effect of Stavudine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Stavudine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F180994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and embryotoxicity at doses lower than the usual human dose (based on BSA). Hydroxyurea may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to avoid becoming pregnant during treatment and should use effective contraception.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     General: CBC with differential, liver function tests and renal function should be checked at baseline and then periodically throughout therapy; serum uric acid, signs and symptoms of pancreatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sickle cell anemia: Monitor neutrophils, hemoglobin, platelets and reticulocytes every 2 weeks throughout therapy.  If neutrophil count &lt;2000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &lt;4.5 g/dL, and reticulocyte count &lt;80,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     when hemoglobin &lt;9 g/dL, hold therapy until counts recover. Decrease dose by 2.5 mg/kg/day before reinitiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic use: Monitor hemoglobin, platelets, and WBC counts at least weekly throughout therapy. If WBC &lt; 2500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hold therapy until counts increase significantly. If severe anemia occurs, treat without interrupting therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with synthesis of DNA during the S-phase of cell division without interfering with RNA synthesis; inhibits ribonucleoside diphosphate reductase preventing conversion of ribonucleotides to deoxyribonucleotides; hydroxyurea also inhibits the incorporation of thymidine into DNA; in sickle cell anemia patients, hydroxyurea increases the production of fetal hemoglobin and decreases neutrophils; increases water content of RBCs, increases deformability of sickled cells, and alters the adhesion of RBCs to endothelium.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1047768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Sickle cell anemia: Fetal hemoglobin increase: 4-12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Sickle cell anemia: 6-18 months",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients, large interpatient variability and phenotypic differences have been reported (Ware, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Relatively rapid (Rodriguez, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Readily crosses the blood-brain barrier; distributes into ascitic fluid and peritoneal or pleural effusions with estimated volume of distribution approximating total body water; concentrates in leukocytes and erythrocytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: ~12 L (range: 2.5-52) (Ware, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: ~20 L/m",
"     <sup>",
"      2",
"     </sup>",
"     (Rodriguez, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 60% via hepatic metabolism and urease found in intestinal bacteria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~100% (Rodriguez, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.7 hours (range: 0.65-3.05 hours) (Ware, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: \"Fast\" phenotype: 15-30 minutes; \"Slow\" phenotype: 60-120 minutes (Ware, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (sickle cell anemia: 40% of administered dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">",
"     Children: ~7 L/hour (range: 1.6-22) (Ware, 2011)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">",
"     Adults: ~7.5 L/hour (Rodriguez, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/61/29653?source=see_link\">",
"      see \"Hydroxyurea: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequent monitoring and blood tests are required while taking this medication to assess effectiveness and monitor adverse reactions. May cause nausea, vomiting, loss of appetite, constipation, diarrhea, mouth sores, and increased susceptibility to infection. Inform physician if fever, sore throat, bruising, or bleeding develops. Report persistent vomiting, diarrhea, constipation, stomach pain, or mouth sores; skin rash, redness, irritation, or sores; painful or difficult urination; anemia (unusual fatigue, lethargy); CNS changes (increased confusion, depression, hallucinations, or seizures); opportunistic infection (persistent fever or chills, white plaques in mouth, vaginal discharge, or unhealed sores); unusual lassitude, muscle tremors, or weakness. Advise women of childbearing potential to avoid becoming pregnant while taking hydroxyurea and to use a contraceptive method. To minimize risk of exposure to hydroxyurea, wear disposable gloves when handling bottle or capsules. Wash hands before and after contact with the bottle or capsule. If the powder from the capsule is spilled, it should immediately be wiped up with a damp disposable towel and discarded in a closed container.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 21",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10528705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 40 mg/mL oral suspension may be prepared with capsules and either a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of methylcellulose 1% and simple syrup NF. Empty the contents of eight 500 mg capsules into a mortar. Add small portions of chosen vehicle and mix to a uniform paste; mix while incrementally adding the vehicle to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label \"shake well\" and \"refrigerate\". Store in plastic prescription bottles. Stable for 14 days at room temperature or refrigerated (preferred) (Nahata, 2003).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 100 mg/mL oral solution may be prepared with capsules. Mix the contents of twenty 500 mg capsules with enough room temperature sterile water (~50 mL) to initially result in a 200 mg/mL concentration. Stir vigorously using a magnetic stirrer for several hours, then filter to remove insoluble contents. Add 50 mL Syrpalta&reg; (flavored syrup, HUMCO) to filtered solution, resulting in 100 mL of a 100 mg/mL hydroxyurea solution. Stable for 1 month at room temperature in amber plastic bottle (Heeney, 2004).",
"    </p>",
"    <div class=\"reference\">",
"     Heeney MM, Whorton MR, Howard TA, et al, \"Chemical and Functional Analysis of Hydroxyurea Oral Solutions,\"",
"     <i>",
"      J Pediatr Hematol Oncol",
"     </i>",
"     , 2004, 26(3):179-84.",
"     <span class=\"pubmed-id\">",
"      15125610",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, Boster EA, et al, \"Stability of Hydroxyurea in Two Extemporaneously Prepared Oral Suspensions Stored at Two Temperatures,\" 2003, 38:P-161(E) [abstract from 2003 ASHP Midyear Clinical Meeting].",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed., Philadelphia, PA: American College of Physicians, 2007, 100.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferster A, Tahriri P, Vermylen C, et al, &ldquo;Five Years of Experience With Hydroxyurea in Children and Young Adults With Sickle Cell Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2001, 97(11):3628-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/11369660/pubmed\" id=\"11369660\" target=\"_blank\">",
"        11369660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hankins JS, Ware RE, Rogers ZR, et al, &ldquo;Long-Term Hydroxyurea Therapy for Infants With Sickle Cell Anemia: The HUSOFT Extension Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(7):2269-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/16172253/pubmed\" id=\"16172253\" target=\"_blank\">",
"        16172253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeney MM and Ware RE, \"Hydroxyurea for Children With Sickle Cell Disease,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2008, 55(2):483-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/18381097/pubmed\" id=\"18381097\" target=\"_blank\">",
"        18381097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeney MM, Whorton MR, Howard TA, et al, &ldquo;Chemical and Functional Analysis of Hydroxyurea Oral Solutions,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2004, 26(3):179-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/15125610/pubmed\" id=\"15125610\" target=\"_blank\">",
"        15125610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maier-Redelsperger M, de Montalembert M, Flahault A, et al, &ldquo;Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell Patients. The French Study Group on Sickle Cell Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 91(12):4472-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/9616141/pubmed\" id=\"9616141\" target=\"_blank\">",
"        9616141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodgers GP, Dover GJ, Noguchi CT, et al, &ldquo;Hematologic Responses of Patients With Sickle Cell Disease to Treatment With Hydroxyurea,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 322(15):1037-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/1690857/pubmed\" id=\"1690857\" target=\"_blank\">",
"        1690857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodgers GP, Dover GJ, Uyesaka N, et al, &ldquo;Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(2):73-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/ 7677965 /pubmed\" id=\" 7677965 \" target=\"_blank\">",
"        7677965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez GI, Kuhn JG, Weiss GR, et al, \"A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 91(5):1533-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/9473217/pubmed\" id=\"9473217\" target=\"_blank\">",
"        9473217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strouse JJ, Lanzkron S, Beach MC, et al, \"Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(6):1332-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/19047254/pubmed\" id=\"19047254\" target=\"_blank\">",
"        19047254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thornburg CD, Dixon N, Burgett S, et al, &ldquo;A Pilot Study of Hydroxyurea to Prevent Chronic Organ Damage in Young Children With Sickle Cell Anemia,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 52(5):609-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/19061213/pubmed\" id=\"19061213\" target=\"_blank\">",
"        19061213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang WC, Ware RE, Miller ST, et al, \"Hydroxycarbamide in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BABY HUG),\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2011, 377(9778):1663-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/21571150/pubmed\" id=\"21571150\" target=\"_blank\">",
"        21571150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang WC, Wynn LW, Rogers ZR, et al, &ldquo;A Two-Year Pilot Trial of Hydroxyurea in Very Young Children With Sickle Cell Anemia,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(6):790-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/11743503/pubmed\" id=\"11743503\" target=\"_blank\">",
"        11743503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ware RE, Despotovic JM, Mortier NA, et al, \"Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Hydroxyurea Treatment for Children With Sickle Cell Anemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(18):4985-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/21876119/pubmed\" id=\"21876119\" target=\"_blank\">",
"        21876119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimmerman SA, Schultz WH, Davis JS, et al, &ldquo;Sustained Long-Term Hematologic Efficacy of Hydroxyurea at Maximum Tolerated Dose in Children With Sickle Cell Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(6):2039-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/53/25431/abstract-text/14630791/pubmed\" id=\"14630791\" target=\"_blank\">",
"        14630791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13367 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25431=[""].join("\n");
var outline_f24_53_25431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708910\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181021\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181022\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047762\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047754\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180998\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180983\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047766\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047758\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047765\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181070\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181067\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047770\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047753\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047752\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299494\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180992\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180994\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181009\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047761\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047751\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047768\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047769\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047760\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047771\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528705\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=related_link\">",
"      Hydroxyurea: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/61/29653?source=related_link\">",
"      Hydroxyurea: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_53_25432="Antigen presenting cells";
var content_f24_53_25432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antigen presenting cells",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/53/25432/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25432/contributors\">",
"     Matthew E Call, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/53/25432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25432/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/53/25432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25432/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/53/25432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which an antigen triggers an adaptive immune response involves several steps. Potentially antigenic particles must be captured, processed, and presented in recognizable form to T cells with the appropriate concomitant signals. The cells that perform these functions are antigen presenting cells. Most nucleated cells express at least some of the major histocompatibility complex (MHC) proteins required to present antigens to T cells, a feature that endows all cells with the potential to become targets of the immune response when damaged or infected. However, only a select subset of hematopoietic lineage cells possesses the specialized machinery required to efficiently activate, or \"prime\" naive T cells and thereby initiate a new adaptive immune response. These cells are \"professional\" antigen presenting cells (APCs).",
"   </p>",
"   <p>",
"    The antigen processing and T cell priming functions of APCs, as well as clinical implications and applications of these cells, are presented in this topic review. The cellular interactions that form the basis of the cellular immune response and an overview of MHC structure and function are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Professional APCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three professional antigen presenting cells:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Macrophages",
"     </li>",
"     <li>",
"      Dendritic cells",
"     </li>",
"     <li>",
"      B lymphocytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MAJOR FUNCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;APCs perform four major functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They constantly sample the environment, both intracellular and extracellular, for potentially antigenic molecules.",
"     </li>",
"     <li>",
"      They contain specialized intracellular machinery to break down these molecules and particles and present components of them on the cell surface in a form recognizable to T lymphocytes.",
"     </li>",
"     <li>",
"      They shuttle antigens from tissues to the sites of lymphocyte priming, which are the peripheral lymphoid organs (ie, lymph nodes, Peyer's patches in the intestinal wall, tonsils and adenoids, appendix, and spleen).",
"     </li>",
"     <li>",
"      They provide critical accessory signals, without which T cells cannot become fully activated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monitoring the intracellular environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen processing and presentation is an ongoing process in most normal cells of the body. As old or malfunctioning biomolecules are recycled through specific cellular pathways, an ever-changing pool of molecular fragments is generated. If the cell is infected by a pathogen that replicates within the cell cytoplasm, the foreign proteins of the invader are also processed and presented along the same pathways, in parallel with self-proteins. Thus, self-peptides are constantly presented alongside non-self peptides. The ability of T cells to discriminate between the two is not intrinsic to the T cell itself, but rather is enforced through a complex network of regulatory mechanisms that are active from the earliest stages of thymocyte development. These mechanisms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of autoimmunity\", section on 'Pathogenetic mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The processing and presentation of intracellular antigens is principally MHC I restricted (",
"    <a class=\"graphic graphic_figure graphicRef76821 \" href=\"UTD.htm?9/9/9363\">",
"     figure 1",
"    </a>",
"    ). MHC I molecules are expressed by most nucleated cells, although professional APCs express significantly higher levels of MHC I. The antigenic peptide:MHC I complexes, assembled in the endoplasmic reticulum (ER), are the priming ligands for CD8+ (cytotoxic) T cell responses. Recognition of the T cell by these complexes under appropriate conditions leads to the destruction of cells harboring intracellular infectious agents.",
"   </p>",
"   <p>",
"    Antigens from viruses and other pathogens that replicate within the host cell cytoplasm, such as the bacterium Listeria, can also be shed from the cell. Under these conditions, the antigens may be taken up as particles, or whole damaged cells may be phagocytosed, and the antigens then processed by the MHC II pathway. This pathway is important for inducing CD4+ T cell responses to antigens from intracellular pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Antigen acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MHC I antigen processing pathway begins with cellular proteins that are misfolded, damaged, or targeted by regulatory mechanisms for destruction. During the course of intracellular viral or bacterial replication, proteins of microbial origin are also processed through this pathway. These proteins are degraded by the proteasome, a large, barrel-shaped, multicatalytic protease found within the cytosol.",
"   </p>",
"   <p>",
"    The peptide products released from the proteasome exhibit extensive heterogeneity, and only a small fraction of these peptides will bind to MHC I molecules. A highly specialized heterodimeric protein in the ER membrane, termed the TAP complex (for",
"    <strong>",
"     t",
"    </strong>",
"    ransporter associated with",
"    <strong>",
"     a",
"    </strong>",
"    ntigen",
"    <strong>",
"     p",
"    </strong>",
"    rocessing), imports a subset of these peptide products from the cytosol into the ER lumen. Inside the ER, the peptides can be sampled by newly synthesized MHC I molecules (",
"    <a class=\"graphic graphic_figure graphicRef76821 \" href=\"UTD.htm?9/9/9363\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Loading of MHC I molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newly synthesized polymorphic MHC I heavy chains are assembled in association with an invariant polypeptide, termed &szlig;2-microglobulin. Peptide binding plays an active role in the initial assembly of the molecule, as MHC I molecules with no bound peptide are inherently unstable, and will not assemble well until a peptide is bound. An important adaptor protein, tapasin, retains newly synthesized MHC I molecules adjacent to the TAP complex, where the local concentration of imported peptides is high, until they stably bind peptide. Only a relatively small subset of the peptides imported by the TAP complex will bind MHC I molecules, although ER-resident peptidases trim the peptides further to generate forms with improved affinity for MHC I [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MHC I-binding peptides are limited in size (typically 8 to 10 amino acid residues in length), due to distinct structural features of the MHC I peptide binding cleft. This cleft is closed at both ends [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/3\">",
"     3",
"    </a>",
"    ]. Peptides are anchored into the MHC I molecule by their amino- and carboxy-termini, as well as by interior anchor residues. These anchor residues vary somewhat in position among different MHC I molecules, but often include two hydrophobic sidechains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;MHC I restricted antigen processing is ongoing in most nucleated cells, as mentioned previously. However, activation of the cell by exposure to microbes or inflammatory cytokines, particularly interferon-gamma (IFN-gamma), enhances the process through a variety of mechanisms. Three proteasome catalytic subunits, LMP2, LMP7, and MECL-1, are expressed in response to IFN-gamma and replace constitutive subunits of the normal cellular proteasome. Addition of these inducible subunits changes the activity of the proteasome to increase the proportion of peptide products suitable for binding to MHC I molecules. In addition to these effects on proteasome activity, IFN-gamma activated cells express higher levels of the TAP gene products, MHC I, and costimulatory molecules.",
"   </p>",
"   <p>",
"    Activated professional APCs also express especially high levels of MHC I molecules. Together, these features confer upon professional APCs the unique ability to prime cellular (CTL) immune responses in the setting of an infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Monitoring of the extracellular environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;APCs monitor the extracellular environment by constantly taking up material from their surroundings and processing it principally through the MHC II-dependent antigen processing pathway (",
"    <a class=\"graphic graphic_figure graphicRef65035 \" href=\"UTD.htm?21/51/22323\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Proper assembly and presentation of antigenic peptide:MHC II complexes is crucial for priming CD4+ (helper) T cell responses. These immune responses are directed toward extracellular bacteria, allergens, and particulate antigens shed by larger pathogens, such as parasitic worms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Antigen uptake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue-resident macrophages and dendritic cells are the primary cells that collect and process antigen from extracellular sources. Material is brought into the cell through phagocytosis, macropinocytosis, and receptor-mediated endocytosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phagocytosis of large molecules is principally carried out by macrophages. Dendritic cells also internalize large particulate antigens.",
"     </li>",
"     <li>",
"      Macropinocytosis, or the uptake of soluble antigens suspended in the extracellular fluid, is performed by immature dendritic cells, such as epidermal Langerhans' cells.",
"     </li>",
"     <li>",
"      Receptor-mediated endocytosis is performed by macrophages and dendritic cells through a variety of cell surface molecules. These include antibody Fc receptors and complement receptors that bind bacteria and other large particles that have been coated (opsonized) with antibody and complement components. B lymphocytes accomplish receptor-mediated endocytosis through the action of surface immunoglobulin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"       \"Regulators and receptors of the complement system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link\">",
"       \"Neutrophil functions other than movement\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Receptor-mediated endocytosis is particularly important in secondary immune responses. High serum levels of specific opsonizing and complement-fixing antibodies are present in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antigen processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteins and particles internalized by any of the mechanisms previously mentioned are delivered to endosomes and lysosomes. Within the endocytic compartment, the proteins are degraded to peptides and loaded onto the major histocompatibility class II (MHC II) proteins (",
"    <a class=\"graphic graphic_figure graphicRef65035 \" href=\"UTD.htm?21/51/22323\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The environment of the",
"    <span class=\"nowrap\">",
"     endosomal/lysosomal",
"    </span>",
"    compartment provides conditions that facilitate highly efficient breakdown of protein antigens. The progressive acidification of vesicles along the endosomal pathway (reaching a pH of 4.5 to 5.0) is crucial for this process. The drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , which inhibits lysosomal acidification, is a potent inhibitor of MHC II-restricted antigen presentation.",
"   </p>",
"   <p>",
"    The cysteine and aspartyl proteases of the cathepsin family have specific roles in the MHC II-restricted pathway of antigen processing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These enzymes are activated at low pH, and are required for processing of many protein antigens. Cathepsins also play a central role in processing of nascent MHC II proteins to form peptide-receptive MHC II molecules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Loading of MHC II molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;MHC II alpha-beta heterodimers are assembled in the endoplasmic reticulum (ER), in complex with the invariant chain polypeptide (Ii) (",
"    <a class=\"graphic graphic_figure graphicRef65035 \" href=\"UTD.htm?21/51/22323\">",
"     figure 2",
"    </a>",
"    ). The invariant chain polypeptide self-associates as a trimer, resulting in a (MHC II)3:Ii3 complex. The invariant chain serves two functions in this complex: it occludes the peptide binding cleft, thereby preventing ER resident peptides from binding, and it directs the MHC II:Ii complex to the endocytic pathway upon exit from the ER, via a targeting signal in its cytoplasmic tail [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon reaching the endocytic compartment, the peptide-binding cleft must be made available to peptides of extracellular origin. To this end, the invariant chain is degraded by some of the same machinery that degrades extracellular protein antigens. This degradation proceeds in a stepwise fashion with identifiable intermediates, and specific cathepsin family members are required for the final processing steps. Tight regulation of the enzymes performing the key steps in this degradative pathway may represent an important point of control over MHC II-restricted antigen presentation in APCs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/4\">",
"     4",
"    </a>",
"    ]. The last portion of the invariant chain remaining associated with the MHC II molecule is a short peptide termed CLIP (for",
"    <strong>",
"     cl",
"    </strong>",
"    ass II-associated",
"    <strong>",
"     i",
"    </strong>",
"    nvariant-chain",
"    <strong>",
"     p",
"    </strong>",
"    eptide), which occupies the peptide binding cleft (",
"    <a class=\"graphic graphic_figure graphicRef65035 \" href=\"UTD.htm?21/51/22323\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subsequent exchange of CLIP for peptides generated in the endosomal compartment is facilitated both by the acidic pH and by an MHC II-like molecule, the DM molecule. This molecule is a product of the HLA-DM locus, and does not itself bind peptides. Instead, it catalyzes the displacement of CLIP from the peptide binding cleft of MHC II molecules.",
"   </p>",
"   <p>",
"    Stability of the peptide:MHC II complex at the cell surface, as measured by the half-life of the complex, is a critical determinant in the ability of a particular peptide to elicit an immune response. In this respect, it is important that DM not only facilitates the displacement of the CLIP peptide, but also continually displaces weakly binding peptides, resulting in a dynamic equilibrium where the peptide:MHC II complexes eventually transported to the cell surface are enriched for those with the longest half-lives [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/8\">",
"     8",
"    </a>",
"    ]. While peptide dissociation is favored by low pH and the activity of DM in the endosomal compartment, peptide:MHC II complexes have extraordinarily long half-lives at neutral pH and in the absence of DM, which are the conditions found at the cell surface.",
"   </p>",
"   <p>",
"    The MHC II molecules contain structural features that facilitate the formation of long-lived peptide:MHC complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/9\">",
"     9",
"    </a>",
"    ]. Peptides are anchored deeply in the peptide-binding groove, and an extensive hydrogen-bonding network between the peptide backbone and the amino acid residues lining the groove contributes considerably to their stability. In addition, MHC II molecules contain four to five pockets that accommodate prominent amino acid sidechains from the peptide. The ends of the MHC II peptide-binding groove are open, allowing peptides of varying lengths to bind. This is a major point of contrast with MHC class I (MHC I) molecules, in which the ends are enclosed, and MHC I-bound peptides are restricted in length (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Loading of MHC I molecules'",
"    </a>",
"    above). A brief review of the biosynthesis and processing of MHC molecules can also be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While these features allow a large number of peptide sequences to bind MHC II molecules, the selectivity enforced by the size, shape, and biochemical nature of the peptide-binding grooves of different MHC II molecules provides a potential structural explanation for genetic associations of autoimmune disease with the expression of particular MHC II alleles. Most autoimmune diseases show strongest genetic linkage to alleles of MHC II genes, suggesting that antigen presentation to CD4+ T cells may play an important role in development of autoimmune disease. The association of disease with one MHC II allele but not another may be a reflection of their effects on T cell repertoire selection during development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their differing abilities to bind and present specific peptide epitopes from important antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=see_link\">",
"     \"Overview of autoimmunity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expression of MHC II molecules is largely restricted to macrophages, dendritic cells, and B cells, which represents an important way in which the presentation of antigen is regulated.",
"   </p>",
"   <p>",
"    A striking example of regulatory control of the MHC II-restricted antigen-processing pathway is seen during dendritic cell maturation. Although immature DCs in the tissues are exceptionally adept at antigen uptake, they process and present those antigens rather poorly. This is at least partly due to regulation at the level of processing of newly synthesized MHC II:Ii complexes. Immature DCs appear to retain an intracellular store of incompletely processed MHC II:Ii complexes, which are poised to enter the last stage of processing where they become receptive to peptides from exogenously derived proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/10\">",
"     10",
"    </a>",
"    ]. They consequently express very low levels of peptide:MHC II at the cell surface. In addition, immature DC express very low surface levels of costimulatory molecules and display a chemokine receptor profile that does not direct homing to lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'T cell priming by APCs'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dendritic cell maturation is induced by exposure to inflammatory stimuli such as lipopolysaccharides, double-stranded RNA, and other microbial products, mostly detected through members of the Toll-like receptor (TLR) family, or cytokines produced early in the immune response to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/12\">",
"     12",
"    </a>",
"    ]. These stimuli induce increased MHC II and HLA-DM expression and upregulate costimulatory molecules. The fate of antigens derived from the extracellular space can be regulated by TLR activation at the level of individual endosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/13\">",
"     13",
"    </a>",
"    ]. Such a mechanism may serve to link each phagocytosed particle directly to information about its microbial (or non-microbial) source, thereby providing a fine distinction between antigens to be processed by immunogenic versus non-immunogenic pathways within a single APC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The maturing DC ceases antigen uptake, but exhibits a burst of antigen processing activity and MHC II peptide loading, and consequently expresses a wave of new peptide:MHC II at the cell surface. Simultaneously, there is a concomitant increase in expression of costimulatory and adhesion molecules, transforming the maturing dendritic cell into a potent T cell activator. Maturing DCs acquire a new chemokine receptor profile that facilitates homing to lymph nodes, and subsequently migrate out of the tissues and into the lymphatics, where they will lodge in the draining lymph node to be sampled by circulating T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/14\">",
"     14",
"    </a>",
"    ]. In this manner, the mature DC delivers a \"snapshot\" of the antigenic environment from the point of exposure to the point of contact with large numbers of T cells in a strongly activating context.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CROSS-PRESENTATION PATHWAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein antigens entering an APC via the endocytic compartment are, as previously described, generally processed through the MHC II-restricted pathway and presented to CD4+ T cells. Conversely, MHC I-bound peptides presented to CD8+ T cells are derived primarily from proteins synthesized within the cell's own cytosol. This segregation of pathways for exogenous versus endogenous antigens plays an important role in regulating immune responses. For example, it prevents the cytotoxic T lymphocyte (CTL) killing of healthy cells that have been exposed to viral or bacterial antigens, but are not actually infected.",
"   </p>",
"   <p>",
"    However, exogenous antigens are sometimes found in association with MHC I molecules, a phenomenon that has been termed \"cross-presentation.\" The priming of T cells in this manner and the generation of CTL responses to exogenously derived antigens are called cross-priming. Examples include CTL responses to allogeneic transplanted cells, tumor-associated antigens, viruses that do not infect APCs, and bacteria or parasites that do not enter the cytosol [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/15\">",
"     15",
"    </a>",
"    ]. Cross presentations appear to be performed largely by dendritic cells and macrophages. The cellular and molecular pathways underlying this phenomenon are active areas of research. Studies with model antigens demonstrated that proteasomal degradation and TAP-dependent peptide translocation are required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], raising the interesting question of how antigens from the endosomal compartment gain access to the cytosolic protein processing machinery.",
"   </p>",
"   <p>",
"    A novel endocytic pathway may be operative in professional APCs and could be a primary mechanism for their unique ability to cross-present exogenous antigen on MHC I molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Phagocytic cells take up extracellular material via invaginations of the plasma membrane, which seal off to create new intracellular compartments called endosomes or phagosomes. Normally these fuse with acidic, protease-containing lysosomes to create a compartment (the phagolysosome) that is specialized for protein breakdown and contains elements of the MHC II loading pathway.",
"   </p>",
"   <p>",
"    However, in macrophages and dendritic cells, an early phagosomal compartment may exist that contains both internalized antigens and ER-derived components such as the",
"    <span class=\"nowrap\">",
"     TAP1/2",
"    </span>",
"    heterodimer, the Sec61 protein translocation channel, chaperone proteins calnexin, calreticulin and ERp57, as well as nascent MHC I molecules. Images of antigen-fed cells obtained by fluorescence and electron microscopy suggest that this hybrid compartment forms by direct donation of ER membrane to the newly formed phagosome. Importantly, this compartment could provide internalized protein antigen with a passage to the cytosol via the Sec61 complex. This protein complex forms a channel that is the site of entry into the ER for membrane-anchored and secreted proteins, and also functions to remove misfolded ER proteins for cytosolic degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/20\">",
"     20",
"    </a>",
"    ]. Normally confined to the ER, its presence in the endosomal compartment suggests a model whereby exogenous protein antigen could be transferred to the cytosol via the Sec61 channel, degraded by the proteasome, and the resulting peptides returned to the phagosome by the TAP transporter and loaded onto nascent MHC I molecules. The observation that proteasomes may associate with the cytosolic face of the phagosomal membrane suggests that this hybrid compartment could be competent to achieve all steps of antigen processing and loading locally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the path by which the newly formed peptide:MHC I complexes reach the cell surface remains unclear.",
"   </p>",
"   <p>",
"    Another group of studies suggests that receptor-mediated endocytosis may be a critical point of regulation in which particular receptors dictate the intracellular pathway taken by internalized antigen, and ultimately determine the mode of peptide presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In experiments using the model soluble antigen ovalbumin (OVA), mannose-receptor (MR)-deficient cells were incapable of cross-presenting OVA-derived peptides to CD8+ T cells. MR-mediated endocytosis was shown to shunt the antigen into an intracellular compartment that was distinct from the pathway taken by OVA internalized via bulk pinocytosis. This compartment did not intersect with the endosomal-lysosomal pathway where MHC II molecules are encountered by processed antigen, but rather contained MHC I molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clearly, the view of antigen presentation as two topologically segregated processes handling exogenous versus endogenous antigens is not sufficient to explain how APCs are able to cross-prime CTL responses to antigens acquired from the extracellular spaces. Yet most pathogens do not directly access the cytosol of professional APCs as part of their life cycle. The potential cross-presentation pathways described above remain controversial, and research in this area is at a relatively early stage. Nonetheless, these studies provide instructive examples of how a regulated intersection of the two antigen presentation pathways could allow exogenous antigen access to the cytosol in a subset of APCs. A detailed characterization of cross-presentation pathways is likely to aid in the development of a new generation of vaccines designed to elicit lasting cellular immunity to targets that require CTL activity, such as HIV and other pathogens, as well as tumor antigens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     T CELL PRIMING BY APCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an activated APC displaying high levels of MHC I, MHC II, costimulatory and adhesion molecules, migrates out of tissues and lodges in the peripheral lymphoid organs, it is sampled by circulating T cells. Naive T cells recirculate through peripheral lymphoid tissues in a highly organized fashion through a series of cell-cell contacts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The productive interaction of a CD4+ T cell with an APC bearing the appropriate peptide:MHC II complex, or a CD8+ T cell with one bearing the appropriate peptide:MHC I complex, is the result of multiple stages of adhesion contacts and extensive cell surface reorganization by both cells.",
"   </p>",
"   <p>",
"    Initial contact is mediated by large adhesion molecules that extend a considerable distance from the cell surface, such as the T cell integrin LFA-1 and its ligand ICAM-1 on APCs. These interactions are initially transient, but conformational changes in integrins signaled by T cell receptor (TCR) engagement strengthen the interaction to induce a firm adhesion between the cell membranes. Adaptor proteins anchoring cell surface molecules to the cytoskeleton then transmit actin reorganizations to the cell surface, creating a specialized focal contact point between cells where signaling and adhesion molecules become concentrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large cell surface molecules are actively excluded from the focal point, allowing the smaller peptide:MHC and TCR proteins to interact extensively in a region of close membrane apposition. This highly organized contact point has been termed the \"immunological synapse,\" and its formation and duration facilitate a polarized, bidirectional exchange of membrane and soluble signals between the APC and the T cell [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/24\">",
"     24",
"    </a>",
"    ]. The combination of TCR engagement by the appropriate peptide:MHC complex and T cell surface CD28 with",
"    <span class=\"nowrap\">",
"     CD80/CD86",
"    </span>",
"    molecules on the APC results in T cell entry into the cell cycle and development into effector CD4+ or CD8+ T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LIPID ANTIGENS AND CD1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid and glycolipid antigens are presented by another class of MHC-like molecules, the CD 1 family [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/25\">",
"     25",
"    </a>",
"    ]. Like MHC, CD1 molecules are found on macrophages, dendritic cells, and B cells. The CD1 family of molecules is not encoded in the MHC gene cluster, although these proteins resemble an MHC I molecule in their general fold, and, like MHC I heavy chains, they assemble with &szlig;2-microglobulin. The most dramatic departure from MHC I structure in the CD1 molecules is in the antigen binding cleft, which is deep and hydrophobic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/26\">",
"     26",
"    </a>",
"    ]. This structure is consistent with observations that CD1 molecules bind antigens composed of highly hydrophobic branched or dual acyl chains with hydrophilic head groups. The structure also provides some insight into how the CD1 molecule may bind the acyl tails of lipids in two prominent hydrophobic pockets, leaving the polar head group positioned for recognition by CD1-restricted T cell receptors.",
"   </p>",
"   <p>",
"    CD1 molecules traffic in a similar fashion to MHC II molecules due to an endosomal targeting motif in the cytoplasmic tail, suggesting that they acquire antigen largely from the endocytic compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD1 molecules present lipid- and glycolipid-based antigens, such as those from mycobacterial cell wall components. Lipids are synthesized through complex biochemical pathways with little potential for spontaneous variation. Therefore, this lipid-based antigen presentation mechanism may represent an important evolutionary feature of the immune system for detecting antigens that are not easily altered by pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COOPERATION BETWEEN T AND B CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen presentation by B cells plays a critical role in the development of a strong humoral immune response. Protein antigens taken up by B cell receptor-mediated endocytosis are processed through the MHC II-restricted pathway, and peptides derived from them are presented to CD4+ helper T cells. In a phenomenon termed linked recognition, the B cell must then encounter a CD4+ helper T cell that has been primed to the same antigen (but usually not the same epitope). Due to their expression of high levels of MHC II and costimulatory molecules of the B7 family (CD80 and CD86), B cells can also be the priming APC for T helper cells. B cells conjugated to activated helper T cells then establish germinal centers in the spleen and lymph nodes, where focused cell surface signals and polarized cytokine secretion by the activated helper T cell induce B cell expansion, affinity maturation, and immunoglobulin isotype-switching. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL RELEVANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the functions and regulation of antigen presenting cells is critical to understanding normal immune responses as well as the pathogenesis underlying infections, autoimmunity, allergic responses,",
"    <span class=\"nowrap\">",
"     tissue/organ",
"    </span>",
"    transplant rejection, and the therapeutic immune response to tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the functions of APC can be manipulated to specific therapeutic ends. As examples, vaccination takes advantage of the natural role of APCs, while biologic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    interfere with certain functions of APCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diseases of APCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bare lymphocyte syndromes I and II are immunodeficiency disorders that arise from abnormalities in the expression of MHC. These diseases are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=see_link\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     APC-based therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapies that manipulate APC function include vaccines and certain biologic therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice of inoculating individuals with attenuated or killed bacteria and viruses began over two centuries ago based on the empirical observation that this could induce protective immunity to some infectious agents. While this idea developed in the absence of any real knowledge of the underlying mechanisms of immunity, the modern understanding of molecular events involved in antigen presentation and the development of cellular and humoral immune responses has fostered dramatically different ideas about vaccine development. In addition to whole-organism approaches, which have worked well for some pathogens, but have not yielded solutions for some of the world's most important human infections (HIV, malaria, tuberculosis), the possibilities of recombinant purified antigens and novel delivery systems are now being explored.",
"   </p>",
"   <p>",
"    The first recombinant subunit vaccine, the hepatitis B surface antigen vaccine, was based on a single purified viral protein produced in yeast [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/29\">",
"     29",
"    </a>",
"    ], and has had great success in widespread usage. This vaccine, like most currently in use, works by inducing a strong CD4+ T cell and antibody response when processed by the MHC II-restricted antigen processing pathway. Ongoing research into the mechanisms of MHC I-restricted antigen presentation and cross-presentation pathways opens the additional possibility of inducing targeted CD8+ T cell responses to specific antigens using vaccination strategies that deliver antigen directly into specialized antigen-processing pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New vaccines will also benefit from a new generation of synthetic adjuvants based on a molecular understanding of how the Toll family of pattern recognition receptors initiates innate immune responses and activates APCs to set the stage for long-lasting adaptive immunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Novel strategies are being developed to optimize antigen delivery based on specific knowledge of how each pathogen interfaces with the immune system, and therefore provide promising possibilities for the safe and effective induction of strong antibody and cell-mediated protective immunity to human pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     APC-based cancer immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potent T cell priming properties of professional APCs have been exploited to develop experimental cell-based therapies for various cancers. Human dendritic cells can be cultured from peripheral blood samples, loaded with potential tumor antigens and activated in vitro, then returned to a patient in an autologous transplant. Both the type of activating stimulus used and the route of antigen entry into the processing pathways are critical parameters, and various antigen-delivery and APC activating protocols are undergoing testing. Trials in animals, as well as in human patients, have yielded promising preliminary results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25432/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Agents that block APC function",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    is a biologic agent that blocks costimulation by APCs. It is a soluble fusion protein comprising CTLA-4 and the Fc portion of IgG1 (CTLA4-Ig). Abatacept prevents CD28 from binding to its counter-receptor,",
"    <span class=\"nowrap\">",
"     CD80/CD86,",
"    </span>",
"    due to its higher affinity for",
"    <span class=\"nowrap\">",
"     CD80/CD86.",
"    </span>",
"    It has been approved for use in severe rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=see_link&amp;anchor=H5#H5\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Abatacept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is an anti-CD20 monoclonal antibody that interferes with the ability of B cells to function as APCs. CD20 is a B lymphocyte-specific molecule, which is expressed on B cells beginning at the pre-B cell stage and is normally lost as B cells differentiate into plasma cells. Rituximab causes depletion of B cells expressing CD20, thus interfering their antigen presenting functions while sparing the antibody producing function of plasma cells. It is approved for use in severe RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     APC functions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To stimulate an adaptive immune response, an antigen must be processed and presented in recognizable form to T cells with the appropriate concomitant signals. The cells that perform these functions are antigen presenting cells (APCs). The primary APCs are macrophages, dendritic cells, and B lymphocytes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      APCs have four primary functions (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Major functions'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Monitoring the intracellular and extracellular environments",
"     </li>",
"     <li>",
"      Processing antigens through specific pathways",
"     </li>",
"     <li>",
"      Transporting antigens from tissues to the peripheral lymphoid organs for interaction with T cells, and",
"     </li>",
"     <li>",
"      Providing activating signals to T cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antigen processing and presentation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracellular protein antigens are processed and presented in association with MHC I molecules (",
"      <a class=\"graphic graphic_figure graphicRef76821 \" href=\"UTD.htm?9/9/9363\">",
"       figure 1",
"      </a>",
"      ). APCs presenting antigens processed in this manner stimulate CD8+ cytotoxic T cell responses, resulting in killing of cells that have been infected with viruses or other intracellular pathogens. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Monitoring the intracellular environment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extracellular protein antigens are processed and presented in association with MHC II molecules (",
"      <a class=\"graphic graphic_figure graphicRef65035 \" href=\"UTD.htm?21/51/22323\">",
"       figure 2",
"      </a>",
"      ). APCs presenting antigens processed via this pathway activate CD4+ T helper cells, leading to specific antibody production and a humoral immune response. This type of response is important in defense against extracellular bacteria, parasites, and in allergic disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Monitoring of the extracellular environment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lipid and glycolipid antigens, such as those from mycobacteria, are presented by MHC-like molecules in the CD1 family. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lipid antigens and CD1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Activated APCs migrate out of tissues to peripheral lymphoid organs, where they interact with circulating T cells. If the presented antigen is recognized by a T cell, and appropriate costimulatory signals are present, that T cell divides and gives rise to a population of T cells that are specific to the antigen in question. These cells then disperse and effect an immune response directed against that antigen. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'T cell priming by APCs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/1\">",
"      Pamer E, Cresswell P. Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol 1998; 16:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/2\">",
"      Craiu A, Akopian T, Goldberg A, Rock KL. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci U S A 1997; 94:10850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/3\">",
"      Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/4\">",
"      Villadangos JA, Ploegh HL. Proteolysis in MHC class II antigen presentation: who's in charge? Immunity 2000; 12:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/5\">",
"      Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003; 3:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/6\">",
"      Cresswell P. Invariant chain structure and MHC class II function. Cell 1996; 84:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/7\">",
"      Riberdy JM, Newcomb JR, Surman MJ, et al. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992; 360:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/8\">",
"      Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996; 274:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/9\">",
"      Stern LJ, Brown JH, Jardetzky TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/10\">",
"      Inaba K, Turley S, Iyoda T, et al. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 2000; 191:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/11\">",
"      Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/12\">",
"      Beutler B. Toll-like receptors: how they work and what they do. Curr Opin Hematol 2002; 9:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/13\">",
"      Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/14\">",
"      von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003; 3:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/15\">",
"      Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996; 17:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/16\">",
"      Huang AY, Bruce AT, Pardoll DM, Levitsky HI. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996; 4:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/17\">",
"      Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/18\">",
"      Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004; 5:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/19\">",
"      Heath WR, Belz GT, Behrens GM, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/20\">",
"      Plemper RK, Wolf DH. Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem Sci 1999; 24:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/21\">",
"      Houde M, Bertholet S, Gagnon E, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003; 425:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/22\">",
"      Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 2006; 176:6770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/23\">",
"      Burgdorf S, Kautz A, B&ouml;hnert V, et al. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007; 316:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/24\">",
"      Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/25\">",
"      Porcelli SA, Segelke BW, Sugita M, et al. The CD1 family of lipid antigen-presenting molecules. Immunol Today 1998; 19:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/26\">",
"      Zeng Z, Casta&ntilde;o AR, Segelke BW, et al. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 1997; 277:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/27\">",
"      Jayawardena-Wolf J, Bendelac A. CD1 and lipid antigens: intracellular pathways for antigen presentation. Curr Opin Immunol 2001; 13:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/28\">",
"      Zhang Y, Shlomchik WD, Joe G, et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol 2002; 169:7111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/29\">",
"      Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/30\">",
"      Liljeqvist S, St&aring;hl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol 1999; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25432/abstract/31\">",
"      Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3982 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25432=[""].join("\n");
var outline_f24_53_25432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Professional APCs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MAJOR FUNCTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monitoring the intracellular environment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Antigen acquisition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Loading of MHC I molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Regulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Monitoring of the extracellular environment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Antigen uptake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antigen processing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Loading of MHC II molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CROSS-PRESENTATION PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      T CELL PRIMING BY APCs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LIPID ANTIGENS AND CD1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COOPERATION BETWEEN T AND B CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL RELEVANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diseases of APCs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      APC-based therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      APC-based cancer immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Agents that block APC function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      APC functions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antigen processing and presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3982|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/9/9363\" title=\"figure 1\">",
"      MHC I antigen processing and presentation pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/51/22323\" title=\"figure 2\">",
"      MHC II ag process present",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=related_link\">",
"      CD3/T cell receptor complex disorders causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=related_link\">",
"      Overview of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_53_25433="MSU crystals in acute gout";
var content_f24_53_25433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F85631%7ERHEUM%2F85632%7ERHEUM%2F85633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F85631%7ERHEUM%2F85632%7ERHEUM%2F85633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Monosodium urate crystals",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 335px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFPAfMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDy6e62Pjg4qSC4MhG1d3Y1Qu7XcCwJq3pymMAt0x1NedK1j9NpynzWZfjJUMrLyegJzihRwAQoHc96Y7qGJ7UwOPMGxSfbFSdLlrZE5ICnJAPb3pNwGGPINRKpE22bkt09qlmIMixKOFGS1HQL7tkY4OOcGnNtZcYwKMckA/jTwoK5J780N9gSYjMAOSAD1J6U2cCAgswaXqFHNSugMZjIGDyKRMID5gGPXvSY0rFeFWd2YDYH++B/WnqAihRnAFSI3OQMK3Xio4SGnLNnyiCKFqJKz8xURZnzuYIOvpTLm5byf9GIEcZ496W5kSO1CxKShOD9KaUW7MNukIRFOdw70LVq4pNxTjF6liffJaRbyAznIFICTwACRxS3TB7sJHkRxDFOwoZWHpzSNHv6DCWwADyKa5U4DKMnqaeoGGB60Ky7eFBIouHkRhl80b8DtimOglR9wzF0JoinEkqqsYMobB3enrTbaFZre9ZWK88AHjNFtCIu7XW9xLUBINqk8HtU8pXy2wPlYYOe9VrctHBvKHHcd6jknNzIIoUZmJ5PQAe9Du2RzKEEW4IhFpihxkQZYDHXNS2sjz2ok8xY1f5SvoKhVXaO5kWYHauFjPfFUWP+gq0ZczyuAU7LS5bsp1HCKtsl99jUj+UBBjYOB701x86A8EtwKkl2rtG4EAc49aZErS3UfysQueaZVuiHO21JZGzhTio42d1Vi3yHoKLl1WEKWxlvmzRAAIwYmLKD09Ka1Qm/fsSJjuav6faLfXEcTnAcgcdaoqu48cN6VueD42k162jVSCJkAx35rGvJxg5JmkF321LfirRYdGupreCZn8sqPm68jpXLSoTJnPy46V2nxDkaTUL2cZ3edyD7DFcaTuwy4BNZYOTnSjJkp80I33siqCMH+I+9PQAEAdDTgikcetIVDZUFgR3FdVyUiUDb1JxTJrjyGBQY4yG7inR8YyS2BTJI3ullaTEaohJI7+gqXbqWk2ny7leK6upolWNFWPHJ9aSWOVowGjjZF5A7061ZGt+M++aeB820N0HSjlW1iE3ZSctStwi+ZBuAA+eNu30qScAIJocllHPuO4ptwCt3E27CuNjD+VTWnERRuMHBzSSsrMN3Zaf5ldJhZ/NtZrV/mBA+77U+586eNGt1BUnO48cVLBDI7XZDBLdRjaemTU0CIjCPdufHB7U1puLlcl2TAum7JcDYAD/tH2okVJEJ5we1OeLbIJfJ8x1Hy7umafHCfJ3ykLIedoqrlOLejKkaoF6Yc8ZNNFt5RJzls1dKgKGwOaaAxbgDDd6LkqCsivApKscVKp7sMDvUjRbWxkY9jTGIMecH6UF8ttGNOx4mZOStMQlhz+FOGFI8pTtPX2p7R7MFWHNFwsVwCACB0NQBY1vZdw2lyGU1ZnQZ4bjvUciROioXyQchj2oM2iRhkiklPlxszbRgZprm5gTorp2xUaQS3JT7QvlwrzsHJehDqNrRLUsW8JS1UfxEbj7ZppUY45Iq0RkEYwcdO2KgdR5hxxx+dJFONkhmCDuB59BTpF81f9ockChlH0J/WnR/Lg9CKZNr6EYg3/fHOKQW/l5BGVPFXFkBcgjB7CpRskjIAGR707kKmnqch4g0FDEZouvUgVw11AYpCuOK9hcoqMHYYI71yviLSIXXfbksTycDFa0qri7NaHiZvllOqueFlLt3PP8AFFX5LUK5BU8UV2c6PkXhaidj06dWMm0AYPXNSAoYwCOvGakBVhlyAegpBEpznIA5Brz7n6Wo9Y6gqJtIODSiZ8DagXFPQHjI470yUsjBY1J4zU3L2WgSOzTx5x7nvUjowmdkG6Miq8LrchmIwy9amExUkAYUfrT2YlJW12HgMDkpzjinhGZR+7JzzTYrh9p+XpSSy3EXC3EoU85CjAqow5tEZVcRGjHnlsAZgeVxzTnbLHC5zRFcbjtLox65IxU/nKxCIis3dV5IolCUd0OjiaVX4ZFSOMBt0pPH8NNkdn3K4CLjC4q81mwyWZVb0PWltY4izAqXY8fvOAPwrKVVJanTGi3otLlGMKdsZTcO5rQSIxqAoAXqcc4q08cESZmUMw4A+6KS61eJY3jWPZHjHyD+tY+0lL4UbKmqb95mIyeXeyZxtfkYqZyvGMmmzhLhAYmwAMA1X8qeNPnkjUHoWNdHRXOblabstGWnA4cYIPamiQBzhdox1qCExG4H2mfgcAL608HLOA3APH0pW1C7eoxmxcSCIbnkTGMUkQW20xlYnYT86jrmpVbdsAi2yIfv9yKJ5VgRpXA+g70+hNre8FuV+RowfKwDz1qTjc4ZvlPUAYzTEkV4w2wqevIxUcsrEBdueeKT6FXSVhZAcpJbqAc4JPpTljij+Y5LE5JHSq6yPKv7mM7l9ehqeBzJEwePy5Yz849adyEoy1f/AACUlQcYyB+tQzGRXV0kZRnpUkpVvlQc9c1Fcf6sEjFC3KnezG6gmbqE4LLkEj1qQNG17JLCjRow+52BqS5LBomBHAFKzKiMSvvxQDVpMGLbQAQDnqe9WdLvbyw1eOeGZQqjPH8LDoaqPLlEaLDZ5ANPLRxksM72HNS0mtQWrv2L2p6rLeSD7TJ5hYku3qTWY3lKGeOQ8HpTC3YjNSIgJPA+bj6URioqyG25aIcASg469DSMrcjnJ44qRYpotvyF09aR8r1BFUwSfUZyqbe4796rvGrQOJpGSXOcDoRU+7J/TNOKbmBbnHapfmO10UY4pIyZYFLI3VD2pwmLOjuDGVBBBHWrUysuXhfYw446UPJIQpcCbYMg4701ch04vR6FdCZ5kwmY0OfoamdI3LmVw0hOQF6ihFnIkXKqJDngdKfFCiHHVvWlYpd+/crRWgFuyrIzF33Nk9auYUuGCgFRxSMQGwFz7ilB+YqOlPfcqMFFWQF2VEZ2U7j0FSuBwRnLd6bbRxyTKGGFzya6bVNNisraKTcGkMfmMAc4z0FY1avJJR6s0pRT+LS5zJQDKjg1HtG0BScU5WEkeVHzdaTLMoBXpWxGj1G7APuZDeuacDuQED5h1HrTJZFjZQ5wD3p7gq3oCPzpiXkNicvCx8vaDxxQwwgHftQBGrKBkAjn2NI/yjn7valqLZahOA0AI9cGoREg/KpyARs6E85pqngB8ccY9aAkk3caVjK7ZD+GakQc/uzhR2pOC5wMjpTXB+5kqTzmmFrD2YLuGM+wppAKgtmhCQx568E+tOGSuOxOKWw9yPacgHBA5FBJ6kDNKIgoOWwSeKcFOcMRjFDZKVyMHCBiASvenhVE6yhyox8w7U5AoDBuhqNmV1wRjJoTuS4rqOlJ3YwCGFROwbdE6jB4FPfLLjuPWoSQeCcEdzTXYHuYs+jB5nZPuk8cUVtByB94/lRTuzF4am3fQtiISxAuNmOxFK4eM4KfKOhrQjmViGIHAxtNOvfIhtjOzhVBAC56n6Vp7Nt3Wxj9chTlyVFyvu9n8zOfMZUE9R+VNZQ2NuR2zSTJLNHkfKOuR6UQKxiZl5P61Mmm9NjtV3oyHCwhgg6/rRGTliQcVPCnmI7KvI7GmJkvlvujp71FtbEyVvQnhtJ5+Io2b3xgVauLZ7ezd57m3hZcfu87mP4UmnyQJHnUJruRGOBGh2irLazp9qpWxtY4Qf4iNzVEpSvaCbMLtv32o/O/4FO2s5bhcywYQfxP8orSjt7SNdqSeWxGCYuB+dY0l8bmTJnzg5+amRv5kz75Vx2GaTjVe8reh0R+r3ty3LNrbkyTi2uDmNyBlsn86dPeShmjtlhd1HLgd6rLbIGeRHwD1INOgg+zxssbZGea1SS6EuLl8LcX3TIhPI7q9xHISfQ5FK08Tl42bZkZAYVJKWWPC/ezSb96kSKDgUNp7otKUfd5vvRRdHtQj53QluR6VJfwLdRiSMh1TnbUkkZ8yISfNFu+YCoQ8dtqEskKt9lbgr6U07kNKKcZbP7x0SQSHgcj1pzEKwwuO2BUtxAscXn24LxN6dqbH8yrxnvmpvfU05OT3WIpIb14pSpkjAcEjrz1FO2kKSQuc96SVvLCOCCe6jvQHmxqBmjy4+nrUUUDS3XzNgjhVzSQRvdRefGdkYYg5PI/Cl0p43nunLN50QwmehqJXs7CUeaUeZb6l24CxKFiwoHHPXPrVSWRIg85G7sw9aZJLJcDe6FWX7wPSnSGM2jGQ8EdDShGysyqlTmdyVZSoWSBVMMoyPUH0psg3soI5JzRY7ltLV0TKANwew9adbIdrSP0B4Bq09fQmzkl5j5ijOwf7pwDjtTFjaMlkl+UjGDzQ08aMxRN5NP86ZVUiJDnnFA/db8wjMEEWVG5u5NRyJ5h3A89SKQvF5/71CrN0FPQRh/vkMfXoKA+LToRBSvODzUkkaeV85Iz6HmpXHlkkkcDv3pkQZlDM3J6CjUXLZ2YwQKu1Y551J6DdkU5IJUkYTzFxjODVhFQg5PI9at6fpomkDkMQ3f+tTKryq8mOFHW0UZ6W8jpuRCV7ADmklQrH5zNgDt3Nek3Ojf8I5oNveylftt+P3UBH+rj7sfevP7uUNK6AAjPU1y0MS6zbS0RUPZzi5xd1t8yhBOrxbghVWJxmpdhEbBeFNLMm9UQsoUdKi8g5AMvy12Cs1oOeTDIoP7w8DFI8f77YCWl/iPpTkkSNiIU3MOrmkSRVmCk4zkk9zQF+5KkOFIjyWHemoG25bGe9KXMvKZWMdu9Pih3naucnuewqdty9JPQaSVAMWPcmnfaWVfLWTIzknORSXcPlgINw3cgkdapX0sSrHHApEa9fVj6UK0tRTk6d76FmRl2OEz5hOeBQ7MsQIOG71TJmdgS+D2CjAFWEDnIfDCm7rUlNSGKRIWSRdwb86fCjwpteQumflz1FPEC7wzHaScqanjBmDIwAdfvAVolzRujGXuVLS+RCVBbHoM0ziP5iAy9SKmVSMqQM9qaFx2yB2NSjZrQjyGPmrwjevam/ew4wSD0qR0xGyhVYMc0gUhODlhQLW5FvDxsx4APSnFMhGDgoaCgcAg4Y9RQPkTBBUD1oYttHsLwXAZvl9KWLq3OeelNYByGPP0NLjGCOCaLXKJ7Rd4cTKBKD9zvj1pZlBbb3oWUoY5YnCzxnKswzn2PtULy3BLMwjdmOTtGMVTSktDCEqkJOMlddH+jEY4IOMimySA8FQcdDRvDDBDKe+aRiCAAMdqi1jXmTWhGxbII6U1iDwMA+pFSMhKcmmcBSO4ppktMUdKKTBPOKKdxWLEUzEHcpAx37VIsnmJtboPUdKiHyMwIJ96YZVRgMge9N+QJ6amnYj5wueDxirFyoRwAArCPOB9ayopWhuCpI2YyDnrV24ufNmCMucRY3VyVIP2ifQ7KUlyNPoyCR/IT7pMkhwMUBNoA2ZHc+lR3bHdAN2709qcZMcdN3eunpsYNe9Z9CUkdQO3FR4yOQOe2KSMsvBYMR3NLuUtj86aBpS3EMa7fuDgc8c0iRwyFPkAOME+9SZ2nI5JGAaqy3QgjfcqBQdpPqaOYiUI/aLUUETljHHtGOeeDVy1ksoQVmVipXPynnNc6l595QZTx98DAotLKe5YPLcMH/hYcAVSqStZ/icdTD0qjvTVm+2hoq7BWZiSC3A7gU/kxsCo2t0xVeK5PmNFc4E8f8Q4Ei+tSqDcSeVEUUE/K7dMVDbk7ndBcqUU7/mMublIVRWIbaO3Wo5Z8BV2RqDzgnqKrzQQQ6pMsmWVI/vg8FqjKqNm9d4A+8etJNWsjOUp3fN91/wDgF21mZd0cbq0Z5Kg1Og6hTWWBEzcAqT0YdQauRzswKTY81FyHHG4elD8jSErqzHBHckOQeehpygCUAqMdMU5dpUMo+U04fd5wBnNPUFFaFOcLbB2TcCxwI1/iNJFJG0ksbK8ZA+ZSuOanu186IhuNv3WFU7aKSOGSGe4d1zuXPUmnpYxestNictMluTIGaNjgAd6ZAFuoXZoyFRtoU8A1Ys4j5REzHd1wKlYvcyLFFyB97296V9TRxckpN/IYqNcTFlY4ACsBwAB2p07eY4jh5VeGou5EiUW0J5PLGmptjiHPTqfWixT00+8dGqI2F4Bp4ByOhpAQQClNO8duexpDSsDgbSHAIPT1BpqISnlyYdux9KcedpJ+Y9qNuW5Yj1xTuS4x3B+YVVxlkNSITwMAGgAkEAZ9zV7S7B7qZA6OSzBQoHJPoKic1BXZUYuT0LuiacbmRSI92TgDHU16n4f8PWulJLc6nLGsdsolnTOW9kqHStFi8M2UU97Io1iQZgt8/wCqz0Le/tWJ4rv44NPGnRO8hL+ddzN96SQ9voK8CvVnip8sNjinUli2qGHfuPd9+/y7eZzvjDXJtZ1K7vGYh2/1aZ/1aDoBXINHsKEylmPWrU80lzMQoJ7cDFQ+XtcDB3r1HtXtUKKpQUUd0uSPLTholoiNyGbA4PY0ICuBIcj1pzMsT/KMu3Q00yOp3SYIJwa2FotxcAdDkUydcxhkUcHnjtUzKN/A+WmGQu7pCAFAwc0DdkrApBUYIFSQlkLNuBAI5NRFFVRt57U//ZToBkVVk1Zji7O6Jp7p2t3EhG4dG9ayXBWeFWwdqlsj1NXQN2Ff5s1UmtFIYwsA8Z3Kh5z61MbRWhM4ufmxwLcnP/6qmiBII7Y4qolxHtCucN0NTpIW3CAbmAx7ClZkRmiWIExEgfKvAJNWXfBt5xxvGGHrVeBVTyhv3Jjn61NIAwKbiQrbgf6VcXbVDnTVSDjP+mWJ4wArxrnzDgMOxphTqH69GIq1Z3aRXJinh8yxlGZQv3lI6EGk1CyaGCNnkaWOTmORemPf3rb2ftFzx6Hn08XKhV9hX36PozLsgYriSzkO48tGx7inKhw2WAYHAqGTfIyW7gCdWzDL7elWrpGILDG9eTis5JdDspN8rXb+rfIikQOmFP70daVXcDbKAe2DT1+dFkjIzjmkZvMx5nyn1qFqzfzRC0cYbcMpikMYKkh2yOlSuSrHPzJ2NNlzsUxcnPIqpdidOxFhj1GD3pw3EHPQUkgbIyTxSYB3YbnGakYuTtOBmkXG4BjyelMyUXGeQabJLj5kGWp200JuluSAlSVPNMONwHenNISoJ4bHQUwFSuWOW9qWwXGneDjLflRUhU54P60UxezkSi4UD96PvU3y1cEHG08g0m0yrtAAPYU64icbUjxtA+Y1RF+ZXEEJU7uDjsalSWJJXRsl8ZGTUaM6SqXO5enSpnhUMZiMtjipauXG/wBkhRQpeSQ8sOPanxkEDbz9aDycYwMdMU12RcYBCnv6UD2JXBC5Bwc0oxICCwUd+KiD4kAwXX2p4KhypB2E9Kfa5W+4t8reQpSWNeQmM9azJFzcrC6j93x8pz+J96uX6tHbK4X5UYNnvis+6xFcrKjhllO5Wzyc1SlG+i/Hqc9Zd/L7v+HNJUzhFAAqa2OHlhAAGNwHpUMON2eamtCFlnuGJ4XaOM5rBu6Z0wSTTRnON8s8wRnEUeM+mT0p+sXUaW8UcLLESoDfSozITdTxxOAskeG56HtUNva5kDSIZOcAGtFtqcsm7tQW+/3/AORDZ7zIwSeOX+EIxxmtWDyJAIyvkv0wxyCfY1HdWFvKwZrby3xjK9apGGazkMch82zY4yTytZtuRpCDpaNfP+tvxNC4tjHkAGoolJuI1/2WDflTre8MRa3lzKF5jb+8Kj8x9sx8o+bJhXcfdRfT604psJygmpIu2LJLaiFsKf4WNIytExSX6Z9aRoAIkQ4yoyMVLbSC5jaGZcyJ0+laM0hsoPfoIgRYdi5yD3oVF3AkAZ6VEWbaWUbo1OCR1FCzq5VV3En0oJ5oq1yc7sKckA0+OaO3jdFRhMeSPUetOTEYQyYaQ8kdgtRXbG53uvysPuHHT2+lTB3dmXVvBc0NyJU2u7N8zNyD7UKNz5Ixn1pqGTyxvxuPXFSLncCxHSqt0M46pEoycAdKMEOD1Wo0AcZBIAPJHenMc7iAzL0qTTSwRqvmSuqnrx3oTPUjPNRRQylNrMY0z+Jq/Z25lkAA74JqZNR1YQXNoifT7JrmVeCSWAAHc9hXrOm2Ft4J01L68VJdclXMEJ5WDPcj1rI0C3g8M2q6leoj3rjdbQ/3P9phXJ+JdeuL26dmcyXEhyz/AN2vLnKWLnyx+FbmVSDxDdNO1Nbv+Z9l5dw8QavJcXEsk1032yRixcHkH1rFfWJp4fKnLGZDgk87vequxV5yzMed7etRyEbhLkFwMEivQp0YQ0SOhyatyq1tLeQ55rqUHkRqD271H50kT8tk4796Y02W287cVIGEhw3Y+lbkXctbhckB43T7rdfaopFZmwvbmpVC5aNx8rd/eoHzHuV+eeoPUUEy7kwYhImHJDYNAVklf+6f1pqFGctErLH6HnJqZA7kqU246Uio6oMYGQOe9NAwuQQBTzkAelNKmQ/Pjb3HQ0FNjCREgcHAHJFNtZIpTI0IIL8HPXPtTrgBoyoIxnseaiuDbwgG1V4345PSjchuzvLZDnthKMEozjkbh0qUA2jRKGXGMuEHJFQrFFBGEE7ee/LO3PPpVxbaCJGeYs0rdWH8IpNpalRUn6+pA1pIrq7ughJJRB1wfWrCgeYip0bj6VDGDEfLdSrryue4PQ059xmjVfvA5NO/USaWyFgkKl0Y/OhwR61t6FqAigfTr/b/AGVO29nI+aFscEH0rBuiFvDJtPltwWHrVhTgBcblc4PuKqM+R8yOXFYOni4OlN7bPr6lu+sPJmW3Klo9u6OYfdcHvmoUiMQAb5k6Zz1rpPC95YXEEvhvVWEdpO+6C5I5il7Ln+7WXq2jyaXdzWtyQk8fA9GHYj1rScFNc8X6nJgMbONZ4PEL347PujEizFPJB/yzPzKfeoJG2qx69qt7mMRHGRwKoXH3QBkgCpStqd8tFZDEnZThjgVNu2NkZI9qz2U49R6VYjMn8X3fSpZMJPZlouWHC5zUboyqSE470+R3G2NAFzzmosOCfnOf50rG90IjKV2NGQexoOwZLfe9qezfPyRnFRSEE/ONpoT0FoAcg/IMnpz2qVCkSlwAdpx9TVaRSpUjp3NL5hxjjI6DFJxuEXyu8iYqM/NnPfFFNQttGQQaKOUOa+tyzE4VACOfWpfMHXg9jxmqqMGHAxSRZjztOSTkmtGjlpTZYcZ6HjpiktiZIJF43R9M96RW5G7qajV/LvVK8BuMGla+h1KVmmxI50ddisVPc+lPAyzZTeccU24j8m7wB8sg6Y71I6MsDSCTZIOQvrSurISurrsLsKoGLAZPIzSvEsrBt3K/rWfezYYCUjcRk4qezuIGxySvfih6IUZJu1jQh2SkxscZHQ1jNp8TBrSNw0wYvC/Yeqmrd/kbJ4Q4KngYwSKsXNpDLBLFZwt5jruZycNmp5o9x1aTkmrar8V2/r1KbSXFvGsc8Q3twCtVL25vYbIRhVj3HO4ck1LbC8g+xs8eSG2bvvZz3NTzMftc1re8SMT5LEYXFCsn36mfK3C2qe34evyM2xWWyZZpYkdCcSHqfrWpteGR3CloT8yOOhB9ait90UZgnXMinBJ6GrgR1hKow8r+4TxUzbbuaUIqnG39JjbW+ViyumGUbsiqd67T2++IATOcBabkyW7pbDEzNgg9xRckW9sd7AORt+maUYq/MKpUlKPK+25JbWf2iKCCYARRHaZenzHtVm4kLObOECO1Q8tn7xqsTd+ekgKPaxqNoX7pPqajjlh3GSWR5ZpD0UYAroUVypmDlKEnFLTq3v8A8MX1UIeDkdsmo4gy6lE6chuMVIqqVC5xj86ik3W88UqtwrDNQnqdDskn0J4nIuriMgKFzlTTTcFFPkxopPcCl1AH53hx5knJNNjfMQAGWHXNC7luTi3G4k+5LZQOZJOpPanxsVTZ3HfNR3RBlhJ6DqKkUBcE96XQnZkZQlzznNSDarDzMcdqRQA7OfypwCMQ2MntTBII7hfuRRF2+nFSxrKD+9wN33QPWmSSSBAtuArDqakQkRfMd0nXNTYtPoLpXm3kkyTcNEcGu00WG301PtN1GGkAzFGe3oTXAtLNbail2xxAoyyr3NbWr6hNd2sMlq6sZv489K5MVTnUkox2ChJum4VN/wAWifxLrzyszljJO5woHaucPnTKPObb67T1pt9Ntuo0OMouN39496a9zuxngH0ranSjTjZESqOTcdkuhNDI1s/l5MsZ55PSlnAhiBKboZzkleq1UaX5CVPtV2Iy/Y1W1Hf5gea02CL5nYhVGVD5S7lPTNKCwOJeG9jTbljIVVmIEZ2kLxQkf2hJTFIEWFSSZDTSvqF7KyWpMFyvzc800Ro8TAk7hzS28gkCHGcrQRtukx0IwRTHoMTcoEary3elnQz2piaVkYNwwqYHDYB4pjLGSGD9OoxQgt0FOFjAGTgdahk3Scs20DnAqWTcvzgExn2psaiSXCEEkU0m3ZCeqsNIQwxqi/Mclie9NKh7VxPMoGeB3qc/KCF5OajZQCGwCx6DFDVnyg9dRYzEYo98OUUg7u9WYJy15LIyN5QXAXHU9jTACVUNg47UkkrRnduKkdxUNcz1LT5URhyyBZGOVPJPWgSomSyseMb/AEqCW6Rp0aFSST87EcfjVhDuZsLuJ6AdKrYyU+a9mTIQ/wC7yPJboTS20LxTlEyy/wALE96SRJI4xDviw53EZ5FOYEw7QSsoPY5yKpxuvdJhUmpWqxs1+PkWYbQi1lSTDsG+Yiuksb2PWtLXSNVIGoQr/oV03Vh/cNYujNpTSyJfz3VqSmRPGNybvcVeurNBbSyWOrWd/Eg3DgxyA+2aujeDs9jxswr0cS0pJwnH4Xb/ACZi3ULpI4kTypEyrp/Ws24UgAKDzWld3jXckbz584LtPv8AWqrjccHjvgGirFRlZbHo4OrKvRTqK0luUAh7jOaciHzME4NWGj2jJOR60hU/KepzzWR1qLI5OZz2wMA0zo5AJJHeppWCMDgEnimKoO4AEN1pIp2TEIXZjHPrSbS3qTU0SEsoA5bitKysCWwBluvPaonOMFdlwpuexjG2dJNhzzzUMYUlvmG5e1dLqUtrDDHGgUzBstL6e1YTQRJ58oYknhfeilUc1doVWko7FQB2Gd3X3oqxGrBAOKK05kYeyuSsucgdPX3qNBhmHrUpIL56ClbG07sH0Iq2yacbITDkgDov61HdoWVWUYIOfpUxYbSYxuYD7pOOKjd5JTFHCm3P3g3+NHLK3MglVppuDepPO3mQRTpg7TyTS2s1tM3m8PjjafWmQZiLWcpyG6HtTbYYg2jGVJzxUShfRm0anNJW17+q0Ls4gcqqpEGPTK5xSRTRxuQAgDc4C1U83IBxkjoaUgbgeRnrWfsopbGqnreKsSancssazrIvBwFqt9qFy8QukkSZ+EdCdppBEJbv7OCMOvH9ajDCC6Vbdi9vF1c9QfamoRirW1M51qjbbem34jpZrm1kBEpjgAKiMDJzVHzZ5f3iwyTE/eD9vpU9kWu72WRssOcZq4HZWwQFAp2t6kJurqm+X7yjFdo7lb2F42OAsgPA+tJfQSnMVtdYkIzg+nqK0ZlSWNlZQcjris6EyJs4z5L+WCepB5pQ3Vh1PhcZa+a0/LsJaWr2VuCkmZDzJu6k+1NTz7m7DzwtLsU+UqD9TWy2CfmQHFVpkZAXjmeIYwdtWpPruQ6CSVlZf13ILN7y0V2Nu+1uWQrx9aVHSUEiEhl69qklmvYbi3FtetNG4+ZZF+7VmbVUjm8iKNHk6l8dKpydhxhCzTbSXdL9LjI47qZFxGEU9zTksW3Kbi4jz9aj2XNwrGaZgpOeOlD2ETxbXY9fWp1vqaJrorkkkXl3LSsxZMYGORVYzqZtqghQOWPSpkUwkW5JK/w5NVp1eRiisu0nLqOtOIpt2fKWZQZYAwxuQ547inRSGTHlqNuPyp0EvzFVT5Ohz6VBzbsURCyscj2pbjbskyWRCxHzVIB6du1Rhvl+XrnnNO5JyDzTDqNLB0dTn6+lPiCgDDcbeDUbMDGQQcH0pVQx4CH5enNIL6ke7K9DjkH3FQ6fcxQPLZ3BKxMcxkevY1ZYw+YIppAr/wAPvTXtlRtzRgt6kc0dLGUoNyUo9DPuUXMiuckn8jUCy7MCXtxxV2SHc2egFNWJd2cD+dMhxbdhkI8whVyNxx0rQAmA8qH5Wib5j2qvDGd58yQKH6H0q3EksNuwQh5HPzMT2p2vsawT3Y2YeYw3YVlOSfWq91bRXUjbWKrjJ7A+1W2GyNTjdzyabLb4YmNxg8kmp1RTgpra5CzjfEVjESoNu1elTBwJ0xgk/pTBm4J3Y2JwT6052SKUmOPLMMZNALv0CRAozK4H05pimIckk5psYAc+cPn7DtUiDHBAxTd7iT5h6upGxW6dAaYy4dSw2+4pGVctlfoRS5aMElsp6Gld9Cr33FEb9pAVPT2oMZhUMzb5G4HsKTcPLV1GUPUelSND5iq6yEY6A0h2utBT8oBPzkCiUkkMBjPak8w5Cqh3njnpTWJVmVDl+/oKBX6IgMUjO8YYRwtyasJhUEaNyfSmAqAHdsnpUbMyY2xZKAsGXqTT3J2d2yxFaoAzcEjsx5NPUiN1AOY2GGHdfeqcLiZ2+2K33SQynBU1LDJ+4YgbgRgP3xTITUkrItyeZbSqyyAxEA4HcUtxExmxHGAvJ398VVuptlvDldwxx61HNPdRwpMsuUYjKY7UouRc3CN7rRa+g7eJHZoRwOCxoSMOoIkfzc+nGKmQJIeV8tX6Yp+lGS5SRrVRtifbJnqambaTbLhG79ewydViYI7kYXLZqtMHhkRirKjrlQe9S6i4eVfLCyOzfwn7g9KrojIwkuHYSBtqlucLRSV0mwr25nHtYlldH8obcMeac/zM2SAOhpsETNO4ixJgnBqO4RoUVpmCRsCcnuarlaYlLmT/AK8i5ZfLIm3GM4Zj2HrWpqF/HFA0VtkjoSOrVzUV4jOhRpBjhsLxVlZPMUtkFc43VhOmpyvI2p1bRfKRXbNOfmGNtMkCi1jdmYYPT1qZs4HU571YtIhJbEMQQHAAxWvMkr9DJU3OVurI4RbSxK6uxBHpRWdcrLFcSJDu8sH5fpRXSsPBq9zzZY/ERbXJt/XY035BIGcD8qjhO64UY2J3ahGPrx0NJOmRFg/KDyBWS1O99yFZCt1JIEHoDVtdvCnq470xSodsA7QM0Fm8ndjcc557UKTWxLpxlpJCywFIWKnMiEFX9KUZBwxBLDJK+tJOgZdqudhxkUm0Idq59aHNtWZMKEacnKGlxxAUHGNvr70m4xEb/vN69KVX2hgRuU/eBHFMPEjY5U/dHpRokU3JT20GyRH7UssQ+eMcN2NQ3bsun3E7RCGTO0qOjCrZPyeWwJ4yCKqubiazeC4TgZK+pFR0NHvp1v8AeR6cy29wWUkRTJlfarYjznJz3qlb8QKm3fAewHzIamVoEyBM2Ow2nrUyeuoU4+7ZbD3IUfK3zdhVbPlwSSSkqFfd7sewqaGa181htl83aSJMYFRRSiyhhW6iaVmcuWbkAfSritNNzKVnLV2X5GhbSiaFZI+p5OaZfTpFGxcjJ5wO9JaqRLKwKmNjldvTFZ9wzPO00qELG23J7elGjY5TkqehH589ygSNDEx4Dd6txw3dtGzSJFMWXHTnFWFI2gjBJ5GKcpJb5+fak5XVh06fL7zev9dCvYTh42jRWjmQZaNjncPUVpeYZLVEiYbSc7ivSqGpQ/6ObmNts0QypHYU63labym24DKG2iiLtsTJX92b18tLj7o4VRwXVuDTprdUnLg8sASKeiNNKqleEOSKkYpJKQzqDj1pm0VuyAswzt6UobzYsP8AKRTiJowRgFOxHNICFJyeaAI1kJZkOQV43EcU4Mecjn2ojBUYZiyE/lS7G6xMCB2pk2AcKeaeCRz/ADqDzCDtdTjvSl3bKRAknoT0FKwcyIdXs/tMCvCAJkOVNXFeWS2i8/HmY+bFIqgmLcSGA+YetMSXzZJONoBxin0sJRUZOfewjxAnJ6elN8sqCABzUiGTcS5GB0pBLgr8vU4pWGrEawvIw8wcAYFSOZBKiRMoiAwwPWlY7iWzgj0NMLEr82AD+dALS5GECSB2kJUfwdqB85xyFJo+XGT0BpHk8ocdT0HpRYSklsSyOFARFwB2/wAaQKcktwD0psQ4JznPXNLgh+WyvYUBdvcOG+Yj5hxUikKCWBHFQmUDmT5QTipFZpMfZlJf1YcUw8kEbCY8HaPVqYzjyxuHJ49qRDO0brL5bybuAvapRG3lKrhevy+9K6QRvJDUwuAn3T2p0eQ5ByVHII7Uwg5xwCOop4L8IkvljuMdaBryJmdzC5XG7HWoIwoiDAnkYp4zbuofLHvUkMO64DQ8qTyP7oqW0tStZNJkbLGY1V8Y605d4Y+SBkVYubZYyzS4RfvDPXFUvtEk9wVt12xno+KUJcyuthzjyAoSDc80295FwUA6e1PgSTb+8KxQ4zyKjcxQylUzcTHnd2BqKUSSSKzuZB3X0q7djNaW5tbf1/ViU7XViJFZwwCr2NNmd0u1aRAqEYAPSmi3iOdhIOeoPSpmmbyfLulEsYPyv3Whj3Wun5D4n+blgccimWE0dnqd0hYgXCblUetRTRNCqyRsGQ9/8aW6/ePa3CYDxnBOO1ROKktdiruOq3X/AAxK2+E/cGw88jBqOUKzE4ZiPmIPWpZ0edpZnckqMgHgCqyESxLPbh3Cf61T/StebTUw9m4ydm7dvQu/LBNOqnCOodCDjB9KzbmYT3ziQbY4xtCk557mrMDR3AYIwHdQfWs27fN6jFCEcYJ/2h1qpyul3MOVwnLl+F6/jr+OpYXIGPuqelJuMYDFSV67R0NPK5wAeOmTTG4A3fxHFYWvqdlrbFsAvPG4YqgHPpVeHUAVlhycOwKsPX2qGaV0imhwFjXG0k9fapFZ3YRtGqrBwMDmqir6Ml1Nmnr/AEmXjj+JwD6UVWJ3fMVyT3oqeXyL5yVvpzTwQB2zjmmZ7Hr60Jkk5+6fTrWuxA9zn5iMkDPBxQCSAxG3PVaFcL1+goJ2sCDwO1TctA5DYCjv1pWB9eajMny5XoT+tTzK3lxyJj5fvLQG6GMep9etKy89snpTQwPI4WnFQ5B5wOaTKST0AMxZVBAzxzTChJxuxIp4OelK6pIRjqKSJQCeOSeTRa61BXT0GOBuZmJilB4YdDTHkuBjESMeu6rQU7iwwRjoagmPl/LjLN0A70kmnuKpZptkSWwcm4mnBZVwEU8DNTw20AtoizFpc4KtyMU+W1W2hSIR7rmXlsdhViKFjGvQN71bdtSVBJ2as+vqRNiFMxjaB0UdqriA4kuGcv5nyGIc7j9K1I7IyEJje7dB2NUG05U1Mq84hKLkbW4DelZc0W+UuUGrO2n9fIrtDNaY85NsY4HtUyMCMqwPHBqPy7mJBcSXIulclSp5BFQG1jkY7VdFbqgOBV2d2iG+X4fuf/A0EmWXUImEbbbccSMOrY7AVctwFaNVBCgcD2p0MCW65zsAHyqOgqZSpRShOD0qrrYmFPXmluNORu2kr6mo/s8TKQQT6mpFBOcrnsTSujEAKSuDzikaPVajE3QFWU74f4l9KWYJHiU8o3TFOVFVMAnB70AbbdomwVzkE9qAW2pDgkOYs8c4NJAyPGzbCvYj1qQxiUqyuFHcjvTCixqQCWYHimQr3HxnaOnHWgscgjHPYUxm6cj3zTkKgArg+xpopPWwhZjISuCBSGMbt6MA56+9Iu0kYVh1ye1Kzwh9oY7vTFIV7bjwHGcsnNRqf34TILUrAbyAhIA4Jp4dkVflQNjrQOwhRgedozUYRQct8zfpVWYSNKxZyB2xU1uDs/iJpmakm7ND8gEs2MDtTIFyzOeuap3LOoZeevNWbFyyDnii2hKleXKT5AXcR1oC5zkYHrSsME98Uw4LKTk+wqTS4OysApGSORgdadNO58soNuSBsHU0kbEyYPyDscdaSLzpJW+zkK6Z+ZucUDu7pIdD5cdzIQhRj1U9RUzPGZFcHgA4HpVSAvGWbb5spP3j3qXYNivLhGJ6A5pON3ccZ2jZCxsXfJQL3JNPwsvI5HrTlUEMB8wp6KEUbRj2ptgldakcSsVZnJfHr2qe3lijCpGWMpOXGOD6VFEAIbjB6tUOSI9y9ehNKUbpxLUuW0i5dzCcBpBuVfvEd6ptNI6BIlVYe/rUkudqQg/KfmY0j/LgBRtHb1oSSVhSbk7/AHkcaxQQsuSCfT3oK+WFSPpjJqRwJD93bmojIpbbySP4qCbDQqfwowcjtT03OPLPUDkds0mdnzBj5QHJ9/SoYSbqQs0hWEH5SRgn600lYzlO1rK5MseyUbThcYZc5ptxCRADbktCD1PanyRjcSrIR7Gore5FrdYf/VHr6fjUvQ1XL8MtF+RLCBJtOSYxwwJ61VLvbXFx9kRntT+bVNeW6PN51qzGBz8yj+E0lu8cBuc7jFj5if4aa2uTJNNRbtrv8hL6e0t3jMCOs7DLow+VfxrJkkae6YwNlU53ds+1TiM306tKcoBkgd/SrUOxZNgAC/Sh2XqYrmqvsr9Cmbt4W2lee5HSpDdKB5w2swGSFOQtWfkS4UOowxwc+lZ9xEmy+FoW8m3B+bpljUqKe45OUbq/9LUdbxzXtzu2goEJweNo9atIqBPkc7h1otYRa2KSm5HK/M2f0prNGJYwrZEo4x2NaPqjKCtFN7+vcUFsfeIoqY7VOGjYn2FFTzo25JeY9yw+8rfWmKwzwT681aUsBl+R79qiaYqM+TnJ9KvUpoesgIAycUjShcAKSD1oiljkLYi2ketK7YIAGGHSpZV1bcdHGc7nAAHQUCV/MbbwPzFKy5IMh/Glilj37McetPcaXRD9iMMzcDHGKrssQXLSlSOwpWjDFvmJOeCDwKTyv3qyIM7Rgg9zS2G30sKQoQMJ1x704JOCCoDj2qDa80RinjHsQOlSxxSxACJyR9aNNyU79BzrcOzAA4I6DtT4IYbZopHcNOTgAnpSQzlmKSttYe9NvFjCRziMOVOQ2e9GvUa5Uubdov2mn3N3dvIZWVv4QvJrTfTIbNAb9nkbqIlPzH6+lUdMvjb28n7wp5v3iv3vwNNur4nKRnaW/iJyT9TXPONSTstEarkXvPdk1zcMybIv9HhPISPr+LVm3MkRcH7wX+EfzpGRkbbcSHym5BXqaWFIoWfeBkDJ9a0hCMNUTKTk7MbaWTSROyHyI+q56E0rXEEf7u3i3zEYdu2ahlea/HzN5dvn5VHGanihWNNqDcQOtaW7kp2+D7/8kCDkKfmfqc9Kc0e4hhx9KQdAMHkU9VVBjdkHmnsFlsyJl25EbMCetKGUMQxwT+tNYqHIL9ulADK4J2mMcikIcBsUjqaCQVw+dpHOKcx9jz6VFklD0JoH5DggRAoGFHqaQuEcEMpqKWJJoklZ2IBwwBpVijXnbgMPlNMjXogngWZi+SNvOBTk2bflyBihVIXDE88cUbMDJBwKEO3W2osjYThiu40zytjB2wR/OpHC7cnkDtUe0FcISwPf0oC2zsMkd3b5DhadkNhgT8tNkVIGMkhIxxxT4jvG6P7hpiW9mMkty8obeNvcVJs2fdIwOuKRkPQcH0pgQxvkvwOooDboBjVvmfG08Go1SOMkITsqRgHkWQOFXOCppZAFkztwjUgt1G7hu2ZNLmXPAXFOJ+feBimOxj3OFLlqYCqXVWeYKEHQ96FO6FmicqH5JpXjZo1yw+bqKkZ2kYKkW1EGMetLcaVtyqr+WAhZlTGVbruNIpJAO35+5qSXAIPbHftVX5slmYkGgzbsX1cBhsGQakNzHGzKwdmH8K96oxyAcDNWoW+bknJpWKjJ9GSg7492woGOcN2pFyXKcY9qa5d1PYjt606LiXpztxQzRPVIhjJkndycY6ZNSMSw+9UcABU7yDk9Kc2P4AB+FIURJOQrKxJ6EelIVYlVQhfU0MQ2VU8+gpvlnaFxg4POad7kuw25RFt4yrsweXbz0FPMfBRTwO9QyQbrWJ0c5Q7ih7/SrCkTqHBAOMYqW+g4x1vbt/wSo6lM5HTvmpLXEoZHGQwxk08ozEqYyT7Vm6zcm2j2DKsRhQvJz70JczsiKsvZLnexZ0+dvtBt4wcqCj+mKfqrSWiebEokiuEMZQ9AaraSz2dsouYGfd8zMp+YVquqXNp5aMGgJykndW9DTTipcr2JSlVo3T1tp5f0jO0fCwkHO/vinSDZLz9aQAwDzolGAcOgPIPr9KkkuLefBTr6Y6VMk+Z3HSlF0kl0GTjczbT8+Bgkd6rzmCLzA6sWQZePvK3bPtVxkCZdyBxkZ6ZrH021aW8llu3Od33if5U4rS/YirJqSst/wLVlavPsaY/J1C44FXhZwgncvDdKkZQpUFvLB5AHpSoI1yS/m45A9KTlc1p0IxXKyo19NbHyVnVlTgEiioZ7ZJZWcKRmir5Y9jldTEJ6M1IJkuINyduvsaVXfacryOlVZ1Ualuth5Ubrl16jdThI+Dk4Knketa1IxUrIrDV5zgpTVmiym45yhG7nk0ZIJKqr4/SoIpHZ+uRT4lxMVH3TWVrHUnexIELsDnj0p3llgSNoUdaYpbkA9OlOUk7l7HpSV0Vo3qMjGOBkCl2sh3ruIzzk1KW3oFZQHU5LDvWbqRkQ745GAA6VUVcmo1BXSNEAEEsdpPT3poyp5PI6e9Y9letI/wA5z6c1sA/Jkmi1tBQqKaugkRHOW+9UkATyij8pjj2pqbjhguB3zQ5VF55NHkWvdd2PEMSocsSp54pINqthcEntilEUrpmMJsb1pJJZPL8uNEDLwT6UONtxRmr2S28mRoAzySO2ZI+kWeSKZFcW9zbzwspgkc/fbrUttFHHKzH/AFpH+spfLhKncgY9xQha7/ePhj8iGNXlSUAdVqVMliqYwRzmqqbEAAXaP7tOWUFz0x0x6UEc6joXPOiAAl2KOx9ap+cu7zpEYWx4DrjBNQ6lJFdWhSfiJOCU4INVYLWO6QpJKzKuNuDhQPYUIh1nJqKXp/XY0gYpwFKY8zgNmmJFJbsIZeh5Vm71A2jK2BbyOGHTmrFgXnjEMpLvCcEHtST6GqbbSa32FcO0bFcBh2FNjQiPLH5j2qcqEOGzzyKGVX+lO6K5Svbo7eciDf3AAzStkgc/IKkt2eKYyoWibGAVPNRYw4UH8KellYQZZ1/dsAeuSK0ljs1gjddVQSkZeOePAB9Mis1QNzBGwRUjMqD5/m9iM0Jo5q1CdR3jNr0t/kVizzPKuAMdHHRh7VJkxwgRgE0pklkAaQjA4AAwAKEBAx2605NdDanGUVaTuxHZJU2zLtPrRIZIUja32uinBB600nJOTQreUOuR6Uhti7JDK0gbKnkj0pARyT0NSKcnCcZpo4O1l+hpFWIpQrId/GPSpY/nj2se3ymmS4yFKnBP4UyVgspjBJIGRtoJvbUVSQQjHkGlGc7QTjvSj9/bhiMOOPrSK+UJA6cYpj2HJjepUE9jmpGDbg2ePQVGmd3XH0qYAEZHJqS90VJyCBuBJJqJkxx27Yq5t3jP8VMKc88UXM3BldYiWBHFWbcAzEg8KP1oA24IOSe2KmjjEaksMA80mxwjYbCRncW6+1LGu2dzzyKGlghVcxO+fSgOkmQgKt6HvQaK33EcRCoQRzn8qGORhelK52sRjC96HAJwrYHamTeyIwCjhlXOeppcL1DAn0NO6KOuaRVUbi2D60CRIrHy1STy8yjhemPpVdY5Z7z7PaxqZowWwTgEfWnsYmnjlC75F5APQVbgNpKZDPBIZG/ijbBX6VpzKemxzPnoRurz18r2MSWSV1by5H84EqVHYj3onsPs1rA4dZZJSGcucsproIobJIGFrgAj7z8MPrWVFGkUG+aVWO4jZnk1Mk4ak0p062vW3pb5MadynJ5PXPvTC5gkV1X92/DL2LU6WOaLnAKMNwz6elRJJNcukflKI4/mAByWNZJX9DeUpQ23JYhuZpjlXf5eD0FJII4DsdAxbnaByT65qeQKqKmR8wzkfyqq8VxkSxEB1+Xf3xVvXcLcsbIqQhbqWOIfaXYHO4n5VHoBVmVWtFaVz5judqJ3U+pq0WYxkxoEeMA56F6ffWJjgivViaSF3wj9t56qTVOLtc5HWhTnyPd7MroruPMbl2GM0AYOQADVnaqb13q5ThihyBUbJnJA4HSsfI7krq6E80/3FophGD1oq7xNPaS7kDs3mdOeuanR/MUb/veopkhUHk5qSNPLj3Nyx6CrujlinfccHCsFQZHQmpQBuO1sHtmmxl8cKB7U4vj5ZE/GkbRt3FUmTIZMYHrijJU4fHPamDjDo2RRcKXjVgP3gpsOhKDIo4Q8frUUsEsjAlcJnkGnm5JiIXmQ/pVcfa5kZZWKHPQd6FpqKXK7J3GJpyJMTvUD0FWdsSIN7E46AUyKMw9Fyx61Ns+bPA9qTCEUtkSo5kUc4AHFVlDzS7SMD1qdSN445FL5g8tiDzU+hpZS3G3TsrpHG4CIOV9aFUockYLdabDDvXzt2GWnj96udp/OqsTu2xzDJG7laGGJVAUk9gKfHuLYxximHab1Yi+1mGAaAm9vkVtzztMsSbmi5c+lUWnkV8qqkd89/pV+ayjszcmK5Kuw/eD+9WOoFzNvR2BHGfQU1Z6nm15Ti0m9fkWSbedCJlMUueeuGH0qwqPp5BPzwH7sijjPpVaOEAEtu49atR3B8kx8tAfvIP6VG2iKjLm1e/f/ADND7QFTzEYCqayiKeWaMlpHwCw6Jnuahe3jzG8AeW2Y7gmeSPQ1YWS2+zTxtMTJKdrRoOFHbmmkrdzpjOTdpaW8yxi4tbiKK5lSVJB8rJzirLr8o8vqeBWfa2yW8SgszMvTk8VoXd695JEXjjiWFMIkfH4mrktBRrTVSKUPdfnsRycyAnoBVZkAmLk9BwKeXaVhkgHvSMAQQp5rO1lY6m1IaNoxkAbupFGfnyBwBimSErICelPH31JGAaom99BDkDb2pGDIhwMkc4p5AZyBTtucdj60CauivbzRzEh9yMD0IqZoX2llKlc8Ypy7C5xitDTY9Mluo49VuLjTrUja91AvmBT2LL1x9Kt8trnDUrVaN+dcy7r/ACMsA/xDBHpUsv7xBjO4Vvan4ZvLRBNZXljrFiOVuLR8Nj/aQ8g1hts3FQSrDjB6ioWuxtQxlKuvdZX3OVAkXB96aVAYshxkYyKlztfEnPpimugz0/Cg6LXGIAjcfU80jL8+9OM9fenYKN8q/iaZJ5hU+W4UnvigNgB+YZ+UirMbZwMfT3qEZAUOu89zTtyKBlGAFJgh8YcMxfA9KR5AMcbj/KnkAgYyVPQmmN8mNuPekWNMpjKhY9zk9T2p7tJI4yeBTN7E4Xp6mmwn5mUnmgSetiZsdc4HpTH+cZ6Ed6dwR0zioQsizuVOU9DQN6dCV1Dp8p3H+VMjJLYP317e1OQEOVA2hqUrvUSxn5lOGpidmBAJJ5Jzxio/KBbcAQ3cE07cM7iwUr2pAckttJPY5oFoxC2EwF7UqPNHEstoyRjO1w3U0ittYBuvpTcbZpHmAbcuAB296ELroOEqqjPcJuIP8JqGPyFdpZEUs4/dqT096RCpC4BLJ+VSmSOMbZYBKcfKR2quZrQz5Y3Unuv66CxRBmMt1KfKReAOeaZDIgISIBUHIzwaECPE6OGQHsalkihn2/Yo2M0a4O44z9KGrFU3zaR37dWLDGJoXjYqWBypNQW4dnMbcK33j6VZsXXeykfOBj6Gq8C8yfPzu5NTaysU9VFiyO0ccTo26IEjJ6kVv6RqFnGTYatC8/h69G8orYMUuOHX6Vg2sT5lWfa8YGQKSC0Mksckc52xk4jPRR6VcZW3ObE4dYim4tb/AIO9jQ1jw7eadaWYWzKRSOdt+jZjnXt071mXLzWZaOUK6jo68g10GmeJ7nT9Nv8ATGt47zTrkZSKdiBbv/fQ9q58jeQpdXAHRemamcU9UZYR1YqUKi1Wz7lVb/5RmB/yorSNhPJ8+0Lntuope75Hd7Cr/SItkMT4PL44FNUHfufkjpTZCWbfwPTNLHIrKWTqKq9tTNWZMHwp7Cg4PU5FNZS21mAVW6A96aMl8A/L70bmmuwIQr7GOEapvL3xuqkZFQsDkHjApzN8+5QRxQ9RxstxIMxg5AqTezdOTSDDAk8GkhXbyTznilohR0S7EjkrjPU9qjVm3/OCDnvSHLSE7sEHpSKkj3ReZvlA4FC0BvsSk7JiT9006TaoVVI55phXLMxPFO8oSoHTBZB0ppXeg9loV3+0C7jVcCAcn3q6e+OPQCohIrfLyG96crZYAcfWh9hRsk2SJkYJI3VJYQme+WUGNlUc7qghR5LtUY/IvzH3HpQJY1unQBkgmb5SP4TSte6G5Ws3tcS/HnRSOigTbiNvXAqva2n+iRuuFOSGHqasPZrbXIMd0HDHLc54qT92UJtmyAfuj1o2OeUObda/1qRyW4EJ3HBqisDqTxkscYHetOS4iEWJWCzA42tUMD+a6xkgOc428ipaa1ZmlDZFaEtbXGyM4JBYAjvVhQkgE8ARZc4KEfrUMvmNdZmC7YwQuw5LE/0qwrGGJRsBbpj0qtiobWeyGTMwc7+M+lRIxEw3DGO9T3MawDbGxedjk56CopMnl2y3emayT5tRz7l4iAJY8mnghQoPXuaiiOOp461LIxVRtAY+lLQtdxGTKg96VeEIPamo3Unr6Urr1Kn8KPIa7itkY4NIHyOQfqKF8wrngY7GmkyFQVYBe470rgxwAUZVQv1qTewA2t+VRrGGyWfI9DTtoz94cUJsPUcmyJi0f7lm+8YiVz+VMnRZxndlu7d80AxmQKQWao9xdiwG0A4xVKVtjGVGEtZJBGjoG3ybx246VGwySzMSf5VMOuQfl70x2wTtGRSvqWoqKt0EAbsc4pxAI3YwT2pHcKE44PWg89D9MUFDXYAj5ioAqWKRSpYHdmoyEP3sMRUfyoCoHI5AFInmsW94YfMeKCqE4OSB3qJZAwG5cVIxB5XgAUilIjIAYc89qT92JggJ8wjOPWpFw6nAxxQ0W7bKvEq96C7O2g6M/KOCD0OaH9jg0jO0hG4YI9KbvyenWgd0hTuPXmmsqq2Dkc9u9Kfr0pG5460yGk90SEYZWKKwHUUx8b2IIRMdKYpdT833RxTsp5igjKnrSKumAC7QRnPrTT1z+VNkU5YwPvjz07im79q7WUk9hQJuxICOoAFMcKqM+G30iyqy543dhTg6jngt6GqsTdMWUrLKioS4ddvI6GulEmkX+nx20sLadqMChFlQ5SY+/oa5tsMvGQMduKdCqouOSDzkmqjK25y4nCKvaSbUujRevbX7DfRwuq+Yw5KnI+uazo9y3UycdTin7yZdwJbb0yc1HM4ciVztz1xUu19DopcyppTd2hHjyxU5BPfNALpzGRt756inHaxzGGb60qOoYblwPWpNFZMEaG9kDAkxJ1UjBzTJzAwxbKVkQ8+4p08ayuHRhFJ3I/ipCgVSGGSR1HWraWljJSm21NL17/5ETGRjkuxJ75oqePcUBVRj3oqPkVZdn+JCVLIoB/ToKbbvHCcS8ZbA9zU5V1bLAYb0qGZQ2MjIB6Vo1dMlrld+xt6gluVjWQgyKNzMvT2ArI3Hdz61GpcuQ3CjpmnPvwpTAx1GKypQ5Ea1Kim7pWJOpApGDpNtbG0DIpj7sDJPPOKnkGWXHUDkVrsrkbkWeflwR3FOEi9hyKYkK7nZc8+tKseNuSCaTBXJNwJyF5pWJ3DPQU3Ixg9aSNy5KMuKVi7vYeHyMY7UyJsMWRiD0IFI7tGw2KDt6inJgtvC7S3Ue9Mnce80D4WZCjD+MUrI239zKsidjnmlK5Y5xtx0qsCI5iI0IB/T3osEpPr/AMEf5jxuCVZSO4qaKZA370b0PIB7Gq26SKRm+8D2NSiWTaP3KbaaMudL/hi/D5HKRQglhnntTY7RIw7Jw7dcVXFwR82wjjGQelX7bfK4CsDgdKJI0jKMiGO0YuDJ5cnPG4ZNVriwUy5jZ49vJKdqsyybJSrDvjcKqSybWYbm35z+FODcdmY1qFOa94YzvGMBVm914ampcRli771PRVcd6jkWR23McJ2pyB2YbgWA6Cm5J9DOFOpHRO689SdsY3AAseKGRUTdIwAp67YkclcsOw7VWEO5g0jZ74qWup1PTzYqSBjiNCR6mn7mUkphW9xkUp5bHb0ApVyDtJ496WwcratcrkPvLPGSD/EtTQTwv8hba44w3FKz7RvU4NMMpcYmjRh645p3T6GfLOOzv/X9dCzhh/8AXqMjANNEIEe+1lZSONrc0oklC5lh3j1XrS5exXtLfEmvxFAzzimsrqRiPIHUikEkc55IT0HSpEiZOULUmmtyoyU9ncikmSNtz5A9aTIU7kPDcmpJQVjxIgYHnNNRVdQV6YwaAs2wATOVORSI5WcGNVdccg9KaqlWxjPOKdA2Q7ADrjAoC79CIhgHMhB3HgCnJGYisknJPRfSpnVU25HzN29KljVQfn5PvRcXK7kIHytlQCT1phj2ncMnPWrUoBwQaY2AtSwsQSAfLt4NNRsN8x4qSQBlyKjCrgHP4UIFEkVsNjtTx0bJOajzkALUrJkccmg1jdjMnP0pgJJO6nupI4696WJC00UYwGchQWOAM9zTViJvlTbGr91vftS7lVckV12teCtY0S1+0y2i3Njs3i7tnEiY9yOlcmGWQYXoeQTS5k9mRQr06yvTd0QzNkYBwT602BCNwBDEjrnpQ67idy0uI4V5OMjHFPoU7X1FSLy8YYqDyaCQpLuwOBnPr7UqIZIQ7Ntiz360uVIIjTKDjJ70i0uqHwbJB5kca560x0jMgLDk9SKREZiSjFcdfenEFF4bApXsVuhMANjeB6ZpGiJ4Z1C+tBYk/vFGemaUgdxuTrTJaQrOUlWOBFKY+ZqbLtHVc5PSlCgZ2daa2Q3I3ULUb7Mb5e8jym2H0pNkg6lWGPWhlEi5J2miOLYQASadyd3sLGrnkDHvSlpCd2Mke3Wmv55b5cBR2qSPznI2rn1xQNa6K5mz3FykzqEyAep4oq3cM/nNugy3c0UXOZ05X3Y5GIO1j8v1qVkBUbGyfSoQMALnPrTZMrtwTVGqdtyY43fOVz7Um4E4VhzTQi7t65ORzRt3EDGFpFX7CmPBJmP0FORsn5TwaVwMDIOKhjwm4IDtzmmJ6NEjyMX28Kg7+tOQbX+XBqORsspAyO4p9qAE2r1HOTSEm7i4OSfTrTVOJdynnHU09cZLFjk9u1DKdj7RliPlxQi/MaPvEnoefrQCSeV4zwRUNvOJ4toQpIPvIeoqx9xdwPHpT2JjJSV0S8DBP41HdKyKLlTkKcOPUUwXG3Kkce9SQskqMgPDDB70tVqU0paf15CkKy5XlX5HtSoGAUZyKpWMr208ljKCTnMbHuPSrauTIyMpRh1FU/IiNnq9ySPl2B2gN+FSwKEYecWUdMxnkioWUEcqc9qcmUUCT5gRx7UkynBNWY/cInLRb2T0c96VnViQAu8jmmqyjdg5xyRTHdFlBMZIK9R6+lF+qFCPLGwjoNowc0ru0UeF/wBYaWB1dcgYU/pUJbfLnI9hR6jW10KoCcsTuPUUb9zcdKRyC2B940j8su4kEdloDbYVnY7Qig0vTJJpp7npmlUAUhjcb1JU4wcUAYbr780/Z0IGMc0mcnJpCsKwK4ZcgHripCdgBQ4Woy3bqKWAllIPUdqBrt3HqBkE7QT2YdaXyUPDM0JJ/hOQaiR5PNYuoZR2NSNKNuCuUbqnetYzezOOrS5XzQV/L/Ir6k8lnCf3iOAPXBrItNdiEnzrjI+6e5q7rmnwPZ+Ys6tI3YNyv1rjgj+YQozzjOKqMU9zhqYuopJwen3/AOR3NndC6RWjkUEclO9S2n7oPk4OSeawtItkKbpYjx3BxWjNBbkgKsi++6okknZHoUqk5QU5LX1LEcollcn72asGTAXjtVSOEEZjOTUxMi4DY9BUNG8b2JS24ZBwPeojJuyM9OlIGdsoFwfWo9uH55PoKQ35EsZBb5jk025YxgkClgDEFjgEdKbMrSKQxyTSsO7tdFOG4LSBe+a1BK2B5YB9SayUgdJs5AX071owg+WAD9apoilJ31JixOMnANLEQH3A5x600YPbpQBgcdOtQtHc1NGPWL60s57W2vLiG1uRtmhV8o49wf6VkSImR5TYC9qdM/YGoNw35J4pozjThBtxW47MjtzgDtUioigM3zvnIWoYc7GINSoAVV3HI4HNA7v5j/M+0NhgVC/w9KeVCKeM+1Cs7A9l9aEXAyr7h3FBa89WMIwAfugU7YoXKktn9KJFXK+WGZ/Q9KGVmLSZwehQCiwuZN6CIOVyjSAnpStt3AJuCdMMMYNIG28ruB9DxUbuxAJHOabsTaSle+gjqykFW+YHn3pWDEnIwfShl3S4UHHUk05lkAJIBHrmpLsiN9gHyctQCxH3sUzqSMYB6YpSD+VMLksMy4IbOe2RUUjuXKxyEAdhwTUm5vlXPFNYHgkfN0qvdM37Szu/0FW5l2jMRPuaKQ788minoO77v7g+QA4OSBQvo+D7U2ODDE5605toI5zz1FF+wRT6hz5YCcc075sgcHtTWGG4IwaawK4OeaQ9tCVx8wLZC9xUTEbjz9KcspZAx57UrKrZ2kA+9APXYarZIZenShWIbHQd6a2EBBPI64pIpUkX93nr3pkbaMmGScqOOlKHMZAzn2qI7uinBFICZIWZlwwPFBSY+4iDN58J2TDk47inFt6A7dhP8PpTFJAOKeMkZ70ndsI2WxVuhJHAzquW6Uy3kZQhYbZBzxV6VdykckkYqukA3ICCSKp7EOD5ya+gN1aeZCdtxH8ysKfp14l/abm4mT5ZOOc1MH2MduMZrHvw+maiL2EZt3/1iipW9mXUfs/3nTr/AJ/I1ioHVsj1qJoy8gYytx0qZRGVEkRysg3Dmk4xwOPWmU1dAJFD7ZUwxHDDvSuWV2XzEAHQGoJT/BnJPIoAQqGkQs3TikNascrJFDw2SPSoFKg5Yc+tJK37g4G3Bo5xk85FNGWl7Co4Uls8VMrpIOMfWqkkYwyoWyR2qpHvjfy9xU9RnoapRuiHV5Gkza8oEJtPPcHvUeGBIK8VveGF0lraeHXoZl8wYS5hbmE/3sdxVzxR4TvtCs0u0lj1LR3GU1K2G5QPRwOhqHZaHPLHQjU9nUTj28zk3DZDbmQDtSs2cZA20+SCRo4po3SWI91PWmFgQeufbtQdlx65B4+lJFtWZs5zijOFO6omkEbb3BIx2oHorNjpG2SHHO7kc0oc5yPvHp7VFKTsRh0NSrnGTigS1djdtdceDRhaLp2mfuyWM7x5kb2Nctc6erTK527pTuBUYAq8G/dlccHqKimLM3+sUBRwKUfdd0jFYanHa/8AwRsAEBKHGDxkjqalBXPz9ajVfMVA+WUcj2p0iBB8mQaZsthcANmEgH0oY5yysSfT0pil2cbEU460kxZfmAwT1AoC+lxHkbbgHPtT4ST8p7+lRsPnU8jPpUqJyd5Kr6imJXZMVIODwPWmSM2QMjHtTo0RVJ3FweeabgAnA+lSaN3Q1iu3pzSBiDx07+9JnAG7gGgNtU/LuoZNycMpbJOMdqa7YY4AIpVIxuxyeTSFuCoXOeaRZFIcg4yTSbMYXI3HmpDzgHjPQUkkTNIroMbf4qaJd0tCRVKkgAZNEhKjJxwM0b2XgjORwajuCSq4HAHzGgJPS6CKQ43IfmPBq5EF2BGHXmsVZgHIzxngitK1nDAZoaMY1VcvBGVgYto4wM+tQyOSwyQkoPIFWN427RjOMiqzbN4ItN0jdJScZoUeprz82iIWyXLOcj1FRspHOVPpVtUlnD7IQwHykhu9V5YTGwYrsAGDznNFiPb0+bl6kDl3yHY/QUCRlbIJx+lWntykCSkMS3Ydh71UkjbPy9AamMk9DaSktXuOl6eZFyB1FM3MoBf5g3YdqWNmjJbGQeoqQIAC8Qyp6iqSQt9UJAVlfYBgrycng1PIr55hOAeGU8UxGUjO1c/Sl4bK7ymejDtVrl3MJKrJtLYafMz9w0UAzAY+0KffFFA1OVvhYzcoRhn86aq4XNQXMe6Fombb33d6jgtzHIrLM7rjADdKRTk72sXMgjHYU4nIwccUwkg/MOf50/AYbuh7gUmWvIRQFiwO1IFABJ705VYcHjP60kqEPhTx39qVwS0BsNnAH0qHBQ52jOe1PK7VBJ/+vTUPzjJwCcGqJe4j7txIPI6ilikIB3g7ScZHSp1RTNxnPTmoVhMdw43ZBbGPSgOVpjwv7zPQdqeCRnuKSV9hyFBPrUfnR5COSmelA7okk5CkPjHapoCdrSuegwBUJjGTltwH60SPkiNRx1peRSdtWPX5h8xwDT3iS4tWhkwUIwCeopgwACTzRFwWJyf6Umhp9zP0eV4Jn06fqOY2Pcelaoyue/qKoaxbmaJbm3P+kxc8elWbC4F7aCYY3/dYehqr31M6a5H7N/L0/wCAOYB33gfNjH0psJPzxn6g0KQxZQuCDzSpt+0qFoL0uRyjEDlRzTY8lVyOtWNqyBk9etNg2qfKwcjoaRNtQjhaaRY40ILccVauNMa0iMl5GxjHYDJq7pVzb2GoQveSKkeRnucd8V13jTxZpl7bwxeHtNCLE2RLMMux9/auedaUJKKWgSi7qKje/XovU4q0hmxu09ZZUA3Mkq7do9ia2PC3jWbw9fE2s+bOfie3274n9QVPf3rIvJLu/Ja+umx02RnaB9BVdrW2jTEY+ZT8pPSt3NT92xw/U604ONZJrtudJ4j0/wAPajbTa74YlbTJmI83SZh8rHPJjPYVzDwrGSyAKzYJHYU+4v1N+Ld0KJszkdM1FM2R8nzeoqLSvbob4TDQw0HCD5tfuImClmJP41EB5uVQFjUpdHGSMLnGKrxw+RJKxlJJ5Va0Ru32WhJGN8JQ8MppsZOBuIXHGMdadAm9GKn6+1SieFSFEfmsO/YUCWybHRuGcAYGeOakvreGJ12ssvy7jjtUME+xCskIck9farNzOksUafZVCgdjyaWpM5O6UVcpRuzcRxkilEmXxsf8s1JG8yqBHEFAoWa7LMRIEPYbaHY0Xnf7iMo0g3IjRyA/TNI8EpTfPMig9B3qRg7MwnlJJGc01IUwr8tjpmlcOW/9WIEQ4+8TUydMY3L3p7NsXcMbvSm+UFYMrYB6k9BRcFG2qHxrnIXgjtSOQGOeooljKBWWQMOuRTZGBKlgMtQU9BhClvY08MYiBjPpTCobpTkUBB5j/L60yVceT83zAAZ7UgddzEjHoKRCuAVBI7ZpQF8zzH6CkVd9xY2yrEDax6e1OGQm0yBhnOaFKspqB5FXCBQOeuaAb6stM25QE4PWqsschww/EetSwSbWAYbvpV5YRKcULTUiXvGO1oswJA2uO1SRIYflfFaMiGE8qDjnNVbpN/Jx6571rFKxwVouLuhUmG3a3SpnvSY1jLEoowoPIH0rKbIJGCakTcACVAHbLUruGhrQlzasv7oVhOVbeTnAPFMmGQ3zBQF4HfNV42Lc8Zqyx3oORkcjisup3RY2C5kFn5bSZyckY6/Wq7uVYfNvLVJIsbYHNIEjeIt5gRh2oSS2F7zsuw3Bzkjr1pVJSQYHWkAIw2eTUZdiwyDn1qrCbsOMy85Xb6UIwz8rYHvTJ4gpLcketV9nzZzx6U1YylKUehbKBuS3P1oquBx1NFA7k4dWOGHNSlWAHH0qEK2BgD0FKoKyAs5AHWgpPuPwoOHbDfzpMF8YOFHb1prYDbmwTRC3yjGQRmjyDrYkU4YDHfipDESwbG045rQ0ayF3cIrMA3UZ/hHqas66lksqtaHiMFS3/PRvWsHWXNyI3jTutTClhLYBOccnFN2gSDIyPp1pyknG4nPXA701iQM549K2TdjKSQ9HwSSOfrSKQshlI+bGP/r0m/5uV60jMBwe1UK9h2QTkYxTJdsy4KBiD+NKGEgJHTvSDGML17Gi5LV9B6gJtzkClcES7uNjdDTQCVIY596euJECjqPek2Ul0E+bBAIOKcGJwO9N5U4fgDv60oPQ54pXuCdtCaFizbNoBxj1rO2HTNQ3f8sZfvj0PrVwITuZX2saRh9oh+zuFYjq2OtLbVDa5kl1WxJIoEgbduVh2qDesUhdV3vTbJp/Le3lQ4j+7J7U5UCvlSCSeapC5rq60JJHcBSVxnsKfO8QgBuMorDAPeq7kvtZWIYGkfMsaM/JRuQe1Ac1ggi02Nt4mlaTqSR0+lXPPj2sEucD6VWcbXBCgYGaRvLbgjAPp1qWkJSaVrW/AtLl8bLmM5/vHFHl3UZyQkij+6c1SaOFtiuMIevNRQRbLp2imcRjoM5Ap2Dn8vx/Qu25f9/JMCWJwF9KjknyvC4A4AFMuG80rIGIfpuXp+NTl1EQO9Tu4BI5JptWRMZSk2paeY2RsFN6nkcU0AlhlcHpzTrZ55S25Aqr0LHrVyG2MgeSQbinX0FTKSjuaRjz7FCTaD5MDn/aIFSxxYG0AHjqKRUKSvmMpnnmnFADncR3xmi90TFa6hjDDpSiULN5SsWY9qYsZeXERyzfrW5oemtPcx7YWkuCdgUDkmonUjBXkaU4Sntou5BZadLdlURSGY/LngZpl6uzMEezzQSGc9OPT1r0OTw3NpgjfVmSJCu8xD7xFct4ivrV7hXECBU4RVHIHqa4aeLdafLAqHJN81OV49X0OZmXYMNhpAOaiubgW7wKyZDnG8dM025dI8x2/wC8MjlixPIz2pJpEktXhkXGOVYetehEyqSvfl3LDeQi/MrFm6nPSogVkQiNdo9DS+YpRQMM2OcUkpAjOO/aqsPmutSKNf3eCRnpx0oHzxskg/1fINB2FV28HvRtVnC8qrcUC1SsgDKUBB9jT1RXU5bCDqTUbskR8lclh6UsoVo40JPqwNAaLcVTGCBHNnsMilBUZEilzngjpSmNNoIApVADYB/Ci9gsIpJJLjb7DtULFIhtCb8859Ks4PB71VmXG4A8mrgryRFS6V0OguHD4RVB9DWvazHaCy4PesOFg52kfMOjelaFrIwG05z6+tS42ClN7M0rjbOpKnJx0rFuSwyh4NXJZiQzJ8pXt61i6peFog6DD9xQhVuW1x7ROy5MhCjsTTVUYyjD865y61abofu+lWNLvi0oB5BrRRZwRxNLn5InRIWA+U5I7Cpo5QV+VtrH1qPYHTMfDU5FDMFdcMOrCsnY9JaEm3gbcnFQvEOp/WnqF3YR6d9nduPMHrmkimr9LiYVDyabIG8vIXBJwBT1WJG+ZwW96ngC+bG24EBuBQ3uNRvudHdaTYpo0czFlnxgHPHvx3rjzGWJbH411WuarBd2MMUUbLtX5v8AernmAVSRz2Fc2G5+W8h1I7EAQY+7RT/Mb1FFdliNCJTz/WhgCTlufamk4BUnINCqM56/WgkkIjI+9TIxtyc5UUrqvBA/CnxYDYPelca1J4p9pBUnkc4OM0SSM7AOcAdKruhQZQ96lkJ8tScZPWo5Y7mnO5JpjJUJkVw5AHpQcgnG31pcjnFNIZYjIACg6n0qr9Cf1FRi/wB/GRTeZGwo470+NFZQSOtRnglIiVHc0xPSzHHZEcD5sdhSbmbooUUIioOpPvTjjHvQLUZvcEkY+lPQozAE7H7elHcDOKj481lIzx96gNlceGl3sJwpUdCKcdh5UkCot7x9PmXuvtUnyModD8vp6UPXca2DMca7pWJXsPWnJfsrBbeIAdiahnQNON4yMdam6IFRQvvRoJN3stLAlxcGRllK7T2HrUTlVA/QCn4/eDnJFRIAz7jwaAu9h5cNgMhUj+LNLblDK0TZPmCmk/N6ikcHAZDhlOQaW+gk7aiqSIysowy+9SLI00YRBll7gdKbuDhZW5LdfrTEYCcgMyk9x3oWo9muwZlbcnlrvPJPqKjtL9HafyEwcbSCO9PtQbZ7gndIXXCgnpRYuYomjFooc5JkPvT0M1e6d7Cyb3jVUCqDwQO9TXqRxJCiAPOBz6Cm20flK0kuGA6fWiIEyEnG/qSaRVvd13Y24iK4E8rbsZIzU1jdy2ZPkMG3DjfyAaLqzuoo0uykc0Y+8o5I+tVzLEVEzALG3Tb2NXKDtdmFLExqSag9V95cM0twd87AyDv7UyRfMnQdB3J6VFGdxAY8Vp2sMbYMx+XooPc1lKSirs64LnepJpFlLeX6R2sTM+8Ku0csfavZLOLSvAGl/aLlorzxDIuYohyIjjv6VwOn6pDocANkQb5hjzAOI/YVg6vqD3cjZkaSQtmRz1avLqRqYqprpFDxGHdVezk7Q6pby8vJfmbuseIrnUt73UoluXJLv6+w9AK5O8mFxIEcqWx82DjFQvOZC4jQRNnAA71FNEREozhzwSBzXXSowpaJFuSUPZwVl2IwltNKfs5w8Y+bJqqgW7nYu52A4wtNa1VYz5Uhyv3iT1pulKsMhEpAyeM12KKZx87lKMZLTqWZLWS1RpbXJ9cnqKeZflRmOc9x2q1d3cKwtHH87MMbRUVnYutvhlKgckE1Llbc25Fz2pkY+9lV3L6mnuCcNjGORT44QqqzyNg/dRR1+tNuHUTASthF61PNrZGnLZXYyJcFmcDK8n1NNi/eFnI+Zj+VNEwcHbgZOOeamRyq7Vxz3qiFuhCvA3c+ntS/xDB696YxKkAjOaeNmOcjHNPcZIAAMZ/Gq8uCWHUkVNlCEZfunqarTypnAQhQcZNON+hE7WK6MUbpir1vIdvzHis53AkwHB57VKX3DavUUPUypz5S6Z1ZyF4IHQ1nXtv5gMifiKfCrHlQN1TNuRdpGQetG2wTfOtTmr/SmbLRrnPNVrGzlSUNtIANdLDIA5HPHSrcsdqu1nBDt2Fae1scbwEKj507EdplYfmYA9c1ZgjaRS7fcXq3rTVEQ5AOFPFSIZJnCthYx0Qd6ybuelTXKlcQFI+beI7T0JqNlMjZdzg9qt3r+S0JDKI3yj56DjtXPy6i0c+xSCuaiEnIK1SFKXLJmqIVHI5FKFXJ25GKr217HORGc568Cr8vlRggEkY6U3dblQ5ZK8SFi6jLMTg0jyruBIPsBTs+YDnK55xinp5LkK2VZR3poNXsIjQsoJUgmiqTJIzEr0J4oqtDL2j/AJWO3ZenBjuGACB1OarFjuPpUqnd7GmJO7LC/Nz07UZAfaRyO9RbXD4wSnWpuSBnAPfNKxoncU85GOlOXcyFe/pTWIckEHdimk7eh5pIu4qkFTuyPao4bdxv5Plnkg96lEp6MAM0Bi7YAouSknuEknyDIxu4AFMRRAvl5Ld806chnAU9OooB55HTkUA7XEwQD2NJnjeVyQOlNIJJbdn2pxY4yp+tNCYiNuxlefSnFgPu9qRSWBOPmxwKEOUGRg/zoBDsd84AFRoQkgX+Bu1ObJYAio5cFMt2PGKEJ6aonzG7tE3ykdCajkTypNvmFw3Q9qSYCWKNuMjg0RyfJscAkdD3pWG30Ygjj8zfk8CkAbaSV+hp5X1570j5ZSpJAHTFMSQAkYyPrRu69qaVlUhQy8jilK7Bljkmkg9BUG0Ki/fPJzTlJ6nHvWY87vNx2PWrlrKJE5OMU7WJjUUnZFlSQM596FLTOIo/4jk1EZg7GNOSe/apBFtdfJY7gOfrSLWuwspy4hH3YuvvTmEYwx6Co44pYSWmKfMexzUGpy+XCcZ5HFNK5MpWTlIsw6n5T/uzkHgqT2qeaxgmiN1p21Cgy8LHhq4Fr+SOfjjFdBo+rEuGyFcdQehreMnHR6o8SfLXk5U3aaNeCZJVd8hCv3k7irFvKzsJmcMg4XtxWxpttp/ijbBFILbVVGQ5ACP7GsGWOG2vr2y1DEMsOV+U5Vj7VlUpK+h3YLGuo/Z1FaX4FuS6Lg/MNvRQOwquzBmwhK+prPhmARFUNszWgHaQEIgVMYrKyjsegpc+7GsxVS2GHGBj+dIZDbsiTbg7D5D61G6yeWFSX5Qc5Ip3mzPIjS7WZelUJtka2o84b9xduSOxqYWsF2Sm3DqcLu4FMlaaQDJwfapDJuwTwcc1LT6DUYNtNaGnptpY2S7pcSuOSF/xqbVdWW5tRHa26R/z/OsbzMjA6VGxIYDqvpWKotvmk7s1dSMVywVkWEYxbQAryHnbnpVS/V2kVcFnbsBS7gpL4xnjFPcsm1422vGMjJ6VvGMYmFTnqddOxTgTDEYJZTzmrJ9B931oWVIhukbLPyeKaXicZVio9SMVVm9iE4w0bHq5duBj61c0+2luyyqhznGB/FVRSCBhg341atrt7NlcSGNs/K3WonzJabm1O17jp4XhDRyxGMo3I9T6VUuncLuKbvQVYuLie4dY5JN0XJD9yfWqTCV32+aDjhyelENlzbjq+SKLtGzMzRhCec1YgSNwrLJntiklijRswrv7ZanRAwktIFwO1a9NDiipc1ppWLkexAwH3gKhE26Tj6GluS5g+1IiqCMEDqarRB3KshBY/pUrXc1lLlfKiz5Bdm2Y55xTmhZQsoG4DggGnRFo3YkdutZs25W4kYbuuO9LroVJKEdTRDh16D6elCMPMABOT39KqWpOcLz9amyNy4yCDn602nEaqX1HakiXUAUjO05B9TWMNMmeXABJI6DrXV6XYy3MybkPJyEHU11kdtp1pNCdTOza2WSHG4r6E1zTxMaPurUdTCqqueW/5nIeDNFWVpJDGXC8HPc+me1bWrW0MFpvLxI7cFQM4FWvGGuxajO8Wh2y2Fsq7UiQ449T6muaKSyxjzVIcDJDHr7iohTq1/3stEVSrqjFUrWk1/S/4YgaZMjndjpgU5o2mA3IQp6GlDrhE8nO7g9iPenAfZGRVfzIem0nmu5RurHNKq07z2f4DEidVCr0FFKyMxJCzAH0WinYr2z6GayFzxySOQacgxj9aVEYtwcYPrUqoOc9ag0SQI78levWnsG6kfWhHVV6c00s5Oc8elBaskOH3cyMB7d6QvD03nI7VGEDHLHNPRF6gc0tgT7IUTQsMF+fUjpUkjeVAQOHbBWq8iIykEYJ6U5jnyM9V4zTvZhrZiov8Zz5p6mmuct7inOSCOeD6Uxj82aQvIRyScjikBdWVkA3Ag804EMcml2O+/yyOmeafNYmyew68mdrjcgR5HOWI6fSlkjZCpDAAjlfSsmyYxzkyZCLk8GtGK38+zN40gGfmVQD+tOWhNKTqJ2WpIWwcEc1HIY12ktt9jUVk00kZaYjPtVHUZScrjkGjlFOr7vNY0EkVie4pe52gjismx3ll5NawyVB7A80NWFTnzq4qDCfM3zUrGQkAAbO5o4JNABznORSZokxyooXIzj60KMDax2r6tQ0e5C+7GegFMZTIvzHOOBRcZXe1US7kBIPercSARMQqA+xqKVJmAjVkC9elNjtWVchwSe3NXY5/acj0iZl7dyJMVHyj+dXLK8fy1ijzvb+L0qKezeScMw+XuM1PY2vkyF8cDoM05RVjOlKbky3HGEbdyznqTUd3GZkxnmpcsFyOKkgieR8A8Vns7nVy8y5Tj73S33koc1JY6bcEgAEdz9K7B7BpB8pwAcn3qORoYJMDIbHRav2+ljiWXRU+ZjYVa1hU24KuR98dc0ER3EKyXW1JFP3ieSabEJdpKsFi6nPJqFFtTIyOGkY85PrU3bOq0U1ZeWqJEuYm3IoyB0YDipLdUlzHPKyNjKn1oaYNEIxGuxRjI4NRuu9BJ0delI0Tt5i/wCrIAlEi9OexpxJDDPBNLkTQllVQ3fjv61C0oEY3Ekk4pDaSRK7EKCT1prN8wOMDvQVzg9qVmwoBGaB3vsKPmAwMHNByCdvXuTTlCn+LGBSNg/KO9ADIgS2fvKnr3ofPG/qx6Ukm5I2jgOHbjJ7UxUENrHDPI0lwDkt6CixF+lixkLwQM+1PaQ4CqUYH+8KhLjaNox603K46YBoHKMXuh7IjNmPEcgHUdDTXa4nKQ7FAH8XbNHO0YApohaf90srKijIPqaL9xclvhJDPICI5GGEOQMdTVYTNeqzeV5Tg4z0Bqyge42JsG2MY35+Ymn3AiCCO4ciM9do6GlzK+2pahJrfQiSzNucBmdgMsy84piwTSIxRN3Odxp0KWsRH2OWRpAedw61JI8sgYO21c4IXitW42MIU5Jvm26WIVD+dAAA0inp2qwuUkc7QHJycdB9KrNBHFE/kTvuz0NSABNqu7NIec1nfsbpOLs0P8wh2CjgjJzUWEcAle9Piwbh1PTaSaZanIIXke9FxaO1/MUII9xUitLSzbsWa5crt5GFyT9KpyRsACFAzS8rjmpneStcqFoM221n7PG0doghU9SOWP41nS3Mkm5iS2emapnC8Hg4p45I5JGKzhSjDoXKrOXkWdHEaX9s9wsbqH+dZD8uD612PibR9Lj8iSxtLlYkGWlhbchz2HpXDR/Kw38g1raVqVxaKyJK4ibqoPFdkKltzwMxy+rWqKrRlZrpdnQaJ4Z0HWkYRa+dPugvBuOY8+hPar0/w58RWcQltrS11SBuk1nKGJH0ri7mfdc+YyKEJzvXr+IqS31680+4S50+7uLZ0HyGNyMD6dKmfP8AZd1/XzMaeHrJc0J6rdM15fD+vRyMh0TWFI7fZjRV63+J3ioQIP7XJ46tHk/nRU2qdo/ia8+YfzL+vkf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Synovial fluid from a patient with acute gouty arthritis, when viewed with compensated polarized microscopy, reveals needle shaped, birefringent crystals. These monosodium urate crystals are bright yellow when aligned with the axis of the compensator.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of H Ralph Schumacher, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Calcium pyrophosphate crystals in synovial fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intracellular calcium pyrophosphate crystal is shown, which is pale blue when aligned with the axis of the compensator on polarized light microscopic examination. Note the rhomboid shape of the calcium-pyrophosphate crystal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of H Ralph Schumacher, MD, and Tim Jansen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Cholesterol crystals in synovial fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholesterol crystals from a chronic joint effusion aspirated from a patient with rheumatoid arthritis are shown on examination of synovial fluid using color compensated polarized light microscopy.&nbsp; Note the notched shield-shaped cholesterol crystals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of H Ralph Schumacher, MD, and Tim Jansen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25433=[""].join("\n");
var outline_f24_53_25433=null;
var title_f24_53_25434="Menopausal hot flashes";
var content_f24_53_25434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Menopausal hot flashes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/53/25434/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25434/contributors\">",
"     Robert F Casper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25434/contributors\">",
"     Richard J Santen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/53/25434/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25434/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25434/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/53/25434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/53/25434/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/53/25434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hot flashes occur in about 75 percent of menopausal women in the United States. The flashes most often begin in the perimenopausal period, although in some women they do not begin until after menopause. Hot flashes are almost always due to the menopause; other causes such as the carcinoid syndrome are rare (",
"    <a class=\"graphic graphic_table graphicRef78237 \" href=\"UTD.htm?36/53/37723\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence, pathophysiology, and treatment of hot flashes will be reviewed here. Other menopausal symptoms and postmenopausal hormone therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hot flashes typically begin as a sudden sensation of heat centered on the face and upper chest that rapidly becomes generalized. The sensation of heat lasts between two and four minutes, is often associated with profuse perspiration and occasionally palpitations, and is often followed by chills and shivering. Physiologic studies have determined that hot flashes represent thermoregulatory dysfunction; there is inappropriate peripheral vasodilatation with increased digital and cutaneous blood flow and perspiration resulting in rapid heat loss and a decrease in core body temperature below normal. Shivering then occurs as a normal mechanism to restore the core temperature to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hot flashes usually occur several times per day, although the range may be from only one or two each day to as many as one per hour during the day and night. They cause arousal from sleep, leading to sleep disturbances (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Sleep disturbance'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of menopausal symptoms estimated that vasomotor symptoms occur in 14 to 51 percent of women before the perimenopausal transition, 35 to 50 percent in perimenopause, and 30 to 80 percent after menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/3\">",
"     3",
"    </a>",
"    ]. It is generally believed that hot flashes do not occur in premenopausal women because serum estrogen concentrations are never very low, even during the menstrual period. However, the large observational SWAN study found that 20 percent of premenopausal women reported hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stages of the transition and menopause are shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef82933 \" href=\"UTD.htm?34/59/35760\">",
"     figure 1",
"    </a>",
"    ). In a longitudinal study of women traversing the perimenopausal transition, annual serum FSH concentrations, but not other hormones (estradiol, testosterone, DHEA-S), when collectively modeled longitudinally, were associated with both the prevalence and frequency of vasomotor symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 80 percent of women who have hot flashes will continue to have them for more than one year. Untreated, hot flashes stop spontaneously within a few years of onset in most women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, some women have hot flashes that persist for many years. The reported prevalence of women with persistent hot flashes is 12 to 15 percent for women in their sixties [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and 9 percent after age 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence (or reporting) of hot flashes is quite variable across cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Risk factors for symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Study of Women's Health across the Nation (SWAN), vasomotor symptoms were reported less often by Japanese and Chinese women (odds ratios = 0.47 to 0.67), but more often by African-American women (odds ratios = 1.17 to 1.63) when compared to Caucasian women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although obese women have higher endogenous levels of circulating estrone due to increased peripheral conversion of androstenedione to estrone in adipose tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/11,12\">",
"       11,12",
"      </a>",
"      ], women with a high body mass index are more, not less, likely to have hot flashes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/4,13\">",
"       4,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Smoking is associated with an increased risk of hot flashes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/4,13\">",
"       4,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the SWAN study, other risk factors included less physical activity, sociodemographic factors such as obtaining less than a high school education, and having difficulty paying for basics [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sleep disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distressing feature of hot flashes is that they may be associated with arousal from sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] and chronic insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/16\">",
"     16",
"    </a>",
"    ]. In a study of women at midlife (age 43 to 53 years, including pre- and perimenopausal women), those who were perimenopausal were more likely to report trouble sleeping [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, trouble sleeping varied with menstrual cycle phase (maximal in early follicular and late luteal phases, when serum estrogen concentrations are lowest). Not surprisingly, mood and vasomotor symptoms contributed to sleep disturbances. Eszopiclone may improve sleep and mood in perimenopausal and early postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polysomnography studies suggest that nocturnal hot flashes are more common during the first four hours of sleep, whereas REM sleep in the subsequent four hours suppresses hot flashes, arousals, and awakenings [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/15\">",
"     15",
"    </a>",
"    ]. A simple lifestyle measure, lowering room temperature, reduced the number of hot flashes in the symptomatic women.",
"   </p>",
"   <p>",
"    Psychiatric disturbances may also contribute to sleep disturbances in this population. In the study noted above, anxiety and depression symptoms were predictive of subjective sleep disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, perimenopausal women with hot flashes are more likely to be depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary sleep disorders are also common in this population. In a report of 102 women ages 44 to 56 years who reported sleep disturbances, 54 (53 percent) had sleep apnea, restless legs syndrome, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, in peri- or postmenopausal women who report sleep disturbances, treating the vasomotor symptoms alone may not restore normal sleep, as primary sleep disorders, anxiety, and depression may also be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of hot flashes is unknown. They are thought to be due to thermoregulatory dysfunction, initiated at the level of the hypothalamus by estrogen withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/2\">",
"     2",
"    </a>",
"    ]. Core body temperature is normal at the onset of the flash and falls below normal after it, indicative of rapid heat dissipation. Evidence for central mediation of the changes in temperature comes from studies demonstrating that hot flashes occur simultaneously with pulses of luteinizing hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The close proximity of the medial preoptic area (the major thermoregulatory area in mammals) and a high density of gonadotropin-releasing hormone (GnRH)-containing neurons suggest the possibility of simultaneous activation of a burst of GnRH release and thermoregulatory changes.",
"   </p>",
"   <p>",
"    A series of studies suggest that the thermoneutral zone is narrowed in women with hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/24\">",
"     24",
"    </a>",
"    ]. Whereas premenopausal women initiate mechanisms to dissipate heat when the core body temperature increases by 0.4 degrees centigrade, this happens with much lower increases in temperature in menopausal women. Estrogen administration restores the \"thermoneutral zone\" back to normal. These observations provide a physiologic basis for the clinical recommendations that women reduce their layers of clothing to reduce the severity of hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that hot flashes are not correlated with stage of sleep. However, as noted above, studies indicate that REM suppresses hot flashes, whereas more severe hot flashes occur during the first four hours of sleep and during stage III and IV sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A speculative mechanism for the initiation of hot flashes is endogenous opioid peptide withdrawal. Estrogen increases central opioid peptide activity and estrogen deficiency may be associated with decreased or absent endogenous central opioid activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/25\">",
"     25",
"    </a>",
"    ]. An animal model of hot flashes utilizes opiate withdrawal to induce rapid temperature changes, which are eliminated with estrogen administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/26\">",
"     26",
"    </a>",
"    ]. Further support for this type of withdrawal syndrome is derived from women with Turner's syndrome; hot flashes do not occur in women with this disorder who were never treated with estrogen. However, once they are treated with estrogen, they have hot flashes when estrogen is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ESTROGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal hormone therapy is currently recommended short-term for the management of moderate-to-severe vasomotor flushes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/27\">",
"     27",
"    </a>",
"    ]. Long-term use for prevention of disease is no longer recommended. Women with mild hot flashes do not usually require any pharmacologic intervention.",
"   </p>",
"   <p>",
"    For women with moderate-to-severe hot flashes, the most effective therapy is estrogen. The effective dose-equivalents are [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1 mg micronized 17-beta-estradiol",
"     </li>",
"     <li>",
"      50",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      transdermal 17-beta-estradiol",
"     </li>",
"     <li>",
"      0.625 mg conjugated equine estrogens",
"     </li>",
"     <li>",
"      1.25 mg piperazine estrone sulfate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These doses given daily are sufficient to stop hot flashes completely in about 80 percent of women and to reduce their frequency and severity in the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/29\">",
"     29",
"    </a>",
"    ]. Lower doses may also be effective in select patients.",
"   </p>",
"   <p>",
"    In a systematic review and meta-analysis of trials of estrogen for hot flashes, conjugated estrogen and 17-beta estradiol (oral or transdermal) appeared to be equally effective for the treatment of hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Low dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower doses of estrogen, such as conjugated estrogen (0.3 mg), oral 17-beta estradiol (0.5 mg), and transdermal 17-beta estradiol (25 mcg patch), were also effective in some trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/31\">",
"     31",
"    </a>",
"    ]. An even lower dose of estrogen (transdermal estradiol [0.014",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    ie, 14",
"    <span class=\"nowrap\">",
"     mcg/day])",
"    </span>",
"    was more effective than placebo in another trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oral estrogens have similar efficacy because they are all absorbed from the gastrointestinal tract primarily as estrone sulfate, which is continuously desulfated and converted to estradiol. Therefore, even though oral estrogen is administered in a single daily dose, the resulting serum estradiol concentrations vary little between doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For treatment of hot flashes, estrogen should be administered continuously rather than on a cyclic schedule. When given for 25 days of each month or for three of every four weeks, hot flashes often recur during the estrogen free-period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40486?source=see_link\">",
"     \"Continuous postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women who have not had a hysterectomy, estrogen should always be given in combination with a progestin, to prevent the occurrence of endometrial hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .) Progestin also increases central opioid peptide activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/33\">",
"     33",
"    </a>",
"    ] and, therefore, it could be postulated that estrogen-progestin therapy may be slightly more effective than estrogen alone in ameliorating hot flashes. However, the impact of adding a progestin to estrogen could not be assessed in the meta-analysis noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peri- and postmenopausal women should be reassured that taking estrogen (either unopposed or combined with progestin) for the management of menopausal symptoms is a safe therapeutic intervention for the majority of women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/34\">",
"     34",
"    </a>",
"    ]. Specific estrogen and estrogen-progestin regimens are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intractable hot flashes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intractable hot flashes refer to the continuing occurrence of hot flashes despite the administration of what should be an effective dose of estrogen.",
"   </p>",
"   <p>",
"    The first step in the evaluation of these women is to determine if they are taking drugs that can decrease the absorption of estrogen (eg, broad-spectrum antibiotics) or drugs that can increase hepatic enzyme activity and therefore increase the metabolism of estrogen (eg, barbiturates, anticonvulsants, or tranquilizers) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/35\">",
"     35",
"    </a>",
"    ]. Stopping or replacing these drugs may be helpful.",
"   </p>",
"   <p>",
"    Alternatively, changing the route of estrogen administration from oral to transdermal may result in control of hot flashes by bypassing the liver. Titration of patch size until plasma estradiol levels reach 120",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    may be helpful. However, there are no clinical trial data to support this approach.",
"   </p>",
"   <p>",
"    It is also essential that other potential causes of flushes or night sweats (hyperthyroidism, underlying malignancy, infection, SSRIs) be considered when hot flashes persist in spite of presumably adequate doses of estrogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17641?source=see_link\">",
"     \"Approach to the patient with night sweats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, for women who are receiving very high doses of estrogen in an unsuccessful attempt to stop their hot flashes, stopping the estrogen altogether for one to two weeks and then restarting at the usual dose may be effective. This will give the woman a chance to compare the severity of hot flashes on and off estrogen. She may decide that, although the flashes have not completely disappeared, estrogen is beneficial and she may tolerate the residual flashes better.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cessation of postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women have no trouble stopping estrogen. Observational studies report that 40 to 50 percent of women who start postmenopausal hormone therapy stop within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/36\">",
"     36",
"    </a>",
"    ] and 65 to 75 percent stop within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/37\">",
"     37",
"    </a>",
"    ], often with no assistance from their healthcare provider.",
"   </p>",
"   <p>",
"    However, abrupt withdrawal of exogenous estrogen at any age may result in the return of hot flashes and other menopausal symptoms. This was illustrated in a cross-sectional survey of 8405 women who had participated in the WHI combined estrogen-progestin trial, all of whom were instructed to abruptly discontinue their postmenopausal hormone therapy when the trial was stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/38\">",
"     38",
"    </a>",
"    ]. Compared to patients in the placebo group, the women who abruptly discontinued hormone were significantly more likely to develop moderate to severe symptoms whether they had hot flashes at baseline (56 versus 22 percent) or did not have hot flashes at baseline (21 versus 5 percent).",
"   </p>",
"   <p>",
"    Women subsequently used a variety of non-estrogen strategies to manage their symptoms with variable degrees of success. Only 5 percent of subjects resumed postmenopausal hormone therapy as they were discouraged by their clinicians from doing so.",
"   </p>",
"   <p>",
"    It has been assumed that tapering postmenopausal hormone therapy lowers the risk of recurrent symptoms and a survey of 377 women provided support for this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/39\">",
"     39",
"    </a>",
"    ]. A second survey also reported lower menopausal symptom scores after stopping hormone therapy in women who had followed the \"taper approach\" compared to those who had stopped abruptly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a randomized trial, 91 postmenopausal women who were on postmenopausal hormone therapy for at least three years (primarily for hot flashes) were randomly assigned to either an abrupt or gradual discontinuation (over six months) of their postmenopausal hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/41\">",
"     41",
"    </a>",
"    ]. Vasomotor symptoms were worse in the abrupt group during the first three months, but worse in the taper group at six months, with no differences between groups by 9 to 12 months. After stopping therapy, a similar percentage resumed therapy in the two groups (42 and 36 percent in the abrupt and taper groups, respectively). In a second trial, a rapid taper over two weeks did not seem to be better than stopping abruptly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical relevance of these findings is unclear; the second trial was unblinded and, therefore, patients were aware when they were no longer on estrogen, and the percentage of patients resuming postmenopausal hormone therapy was higher than what has been previously reported. As an example, in an observational study, 26 percent of 377 women who had been treated for at least one year resumed estrogen therapy because of bothersome symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, as noted above, only 5 percent of women in the WHI resumed estrogen, presumably because of the strong message they received from healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, menopausal symptoms are the major indication for postmenopausal hormone therapy. Many women have no difficulty with recurrent symptoms when they stop postmenopausal hormone therapy, while others have symptoms severe enough to require resumption of therapy. Based upon the WHI results, one can anticipate that roughly 55 percent will have some recurrent vasomotor symptoms if postmenopausal hormone therapy is stopped abruptly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Suggested taper",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tapering hormone therapy has not been proven to be more effective than stopping abruptly, we take this pragmatic approach, particularly in women with a history of severe vasomotor symptoms.",
"   </p>",
"   <p>",
"    When tapering, we typically decrease the estrogen by one pill per week (ie, six pills per week, then five pills per week, etc) until the taper is completed. The progestin is tapered on the same schedule. In our experience, women who are unable to tolerate a six-week taper temporarily resume their estrogen, and we then try a much slower taper, sometimes over one year (six pills per week for two months, five pills per week for one month, etc).",
"   </p>",
"   <p>",
"    Another type of taper one can try is with transdermal estradiol, gradually decreasing the dose over time (the transdermal preparations come in variety of doses: 0.1, 0.075, 0.05, 0.0375, 0.025, 0.0114 mg patches).",
"   </p>",
"   <p>",
"    Unfortunately, in women who have recurrent vasomotor symptoms after stopping therapy, there is currently no way to determine whether the symptoms will resolve quickly or persist for a prolonged time. In women who develop recurrent hot flashes, we first encourage them to monitor their symptoms over the subsequent few months to see if they resolve or improve. If there is no improvement or if the recurrent flushes during or immediately after the taper are difficult to tolerate, we try a non-estrogen alternative, such as an SSRI or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    . If ineffective, we then restart estrogen at the lowest dose possible (if the value of symptom relief outweighs the potential risks) and make plans for a future attempt to stop the estrogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348974072\">",
"    <span class=\"h3\">",
"     Extended use",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women considering extended use, a Scientific Statement of the Endocrine Society provides the attributable risks and benefits of hormone therapy for a period of five years in women ages 50 to 59. These data can be used for evidence-based decision making [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of menopausal symptoms with hormone therapy\", section on 'Cessation of postmenopausal hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80496635\">",
"    <span class=\"h2\">",
"     Bazedoxifene/conjugated estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of bazedoxifene, a selective estrogen receptor modulator, and conjugated estrogen",
"    <span class=\"nowrap\">",
"     (BZA/CE)",
"    </span>",
"    is under investigation for the treatment of postmenopausal vasomotor symptoms and osteoporosis prevention. [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/44\">",
"     44",
"    </a>",
"    ]. Bazedoxifene has estrogen agonist effects on bone and antagonist effects on uterine tissue. Its effects on breast tissue appear to be neutral [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/45\">",
"     45",
"    </a>",
"    ], but are under investigation. A theoretical advantage of this combination would be to relieve estrogen deficiency symptoms, while possibly avoiding the increased risks of breast cancer and endometrial cancer.",
"   </p>",
"   <p>",
"    Combination therapy with the lower doses (10 or 20 mg) of bazedoxifene with either 0.45 or 0.625 mg of CE significantly improved indices of vaginal atrophy and reduced the daily number of hot flushes when compared to placebo (mean change -9 versus -2.4, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/44\">",
"     44",
"    </a>",
"    ]. The incidence of venous thromboembolic events was low and similar among the groups. Bazedoxifene is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=see_link&amp;anchor=H22#H22\">",
"     \"Selective estrogen receptor modulators for osteoporosis\", section on 'Bazedoxifene'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with mild hot flashes usually do not seek or require pharmacologic intervention. However, women often try (and the North American Menopause Society [NAMS] recommends [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/46\">",
"     46",
"    </a>",
"    ]) lifestyle changes (including keeping the core body temperature cool and regular exercise), either alone or combined with nonprescription therapies such as soy foods, isoflavone supplements (from either soy or red clover, black cohosh, or vitamin E). However, neither exercise nor nonprescription therapies have proven benefit, as will be discussed in this section.",
"   </p>",
"   <p>",
"    For women with moderate-to-severe hot flashes, several other drug treatments are available when estrogen is not well tolerated, when it is contraindicated, or for women who have stopped estrogen and are experiencing recurrent symptoms but wish to avoid resuming estrogen.",
"   </p>",
"   <p>",
"    Any potential therapy for vasomotor symptoms must be tested against placebo because about 30 percent of women get some degree of relief from placebo alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Behavioral interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of behavioral interventions have been studied for hot flashes. Their efficacy has been variable. A relaxation-based method, known as paced respiration, has been shown in small studies to significantly reduce hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/48\">",
"     48",
"    </a>",
"    ]. However, this therapy is not widely available.",
"   </p>",
"   <p>",
"    As noted above, obesity is a risk factor for hot flashes. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors for symptoms'",
"    </a>",
"    above.) Weight loss may help reduce hot flashes, as illustrated by a six month trial in overweight and obese pre- and postmenopausal women randomized to an intensive behavioral weight loss intervention or a structured health education program [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/49\">",
"     49",
"    </a>",
"    ]. Among women with bothersome hot flashes at baseline, the intensive intervention resulted in a qualitative improvement in hot flashes when compared to the control intervention.",
"   </p>",
"   <p>",
"    Relaxation therapy and stress management interventions do not appear to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several trials and a meta-analysis have not found a beneficial effect of exercise on hot flashes, possibly because exercise raises core body temperature, thereby triggering hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Hormone therapy was more effective than exercise in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selective serotonin reuptake inhibitors (SSRIs) and selective serotonin norepinephrine reuptake inhibitors (SNRIs) also relieve the symptoms of vasomotor instability and are one of our first choices in women who are not taking estrogen. Their efficacy has been demonstrated in a number of randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/54-59\">",
"     54-59",
"    </a>",
"    ] and pooled analyses (",
"    <a class=\"graphic graphic_figure graphicRef66833 \" href=\"UTD.htm?2/51/2865\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H26\">",
"     'Pooled analyses'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 221 women with a history of breast cancer and vasomotor symptoms were randomly assigned to placebo or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      (a drug that selectively inhibits both serotonin and norepinephrine reuptake, ie, an SNRI) at doses of 37.5 mg daily, 75 mg daily, or 150 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/54\">",
"       54",
"      </a>",
"      ]. After four weeks of treatment, median hot flash scores were reduced from baseline by 27, 37, 61, and 61 percent in the four groups, respectively. Mouth dryness, anorexia, nausea, and constipation were significantly more common in the high-dose venlafaxine groups than in the placebo group. Similar results were observed in a second trial of extended release venlafaxine 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 165 postmenopausal patients (only 7.3 percent with a history of breast cancer) who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      controlled release (CR; 12.5 or 25",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo, median reductions in hot flash scores were 62.2, 64.6 and 37.8 percent in the 12.5 mg and 25 mg paroxetine CR, and placebo groups, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/55\">",
"       55",
"      </a>",
"      ]. Paroxetine should be avoided in women receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      because it reduces the formation of one of the major tamoxifen active metabolites [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two trials,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      was no more effective than placebo for hot flashes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/63,64\">",
"       63,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      reduced hot flash scores to a significantly greater degree in one trial [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/56\">",
"       56",
"      </a>",
"      ], but not a second trial [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/65\">",
"       65",
"      </a>",
"      ]. However, in the second trial, baseline hot flash data were collected on day one of therapy rather than pre-treatment. This could potentially underestimate the effect of fluoxetine, as SSRIs may have an effect on hot flashes as early as day one [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/56\">",
"       56",
"      </a>",
"      ] (personal communication).",
"     </li>",
"     <li>",
"      In the same trial without baseline hot flash data noted above, investigators concluded that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      was no more effective than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/65\">",
"       65",
"      </a>",
"      ]. However, in a trial of 254 women receiving placebo or citalopram 10, 20, or 30 mg for six weeks, reductions in mean hot flash scores were 23, 49, 50, and 55 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/66\">",
"       66",
"      </a>",
"      ]. The drug was well-tolerated and 20 mg appeared to be the optimal dose. Although reductions in hot flash scores were similar to the 10 mg dose, there were additional beneficial impacts on daily activities with 20 mg, including improvements in sleep, mood, and enjoyment of life.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       Escitalopram",
"      </a>",
"      also appears to be more effective than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/67\">",
"       67",
"      </a>",
"      ]. This was illustrated in an eight-week trial of 205 women with menopausal symptoms randomly assigned to receive escitalopram (10 to 20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo. Escitalopram was modestly better for reducing hot flash frequency compared to placebo (47 versus 33 percent reduction, respectively). Results were similar for African-American and white subjects. Although the effect appeared to be modest, satisfaction with treatment was greater in the escitalopram group than in the placebo group (70 versus 43 percent, respectively). &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"      , a new SNRI approved for the treatment of depression, also appears to be effective for hot flashes. In a trial of 707 symptomatic women, both desvenlafaxine 100 mg and placebo reduced the number of hot flashes per day; the mean difference compared to placebo was approximately 1.5 hot flashes per day [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/68\">",
"       68",
"      </a>",
"      ], similar to that for",
"      <span class=\"nowrap\">",
"       SSRIs/SNRIs",
"      </span>",
"      as a group in the meta-analysis described below. Side effects included constipation, dry mouth, nausea, dizziness, insomnia, and somnolence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Breast cancer and SSRIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs must be used with caution in women with breast cancer receiving adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy since SSRIs reduce the metabolism of tamoxifen to its most active metabolite, endoxifen, by inhibition of the cytochrome P450 enzyme, CYP2D6. In order of potency, from highest to lowest CYP2D6 inhibition, is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    . The impact of this effect on breast cancer recurrence or survival is unknown. Adverse effects appear to be greater in those with genetic variants of CYP2D6. We reserve SSRI treatment of hot flushes for women with breast cancer receiving aromatase inhibitors or no adjuvant treatment. This issue is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is unknown. It was designed to cross the blood-brain barrier and mimic the physiologic effects of the neurotransmitter gamma-aminobutyric acid (GABA), but it binds to a previously unknown receptor rather than to any of the known GABA receptors. It is approved for the management of seizure disorders and post-herpetic neuralgia, but has been used off-label for other indications as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    appears to be effective in reducing the frequency of hot flashes (",
"    <a class=\"graphic graphic_figure graphicRef66833 \" href=\"UTD.htm?2/51/2865\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/60,69-72\">",
"     60,69-72",
"    </a>",
"    ]. In a randomized, placebo-controlled trial in 59 postmenopausal women, gabapentin (900",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 12 weeks) was more effective than placebo for reducing hot flashes (45 versus 29 percent for gabapentin and placebo, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    to date, 420 women with breast cancer (most of whom were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ) were randomly assigned to receive gabapentin (300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 900",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in three divided doses) or placebo for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/70\">",
"     70",
"    </a>",
"    ]. A total of 347 women completed the trial. The percentage decreases in hot flash severity score between baseline and week eight were 15 and 46 percent for placebo and gabapentin 900",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    respectively. Gabapentin 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    decreased the hot flash severity score by 31 percent, but this was not significantly different from placebo.",
"   </p>",
"   <p>",
"    In another trial, women not taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or other hormonal therapies were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (dose titrated up to 2400 mg over 12 days), conjugated estrogen (0.625 mg), or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/73\">",
"     73",
"    </a>",
"    ]. Both gabapentin and estrogen reduced hot flash severity score to a similar degree when compared to placebo (72, 71, and 54 percent, respectively). However, at this dose, gabapentin caused significant side effects including headache, dizziness, and disorientation.",
"   </p>",
"   <p>",
"    Combined therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and an antidepressant (SSRI or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) does not appear to be more effective for hot flashes than gabapentin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , we have found that gabapentin at a dose of 300 to 600 mg at bedtime is quite useful for relieving the hot flashes that awaken patients from sleep. If night sweats do occur, many women find that they fall back asleep more easily than they did pre-treatment. The soporific effect of gabapentin and its effects to reduce vasomotor instability work together. Generally, the hot flashes during the daytime are not as bothersome to the patient and gabapentin may only be needed at night. This regimen also minimizes the side effects of gabapentin encountered during the daytime.",
"   </p>",
"   <p>",
"    As noted above, nocturnal hot flashes appear to occur primarily in the first four hours of sleep, whereas REM sleep in the subsequent four hours suppresses hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/15\">",
"     15",
"    </a>",
"    ]. This physiologic observation suggests why",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    at a higher dose (ie, up to 600 mg as a single dose) may be effectively used before the onset of sleep. It would be assumed that blood levels of gabapentin would then decline by the time of awakening, so as to diminish morning side effects.",
"   </p>",
"   <p>",
"    <br/>",
"    One multicenter study directly compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (given three times a day rather than as a single bedtime dose) in a crossover trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/75\">",
"     75",
"    </a>",
"    ]. Both agents reduced hot flash score by 66 percent but patients preferred venlafaxine over gabapentin. For those preferring venlafaxine, their average hot flash score was 41 percent lower on venlafaxine than on gabapentin. In those preferring gabapentin, their average hot flash score was 47 percent lower than venlafaxine. These results suggest that individual patients might respond better to one agent than another and that an empiric trial of both agents to determine which is more effective is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin administration alone can inhibit gonadotropin secretion and increase endogenous hypothalamic opioid peptide activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/33\">",
"     33",
"    </a>",
"    ]. High doses of progestins (compared to those used for hormone replacement) appear to be effective for hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    (Megace) is a synthetic progestin used primarily in the treatment of breast cancer. At oral doses of 20 to 80 mg daily, it decreases the frequency of hot flashes by 85 percent (versus 21 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/77\">",
"     77",
"    </a>",
"    ]. In one trial of breast cancer patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , megestrol acetate 20 mg was the optimal dose; no additional benefit was seen with a 40 mg dose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be a transient increase in hot flashes for one to two weeks after the initiation of therapy. Weight gain (predominantly fat) is the major side effect of prolonged therapy, and one potential concern is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    has glucocorticoid-like activity, so that adrenal insufficiency can occur after it is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=see_link\">",
"     \"Causes of secondary and tertiary adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High-dose depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    therapy also appears to be effective. In a trial comparing intramuscular medroxyprogesterone acetate (MPA) in a single dose regimen of 400 mg, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    37.5 mg daily for seven days followed by 75 mg daily, the single dose MPA regimen and venlafaxine reduced hot flash scores by 80 and 55 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef66833 \" href=\"UTD.htm?2/51/2865\">",
"     figure 2",
"    </a>",
"    ). During the first week of therapy, venlafaxine was associated with significantly more side effects, including nausea, appetite loss, dizziness, constipation, mouth dryness, and sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/79\">",
"     79",
"    </a>",
"    ]. This is the first direct comparison between the SSRI or SNRI class of agents and a progestin and suggests greater efficacy of the progestin with fewer side effects. More complete data will be needed before the superiority of MPA is more definitively demonstrated.",
"   </p>",
"   <p>",
"    Other progestins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    (10 mg daily) also appear to be effective for vasomotor flushes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    , a centrally active alpha-2 adrenergic agonist, effectively relieved hot flashes in some but not all clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/81-85\">",
"     81-85",
"    </a>",
"    ]. It is usually given transdermally, starting with a patch that delivers 0.1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    that is left in place for one week. Clonidine also may be given orally in doses of 0.1 to 0.4 mg three times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/81\">",
"     81",
"    </a>",
"    ]. Combinations of oral clonidine (0.1 to 0.2 mg at night) and the patch were sometimes used to further reduce hot flashes that awakened women from sleep.",
"   </p>",
"   <p>",
"    In one placebo-controlled study, the frequency of hot flashes decreased in 80 percent of women treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    versus 36 percent with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/83\">",
"     83",
"    </a>",
"    ]. In other studies the drug was less effective (",
"    <a class=\"graphic graphic_figure graphicRef66833 \" href=\"UTD.htm?2/51/2865\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Furthermore, its side effects, which are dry mouth, dizziness, constipation, and sedation, limit its value. Oral clonidine (0.1 mg per day) may also reduce",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    -induced hot flushes (38 percent versus 20 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is now used infrequently, given its side effect profile and the availability of other effective nonhormonal medications for hot flashes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Veralipride",
"    </span>",
"    &nbsp;&mdash;&nbsp;Veralipride is a dopamine antagonist available only in Europe. It was highly effective in a placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/87\">",
"     87",
"    </a>",
"    ]. Total cessation of hot flashes occurred in 63 to 80 percent of women versus 30 percent in the placebo group. Extrapyramidal side effects can occur with this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Complementary and alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many postmenopausal women use soy products, herbal therapies (in particular, black cohosh), as well as other alternative treatments, including vitamin E and acupuncture for management of their vasomotor symptoms. It is estimated that between 50 to 75 percent of postmenopausal women use alternative therapies for management of menopausal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/88,89\">",
"     88,89",
"    </a>",
"    ], and the prevalence may be even higher in breast cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most of these therapies, safety and efficacy are not well established. Interpretation of the available data has been difficult given the small size, short duration, and lack of placebo arm in many studies. In addition, the type and dose of soy or herbal supplements have been variable across studies. However, as discussed in the following section, most evidence suggests that alternative therapies such as soy and black cohosh are no more effective than placebo for reduction in hot flashes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Phytoestrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phytoestrogens, nonsteroidal compounds that occur naturally in many plants, fruits, and vegetables, appear to be no more effective than placebo for hot flashes. Phytoestrogens have both estrogenic and antiestrogenic properties, and are categorized as isoflavones, coumestans, or lignans.",
"   </p>",
"   <p>",
"    Two types of isoflavones, genistein and daidzein, are found in soybeans, chickpeas, and lentils, and are thought to be the most potent estrogens of the phytoestrogens (although they are much weaker than human estrogens).",
"   </p>",
"   <p>",
"    Lignans (eg, enterolactone and enterodiol) are found in flaxseed, lentils, grains, fruits, and vegetables.",
"   </p>",
"   <p>",
"    Various soy-based (isoflavone) compounds and lignans have been promoted as nonpharmacologic agents to treat vasomotor symptoms; however, results from clinical trials suggest that these are ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/90-95\">",
"     90-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isoflavones &mdash; In a review of 11 randomized clinical trials of soy or isoflavone supplementation, only three of eight trials with at least six weeks of follow-up demonstrated a beneficial effect [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/93\">",
"       93",
"      </a>",
"      ]. However, six weeks is probably not long enough to reliably assess the effect of an intervention on vasomotor symptoms. One longer-term study in the review (six months) reported no benefit of isoflavone supplements.",
"      <br/>",
"      <br/>",
"      In addition, meta-analyses have reported that soy foods, soy extracts, and red clover extracts are ineffective for hot flushes and other menopausal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/50,61,96\">",
"       50,61,96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Flaxseed &mdash; In a randomized, placebo-controlled trial of 199 symptomatic postmenopausal women, flaxseed (a lignan) was no more effective than placebo for relief of vasomotor symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Red clover &mdash; Red clover is another source of isoflavones. In a trial of 252 postmenopausal women randomly assigned to receive dietary supplements derived from red clover (which contains some isoflavones not found in soy-derived products, but lacks others that are found in soy products) or placebo for 12 weeks, red clover supplements had no clinically important effect on hot flushes or other menopausal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/98\">",
"       98",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Meta-analyses of red clover trials report no consistent benefit of red clover [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/50,61\">",
"       50,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important concern is that phytoestrogens are SERMS and therefore have both estrogen agonist and antagonist effects. Although the available data are conflicting, phytoestrogens may stimulate breast cancer growth, and antagonize the antitumor effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Black cohosh",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the alternative therapies available for management of hot flashes, black cohosh (Actaea racemosa or Cimicifuga racemosa) is one of the most widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Although individual small, short-term, randomized controlled trials suggested benefits from black cohosh, most have not [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/50,101\">",
"     50,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best evidence to date on black cohosh comes from the Herbal Alternatives for Menopause Trial (HALT), a one-year trial in 351 symptomatic peri- or postmenopausal women who were randomly assigned to receive one of five interventions: black cohosh alone, a multibotanical regimen that included black cohosh (and other herbal ingredients such as ginseng and dong quai), the multibotanical plus dietary soy counseling, conjugated estrogen 0.625 mg (with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    ), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/47\">",
"     47",
"    </a>",
"    ]. After one year of therapy, the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As expected, conjugated estrogen reduced vasomotor symptoms more than placebo (by an average of four vasomotor symptoms per day).",
"     </li>",
"     <li>",
"      In contrast, there was no significant reduction in the frequency or severity of vasomotor symptoms with any of the herbal interventions when compared to placebo at any of the follow-up times (3, 6, and 12 months).",
"     </li>",
"     <li>",
"      The effect of increased dietary soy intake in addition to the multibotanical could not be assessed because most subjects did not increase their soy intake to the target level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, black cohosh alone or as part of a multibotanical regimen does not appear to be more effective than placebo for reduction of vasomotor symptoms.",
"   </p>",
"   <p>",
"    A potential safety concern about black cohosh is its possible estrogenic effect on the breast. As a result, it should not be considered a safe therapy for breast cancer patients or women at high risk for breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105233835\">",
"    <span class=\"h3\">",
"     Evening primrose oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evening primrose oil (EPO), a rich source of gamma-linolenic acid, is widely used by postmenopausal women to treat hot flashes. However, available data suggest that it is no more effective than placebo. In the only randomized trial to address this issue, 56 symptomatic postmenopausal women were randomly assigned to EPO (4",
"    <span class=\"nowrap\">",
"     gm/day",
"    </span>",
"    plus 80 mg vitamin E) versus placebo for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/102\">",
"     102",
"    </a>",
"    ]. Among the 35 women who completed the trial, all showed improvement in their symptoms, but no significant differences were found between the two groups.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture has been studied as a potential therapy for hot flashes, but results thus far are not promising [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. While individual trials have reported benefit, a meta-analysis of five trials comparing acupuncture to sham acupuncture reported reductions in severity and frequency of hot flashes with both therapies. There were no significant differences between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/105\">",
"     105",
"    </a>",
"    ]. However, it is possible that a longer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more intense acupuncture regimen might be effective. In a systematic review of acupuncture trials in women with breast cancer, acupuncture did not appear to be an effective therapy for hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/106\">",
"     106",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other herbal and complementary therapies have been studied with largely negative results. In a systematic review of 10 clinical trials noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/93\">",
"     93",
"    </a>",
"    ], no reduction in frequency of flushes was seen with ginseng, dong quai, or evening primrose oil. Wild yam and progesterone creams also appear to be ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/50,93\">",
"     50,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin E was associated with a statistically but not clinically significant decrease in hot flushes in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/107\">",
"     107",
"    </a>",
"    ]. Traditional medicinal Chinese herbs, reflexology, and magnetic devices have all been studied and have no beneficial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/50\">",
"     50",
"    </a>",
"    ]. A simple lifestyle measure, lowering room temperature, reduced the number of hot flashes in the symptomatic women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Tibolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibolone, a drug that has been widely used in Europe and other countries for nearly 20 years, is a synthetic steroid whose metabolites have estrogenic, androgenic, and progestogenic properties. It reduces vasomotor symptoms when compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/46,108-110\">",
"     46,108-110",
"    </a>",
"    ] and has a beneficial effect on bone mineral density. Limited data suggest that it may also have a modest effect for symptoms of sexual dysfunction. However, tibolone has been associated with an increased risk of stroke and possibly breast cancer recurrence and, therefore, we do not recommend its routine use for management of menopausal symptoms. Results of tibolone trials in postmenopausal women are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Tibolone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pooled analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best available evidence for the efficacy of",
"    <span class=\"nowrap\">",
"     SSRIs/SNRIs",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    as nonhormonal alternatives for hot flashes comes from an individual patient pooled analysis of seven trials of antidepressants and three trials of gabapentin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/60\">",
"     60",
"    </a>",
"    ]. The mean reduction in hot flash score with placebo was 24 percent. The additional hot flash score reductions versus placebo for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    (at an optimal dose) were 41, 33, 13, and 3 to 18 percent. Gabapentin decreased hot flashes an additional 35 to 38 percent compared with placebo. Although these agents do not appear to be as effective as estrogen for hot flashes, they are significantly better than placebo. Results from some of the individual trials of",
"    <span class=\"nowrap\">",
"     SSRIs/SNRIs",
"    </span>",
"    are shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef66833 \" href=\"UTD.htm?2/51/2865\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a previously published meta-analysis of 43 trials of nonestrogen therapies for hot flashes (10 trials of antidepressants, 10 of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , six of other prescribed medications [three",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    , two",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , and one",
"    <span class=\"nowrap\">",
"     belladonna/phenobarbital/ergotamine",
"    </span>",
"    tartrate], and trials of 17 isoflavones), the mean difference in number of hot flashes per day for study drug compared to placebo were [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       SSRIs/SNRIs",
"      </span>",
"      (seven comparisons in six trials, mean difference -1.13). This suggests a more modest effect of",
"      <span class=\"nowrap\">",
"       SSRIs/SNRIs",
"      </span>",
"      than the pooled analysis above (although the statistical analyses are different). However, this meta-analysis included two trials without true baseline hot flash data. Both of these trials were excluded from the pooled analysis described [",
"      <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      (four trials, mean difference -0.95).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      (two trials, mean difference -2.05).",
"     </li>",
"     <li>",
"      Meta-analysis of red clover isoflavone extracts did not show a significant reduction in hot flashes and results for the soy isoflavone extracts were mixed.",
"     </li>",
"     <li>",
"      Relative efficacy of therapies could not be established because of lack of head-to-head trials.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For mild vasomotor symptoms, the North American Menopause society (NAMS) recommends lifestyle changes (including keeping the core body temperature cool and regular exercise), either alone or combined with nonprescription therapies such as soy foods, isoflavone supplements (from either soy or red clover), black cohosh, or vitamin E [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/46\">",
"     46",
"    </a>",
"    ]. However, as discussed above, available clinical trial data do not support the efficacy of exercise or nonprescription therapies. Furthermore, soy foods, isoflavone supplements, and black cohosh all appear to have potential estrogenic effects on the breast. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Behavioral interventions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Complementary and alternative therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For moderate-to-severe symptoms, the NAMS recommendations are similar to those outlined here [",
"    <a class=\"abstract\" href=\"UTD.htm?24/53/25434/abstract/27,46\">",
"     27,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"       \"Patient information: Menopause (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=see_link\">",
"       \"Patient information: Menopause (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"       \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=see_link\">",
"       \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"       \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Hot flashes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For postmenopausal women with moderate-to-severe vasomotor symptoms (and no history of breast cancer or cardiovascular disease), we suggest short-term estrogen therapy as the treatment of choice (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Estrogen therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short-term therapy is considered to be two to three years and generally not more than five years.",
"     </li>",
"     <li>",
"      For women with moderate-to-severe hot flashes in whom estrogen is contraindicated or not well tolerated, or for women who have stopped estrogen and are experiencing recurrent symptoms but wish to avoid resuming estrogen, we suggest therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , SNRI, or SSRI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with predominantly nighttime symptoms we typically use a single bedtime dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , which takes advantage of the soporific effect of gabapentin while minimizing daytime sedation. For women with predominantly daytime symptoms, we typically try a",
"      <span class=\"nowrap\">",
"       SNRI/SSRI,",
"      </span>",
"      as they may be less sedating than gabapentin. These drugs should be used with caution in women with breast cancer who are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Since hot flashes gradually subside without therapy in most postmenopausal women, any drug can be gradually tapered after one to two years of administration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Gabapentin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with breast cancer and hot flashes, we suggest not using phytoestrogens and black cohosh&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Complementary and alternative therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Stopping postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women have no trouble stopping estrogen and are able to stop without assistance from their healthcare provider. However, for others, in particular women with severe hot flashes prior to starting therapy, stopping estrogen can be quite difficult.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women whose vasomotor symptoms at the start of therapy were only mild-to-moderate, we suggest having the patient attempt abrupt discontinuation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This may be followed by a second attempt using a taper if the patient experiences bothersome symptoms.",
"     </li>",
"     <li>",
"      In patients with a history of severe vasomotor symptoms at baseline, we suggest a very gradual taper (typically over six months to one year) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Suggested taper'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The North American Menopause Society suggests that after a failed attempt at stopping therapy, extended use of postmenopausal hormone therapy may be reasonable in women who feel that the benefits of symptom relief outweigh risks. In this setting, we make additional attempts at a later date to stop the postmenopausal hormone therapy. For women considering extended use, a Scientific Statement of the Endocrine Society provides the attributable risks and benefits of hormone therapy for a period of five years in women ages 50 to 59. These data can be used for evidence-based decision making.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/1\">",
"      Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997; 27:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/2\">",
"      Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985; 22:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/3\">",
"      National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005; 142:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/4\">",
"      Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000; 152:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/5\">",
"      Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006; 96:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/6\">",
"      Randolph JF Jr, Sowers M, Bondarenko I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005; 90:6106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/7\">",
"      Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990; 592:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/8\">",
"      Utian, WH, Schiff, I. NAMS-Galllup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/9\">",
"      Huang AJ, Grady D, Jacoby VL, et al. Persistent hot flushes in older postmenopausal women. Arch Intern Med 2008; 168:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/10\">",
"      R&ouml;dstr&ouml;m K, Bengtsson C, Lissner L, et al. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002; 9:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/11\">",
"      Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973; 36:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/12\">",
"      MacDonald PC, Edman CD, Hemsell DL, et al. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/13\">",
"      Whiteman MK, Staropoli CA, Langenberg PW, et al. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003; 101:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/14\">",
"      Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA 1981; 245:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/15\">",
"      Freedman RR, Roehrs TA. Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause 2006; 13:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/16\">",
"      Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 2006; 166:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/17\">",
"      Kravitz HM, Janssen I, Santoro N, et al. Relationship of day-to-day reproductive hormone levels to sleep in midlife women. Arch Intern Med 2005; 165:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/18\">",
"      Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006; 108:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/19\">",
"      Juang KD, Wang SJ, Lu SR, et al. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but not premenopausal women. Maturitas 2005; 52:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/20\">",
"      Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002; 9:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/21\">",
"      Freedman RR, Roehrs TA. Sleep disturbance in menopause. Menopause 2007; 14:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/22\">",
"      Casper RF, Yen SS, Wilkes MM. Menopausal flushes: a neuroendocrine link with pulsatile luteninizing hormone secreation. Science 1979; 205:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/23\">",
"      Tataryn IV, Meldrum DR, Lu KH, et al. LH, FSH and skin temperaure during the menopausal hot flash. J Clin Endocrinol Metab 1979; 49:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/24\">",
"      Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med 2005; 118 Suppl 12B:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/25\">",
"      Reid RL, Quigley ME, Yen SS. The disappearance of opioidergic regulation of gonadotropin secretion in postmenopausal women. J Clin Endocrinol Metab 1983; 57:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/26\">",
"      Merchenthaler I, Funkhouser JM, Carver JM, et al. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas 1998; 30:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/27\">",
"      North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/28\">",
"      Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/29\">",
"      Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; :CD002978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/30\">",
"      Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/31\">",
"      Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005; 118 Suppl 12B:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/32\">",
"      Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007; 110:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/33\">",
"      Casper RF, Alapin-Rubillovitz S. Progestins increase endogenous opioid peptide activity in postmenopausal women. J Clin Endocrinol Metab 1985; 60:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/34\">",
"      Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/35\">",
"      Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/36\">",
"      Berman RS, Epstein RS, Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J Womens Health 1997; 6:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/37\">",
"      Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005; 118 Suppl 12B:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/38\">",
"      Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005; 294:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/39\">",
"      Grady D, Ettinger B, Tosteson AN, et al. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003; 102:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/40\">",
"      Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause 2009; 16:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/41\">",
"      Haimov-Kochman R, Barak-Glantz E, Arbel R, et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause 2006; 13:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/42\">",
"      Aslan E, Bagis T, Kilicdag EB, et al. How best is to discontinue postmenopausal hormone therapy: immediate or tapered? Maturitas 2007; 56:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/43\">",
"      Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95:s1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/44\">",
"      Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009; 92:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/45\">",
"      Harvey JA, Holm MK, Ranganath R, et al. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009; 16:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/46\">",
"      North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/47\">",
"      Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006; 145:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/48\">",
"      Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol 1992; 167:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/49\">",
"      Huang AJ, Subak LL, Wing R, et al. An intensive behavioral weight loss intervention and hot flushes in women. Arch Intern Med 2010; 170:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/50\">",
"      Nedrow A, Miller J, Walker M, et al. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006; 166:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/51\">",
"      Aiello EJ, Yasui Y, Tworoger SS, et al. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause 2004; 11:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/52\">",
"      Lindh-Astrand L, Nedstrand E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 2004; 48:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/53\">",
"      Daley A, MacArthur C, Mutrie N, Stokes-Lampard H. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007; :CD006108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/54\">",
"      Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/55\">",
"      Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289:2827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/56\">",
"      Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/57\">",
"      Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/58\">",
"      Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23:6919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/59\">",
"      Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 2008; 15:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/60\">",
"      Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009; 27:2831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/61\">",
"      Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/62\">",
"      Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/63\">",
"      Kerwin JP, Gordon PR, Senf JH. The variable response of women with menopausal hot flashes when treated with sertraline. Menopause 2007; 14:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/64\">",
"      Grady D, Cohen B, Tice J, et al. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007; 109:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/65\">",
"      Suvanto-Luukkonen E, Koivunen R, Sundstr&ouml;m H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005; 12:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/66\">",
"      Barton, DL, LaVasseur, BI, Sloan, JA, et al. Phase III, Placebo-Controlled Trial of Three Doses of Citalopram for the Treatment of Hot Flashes: NCCTG Trial N05C9. J Clin Oncol 2010; :.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/67\">",
"      Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/68\">",
"      Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/69\">",
"      Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/70\">",
"      Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/71\">",
"      Loprinzi L, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002; 77:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/72\">",
"      Fitzpatrick LA, Santen RJ. Hot flashes: the old and the new, what is really true? Mayo Clin Proc 2002; 77:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/73\">",
"      Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/74\">",
"      Loprinzi CL, Kugler JW, Barton DL, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 2007; 25:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/75\">",
"      Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010; 28:5147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/76\">",
"      Schiff I. The effects of progestins on vasomotor flushes. J Reprod Med 1982; 27:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/77\">",
"      Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/78\">",
"      Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 2008; 26:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/79\">",
"      Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006; 24:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/80\">",
"      Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002; 13:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/81\">",
"      Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982; 60:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/82\">",
"      Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994; 12:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/83\">",
"      Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 1987; 156:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/84\">",
"      Edington RF, Chagnon JP, Steinberg WM. Clonidine (Dixarit) for menopausal flushing. Can Med Assoc J 1980; 123:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/85\">",
"      Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1974; 1:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/86\">",
"      Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000; 132:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/87\">",
"      David A, Don R, Tajchner G, Weissglas L. Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988; 158:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/88\">",
"      Newton KM, Buist DS, Keenan NL, et al. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol 2002; 100:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/89\">",
"      Keenan NL, Mark S, Fugh-Berman A, et al. Severity of menopausal symptoms and use of both conventional and complementary/alternative therapies. Menopause 2003; 10:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/90\">",
"      Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002; 20:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/91\">",
"      Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000; 7:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/92\">",
"      Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000; 18:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/93\">",
"      Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002; 137:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/94\">",
"      Nikander E, Kilkkinen A, Mets&auml;-Heikkil&auml; M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003; 101:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/95\">",
"      MacGregor CA, Canney PA, Patterson G, et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005; 41:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/96\">",
"      Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004; 104:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/97\">",
"      Dodin S, Lemay A, Jacques H, et al. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab 2005; 90:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/98\">",
"      Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003; 290:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/99\">",
"      Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001; 131:3095S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/100\">",
"      Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002; 62:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/101\">",
"      Verhoeven MO, van der Mooren MJ, van de Weijer PH, et al. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause 2005; 12:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/102\">",
"      Chenoy R, Hussain S, Tayob Y, et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 1994; 308:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/103\">",
"      Deng G, Vickers A, Yeung S, et al. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol 2007; 25:5584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/104\">",
"      Wyon Y, Wijma K, Nedstrand E, Hammar M. A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women. Climacteric 2004; 7:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/105\">",
"      Cho SH, Whang WW. Acupuncture for vasomotor menopausal symptoms: a systematic review. Menopause 2009; 16:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/106\">",
"      Lee MS, Kim KH, Choi SM, Ernst E. Acupuncture for treating hot flashes in breast cancer patients: a systematic review. Breast Cancer Res Treat 2009; 115:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/107\">",
"      Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/108\">",
"      Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002; 109:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/109\">",
"      Pinkerton JV, Santen R. Alternatives to the use of estrogen in postmenopausal women. Endocr Rev 1999; 20:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/53/25434/abstract/110\">",
"      Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7390 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25434=[""].join("\n");
var outline_f24_53_25434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Risk factors for symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sleep disturbance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ESTROGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Low dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intractable hot flashes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cessation of postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Suggested taper",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348974072\">",
"      - Extended use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80496635\">",
"      Bazedoxifene/conjugated estrogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Behavioral interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Breast cancer and SSRIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Progestins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clonidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Veralipride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Complementary and alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Phytoestrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Black cohosh",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H105233835\">",
"      - Evening primrose oil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Tibolone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pooled analyses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Hot flashes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Stopping postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7390\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7390|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/59/35760\" title=\"figure 1\">",
"      STRAW staging system for reproductive aging women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/51/2865\" title=\"figure 2\">",
"      Therapies hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7390|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/53/37723\" title=\"table 1\">",
"      Causes of flushing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17641?source=related_link\">",
"      Approach to the patient with night sweats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=related_link\">",
"      Causes of secondary and tertiary adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40486?source=related_link\">",
"      Continuous postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=related_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=related_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_53_25435="Diagnosis of vulvovaginal mass";
var content_f24_53_25435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis for vulvovaginal masses and abscesses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Inclusion cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gartner duct cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leiomyomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fibroma or fibroadenoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Skene's duct cyst",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hernia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hidradenoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sebaceous cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hematomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lipomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vestibular mucous cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endometriosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cysts of the canal of Nuck",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bartholin cyst or abscess or cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Syringoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Accessory breast tissue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Folliculitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urethral diverticulae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hidradenitis suppurativa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Extension from perianal infection (eg, anorectal abscess)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25435=[""].join("\n");
var outline_f24_53_25435=null;
var title_f24_53_25436="Normal range fetal hemoglobin";
var content_f24_53_25436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal mean and &lt;2 S.D. values for fetal hemoglobin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gestational age, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean hemoglobin, gm/dL",
"       </td>",
"       <td class=\"subtitle1\">",
"        &lt;2 S.D. hemoglobin from the mean, gm/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        11.3",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        11.7",
"       </td>",
"       <td>",
"        9.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        11.9",
"       </td>",
"       <td>",
"        9.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        10.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        12.3",
"       </td>",
"       <td>",
"        10.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        12.5",
"       </td>",
"       <td>",
"        10.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        12.7",
"       </td>",
"       <td>",
"        10.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        10.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        13.0",
"       </td>",
"       <td>",
"        11.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        13.2",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        13.4",
"       </td>",
"       <td>",
"        11.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        13.6",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        13.8",
"       </td>",
"       <td>",
"        11.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        14.0",
"       </td>",
"       <td>",
"        12.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        14.2",
"       </td>",
"       <td>",
"        12.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        14.4",
"       </td>",
"       <td>",
"        12.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SD: standard deviations; gm/L: grams/liter.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Nicolaides, KH, Soothill, PW, Clewell, WH, Rodeck, CH, et al. Fetal haemoglobin measurement in the assessent of red cell isoimmunization. Lancet 1988; 8594:1073.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25436=[""].join("\n");
var outline_f24_53_25436=null;
var title_f24_53_25437="Passive proximal Cl transport";
var content_f24_53_25437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal tubule paracellular permeabilities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 197px; background-image: url(data:image/gif;base64,R0lGODlhSAHFANUAAP///wAAACMfIANOooGn0REREcHT6EJ6uZGPj1pXVyIiIjMzM1pXWJGPkMjHx1VVVcnIyERERBNZqGZmZtHe7qG93Hd3d5mZmTJvtHKcyzAtLWKRxYiIiGdlZe7u7uDp9KqqqiNkrrq5ubHI4qyrqz47O2hlZtXV1VKGv7u7u4OBgczMzJ6dnd3d3TEtLkxJSYSBgnVzc5Gy1/Hx8a2srD87POPj43ZzdNbW1vD1+ru6ukxJSuTk5PLy8p+dngAAACH5BAAAAAAALAAAAABIAcUAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLVSFAa5uRRHFAcVS77AeroGVRUHvFEZB3fFTsJM0UsHGZUHA9nZzUYGAwRL3uB62gMSylEGBB9S2Hfl50wfBMbuSOJMA9yTuBsDGwZwrQOg7oO3DBsOjAAwz1hDfAZQHDggQwiBChTGtckGQMYAFAAuZgSQg9kGXhkXpiwIoAKBEdVyJOT1IWFMAPbqcPQIMgeB/wMoFjYcUeFhiG8GGjKkdzChUHpLjekjKJGiRYwaERH4ZnGAsa25BoQggGEALq7i8BHY8HMAMHMc3XD01gzuAAAYJJCVwO6ABAMYQvj0ilPsUQnYQhA8sPZf4Xd36eLVW/asBH3iKlz+BRGpWLJmO4Oburbt28t3FW0dBzakV3wjPINLyzWHDBRlR2OIkw30290AKAywFrtijhCXebV2h89ehYRTc9LpXRajvsb0hgtpnlo0bNkEuU61jVs88EWru359jRY8bXB5ZXgcvU+uvl9CpoafzRWAP8Wu1RMZV+5kMJxk0s2xDX50EeBgWONwt1172fFX4X4ATBXffBnWl/9Ieh0NgAEBR4UFUGXC6YXNhWIZYCB9vKU2hH4ASBBCRGa19JFjyw0IjjvYEBWdjNMRWaMEFRggQ5L9cTcCBSm2ld2JZkW5YocZ3vgiloyAmAM2GKDA3mVICmFgCP5cWME24nnIRlwz7kNBWSEAQwFirrlEGHME3nWnPkNCVgQFYoo1Aj4YjnBZRWem6Q2ZwzTapo6AwmjLpZhmqummnHbq6aeghjENKMigg0SpXKBaDR/MBIdfq6ogWgmNRrSmhK1atEYrHi5hmKAp+PTa0mwvoYCCT/gxlNBJBL3k1B1rjvWBsL1udRsKvLBUUGvIAPWUAUQRYdtExv0UVIBcnvH/ATPnMnMAsy4Z8G4Ow/p6V00TZUCvSx/IkBEw8yx0iYSPbSVBWQdf9sEHBxMggQSuIZYNO3UYiJgvqbmzFWMPowtWayhkQOIABsFVHzYZZABxXqBlRNiuY+Tw8FrNjKWyYthsYCBIfP4YGWP+bFDYZQYgF+IwlhCs8cvNgOURW9ioQ5iBxtihnz1LG0N1ax8TNs8BJR40qGMMCQf0N7q6KYZHw7Djol932VPWYwQ/h00z2NDr2gh5ZaL0XWkHuBVbDs5DGK7TcYM14Id7xbXjXjGMwXPsZYXhhIw9GPgZuMYW1NyL090nAAZmgKCMH4ioHSb4iBnyZeiS5pVwGBya/4HL61Wt040fuK4y4zIoCrFHI5YIljcoyFu5EQ+PwPeRSS65uRm0G1ABCquNcFRhSn4kus+FCYk3kdjkyDpXFBxVXuxNE8Z3NhgYnvsdW1Wp/twGi8XLlyKKKbUx/jjY8gZVqGYQKhshGMH0zPC+b+SATttLjD7o1bPH/OlujxnCms4Tqg6G4VdWMBDSPEjCLoCwCg/TWwlXyMIWuvCFofBAC1qwghqm4IYguOEFLsCBCUzgAjB0hAc8sIIZ0nAFN0wBCEBwgSXu8IlPZKITecgBKHKAAxbI4gQe4MMHePEBEQhjBBZARgWY8YxnLIAa17jGALjxjXCMoxznSMcArP8giHRQQB33SEc28vGPgAzkHwsARzYa8pAFUIAh04hGBSzAjAtw4wLwGIcHuDGHQvDApy4QgAJQEg6EtEAJ3fjJN7ixBSUkJBBLuQYPuFGTJNQjCFjJBlKWUI8coKUaPEDIFUZylrpMgy1JGMlVBvMMw/RgBAJgzGOWoZclXCYwnUkGVwZghctMATXNkMwOLhOV2yQDNOlwAgeY05wnIEECToCEBKiAD5YEZzjFMM45JEAA+MRnAhyAABsgQQAJKMI96xDPeY6hm3EoZwwEEAMHlLOfAJhBDBKAAAQ4AAAAZUECYjADB5RAABadgyVhaVAwIFQOCACpEFJ60RcIQAX/C0UARgXwgo/GgAQaACgJ5jABO5Y0DCeNQ0plCgCWOoChADiqTAEaUaYOlA4WCABJf9qFoMJhqCsVgDlVqlSMBtSrAHgqT6VK1S9Y9Q1YLapWZyCAEjhABSplKljvKQJ2ysGSdyxrF+pJh7SyFAA4BWhcv8pUEeSUBWPVpl65wFc+kMCcHRCACP6A18Vy4ax3WGhbieqHylpWC5jdVE8V+1ksNBZUliRtaa0Q2jWo065XeC0csrla017TDvz0JxWemls4jLa2V2htGvjZTxuE1LgXRQAJNMrRiGo0ASzwKEjNCdEZqGCj7DSuCK7LWTBYcprAncJp30CCj25Vpl3F/2dNkXpPFahAA4FNAAn++gINIKC+NjgqQHO60zCkNrxVGC9atdrV9AaUretEKgD8+VSWnuClABCBAKKrUgl31wuWbCaAoSBgNxiVq4MVAkC7OoQGExjEFkWxGCyZyw1LgZBTRalWH2zfey6VsAHVgAZEIIIXhFWyJ/irBtwa2XKq2L8BaLGLORwA1cr4onAtQUzBCtYTRLawh/3rCVxagp0WWKVhWOYElhwFQjr5DR29J2wTYckxk/kJZqaDft/JCDG/Gc4+nQMIFPAIO9+5CYTMaxwiOUlHLPMBfwZ0AMDbhkgWgAMgiIAjLInoRC9Blm9YgRo13IieVtrSScC0G/8CUGhJUBrUStAjp8+gRj5TwpKSRjUSirmGCyTyEsuMtayNEElRosECatR1JZZZ6l0ToddoUOSnL2HJYhtbCJF0cxkm8OhNNPvZRUC2OIPNiWtjewjRJsMCCiBPawfA1U/ILwTWXQYGwAAANGAADpDgbllEctld8MAjFeDrTvQU3U5IaT6R0AABQEALAmAAAAp+8CMkXBan/gIHzLhqTXDg3FI4qsLh3QAdmMAEOOABAwRwAxoAoAcNYIAJdAAACDQABzQ4OARuwIAbzBsCJnB3DzCqcIbzoAEH//nBH84Dmut84TTAQQNMEXEvFEDYnwg3Ex45BI0LYeQ12IEAaoD/gxoIYAfv3oELGqB1pQvABQIA+tdT3nEBmAAGbuf5wg0OgbS33O4PhwADGnADkmMU7QJgegDwjYVxm5EMSMTiGB+pRkE6/vF0ZEKriWB1AIxcCFqf+8FxkHC+p73gLAeACQTAAyHwYPQNaIDX5c7wui/d9XKHN80f/nVUND0LE2f0Fi4wAUUSEpCtduQCwsjFLFrgihbYIheXHwEwkrGMZkSkHwupgBgbAdZGqPzlLR94ht9976l3ucGvHvghjDz1qWc93e0O+4fDHQZ1V/jDT9FTqFcBBNymQgp6/3vgJzICPmQBKVBub0BSQ3QEy1QAumcDLPB1B7d9l1dwQAcA/y7gAjHnAzTgfQDgAyTncg3AgSYAATpwA+oHAZw3ducndyOnAzRAextnClFlf1PwAAXgbEzgARcwbnO0ABOge42gaT6oVgMHgYHHA15nAgCAA6O3dTqggQvndS7AcqqHT0j4cN4HdzXQd0v3cDiAdiMnfy9YCjGIBYpUcUbQAg+gSHKkAD14CYokbZYWVTYIBb6XBC0QAXrURwtwAUV0CR6gSApwZn92cTLYBCswbkgAAjr4RjUIh51QgwQIahc3h0zAAWpEgIfYf53UhqGQAmr0bZxEiUkAbAVQaX84RwpghpvgiTUoaMYGAgFQiEjgSi3WAnnYSYQ3ChHwdN82BP8rQGpO4HsLYE1vJIqhMG57OAUikHM3AAE/pwMwwAChF401N2/wlnMwsHPxxgA+QEnAyARRJQSWlGStUINByAQk4HYNYAJqVwNkJwDz5o4w4AI1MHfsWAMQ8H6j140w5ErGKARqpEmwGAD9lgr6BnBS0IA70AAmB3s6wH7RiHYUWI8n1wP0mHrz90L+aIeENGZwhAQMiAAswE4nIF+bsGeteAUIMHICAH/sl3YPuXKZl5EY5Y6pZ3L9+I1HEABuxkmOSATpCFDmRWKYsIv/6AQsoAIQ0IIh2IFlJ4E6sHr7iHM4l3ZLuXQ5iZAAQIO31lNWZQMCoAF2VVddNV9CYJb/STVRMcBOGtUBkxVR10VREYUACeCWd+ABeMiGWiACH+V2PVB3UGhyPaB1NbB6PXADaFcDPHCYaDd2eIRxRNAC5DYEnbQEDUhnVadSTzVQR/UCdIkAcKUCkTVZJWBfKlACAFBf9yUAayYHilSQXgB7nwWZ4lhtQgCLTIBV+XRePyYEAxVZumUDGuBjbNUBAKBjMdBPD0ZRUzYHeOlJYyCbloVxbvSJQ5CHTCBhAeUALsWbmxl4YkVlTGVlHwVfAFVRIVWAAJAC42abwcQDPsCQO1dvRECfSxCNRRBv1tgEnZSHCDl4TuBSDdWdXRVZHfBegdeADVVRo5lSiCVfDqBm/zr2WCzQX20wcaS4TS2YT2BYBDSZBBlYBE7IBHEEnZT5BBKVUxrQAfmlUifwUR3gUitVniIwA5GlAXR2ZV0GAFaGTyXwlm1QnT9JSzxwdpu3hdxYczs3fx7HjULgcjB3lUKghAwwckFHczaXBG8kfNH3RqjwkdvEge9GBPi0A15Hgg8Xk+83d2iXckVYgW7qjC6wkBWopXVUANYXCgkYAar4SRLooQrXAy4oegKwc2I3d6F3eRxocgzHgTcQp0hgAQtQfFXERKmgabl4TC34gqU3f4NKhJpHfqHKcAX3qKlXekfQAsbnQ100Aa7Yi4jgdXuXc7E3qBzYdkiogZdXd/8haKWctwM6kI/7WQSaKEeymH3nNANCcF1TwKywygWnh0810I2e2qEAMI9+GarcJwRwN6fjpwNa93WoagRutEUBeEWcdFtNkE9heVFoGQXhaQXx+qxxUJlIwExOgE8AAFcyhZY2cF12GZdrCVj9xAI2QFcbpawA0JZvOV8i0AEdwE4O0AEJAF1J9VEhNbHupLD0ugb2upMfqwT4dF8lwGCBNwM6hgATBQAlAJpD9mM5FaEMBVfGGZqj+WMlwGVFlZz3RALxRQISdqACYJwd67EmegSWtK5CqZkJKgD95U9vlQA59WMK+1QyOpxNZZxWe7IsEKNMKwSRVVEfVbRGuwT/OpkE+jpTvflXQhC0PQae5debvSlXTlV+A1VfLNCAMvWd6HlhZFsGIXsE/imyWtWAqDlQD/YCDkACHTBUfAm3JVa4QwsADTphcjtQbfVWTFtXDdgBDiACMfC3wnS0SRBJkTgE7LpOcvu2IDUDXDa2YnVPOZUAymqjYUln3wlY+lRhh1VUfUm0ostNpGungRu8q1C8qUZqr2q8Xzq8S/B7gsi8pGCdUBBVWzqk0vsJ1CsFxPh0Spa92uu8UDCQ1bkAywu+mNBhT5ACyzRHBWAB54u+j6C+VHCHt9hJkyq/kkC/V/AAkXSnEcABeaq/gMC/XdBDu+i+AkjAgWDAYQAC/xZAg3Q0qTkUvwwMSuoqBymQg40HeYsEScNHfF80AVhUwsnXRWDUfGK0b9HXwX+UqcamR4QAwf7re8UKeTgsRx+cSG50rKgmw40gQyuwQ8eXfFqkRcXHqsaXRSV8ASlQRC0gxFJwcRn8bUAcS1WMbVfsQQ58Z1vcQV38Zl8cKmP8bGX8KWe8a2ncKWuMapG0Qm0Mam98S1n8bHOMxfR6xx4Ux5amxx3kx9gGyKDCx4kmyGhcx8a2TL6EyLtmyJ5CyH/myJ0iyW7MyJNsyZW8yHmMyZtCyXLMyZriyX0MypkiyoVMyphiyn+myCWkynfGysSEyq8sy7bgym8Gy8pEyz8XvMu83Mu+/MvAHMzCPMzEXMzGfMzInMzKvMzM3MzO/MzQHM3SPM3UXM3WfM3YnM3avM3c3M3e/M3gHM7CHAQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the differences in solute composition between the lumen and the intercellular space in the later segments of the proximal tubule. In comparison to the plasma and intercellular space, the lumen has a very low concentration of bicarbonate, glucose, and amino acids but a relatively high concentration of chloride, thereby promoting passive chloride reabsorption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25437=[""].join("\n");
var outline_f24_53_25437=null;
var title_f24_53_25438="Tracheal bronchus types";
var content_f24_53_25438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Different types of tracheal bronchus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 144px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    a) normal, b) blind ending diverticulum, c) supernumarary bronchus, d) displaced bronchus, e) replaced right upper lobe bronchus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25438=[""].join("\n");
var outline_f24_53_25438=null;
var title_f24_53_25439="Lymphoblasts FAB L1";
var content_f24_53_25439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoblasts in acute lymphoblastic leukemia FAB L-1 morphologic type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blood smear showing small lymphoblasts with rare nucleoli and vacuoles, as seen in acute lymphocytic leukemia (ALL) of the French American British (FAB) L-1 morphologic type.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_53_25439=[""].join("\n");
var outline_f24_53_25439=null;
